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ABSTRACT 
 
The applications for engineered nanoparticles have increased dramatically in 
recent years. They have been introduced into the industrial, electrical, agricultural, 
pharmaceutical and medical fields due to their unique properties. To date, zinc 
oxide (ZnO) and titanium dioxide (TiO2) nanoparticles (NPs) have been widely 
used in a number of commercial products such as cosmetics and sunscreens, due 
to their broad UV absorption characteristics, which protect the skin from sunburn 
and skin cancer. In the biomedical domain, biodegradable chitosan NPs have been 
assembled to carry medical compounds and genes as a vaccine delivery vector. 
However, currently there is limited understanding of how these nanomaterials 
interact with the cellular immune system, and what their potential impacts on 
human health might be. 
 
The aim of this study was to investigate the possible health risks associated with 
the application of inorganic ZnO and TiO2 NPs, as well as their in vitro cytotoxicity, 
inflammatory and allergic immune responses using mast cells and lung epithelial 
cells. This study also investigated the role of the various structural properties 
(particle size, wall thickness and porosity) of organic chitosan nanocapsules in drug 
delivery.  
 
The in vitro assessment of the cytotoxicity and immunomodulation was carried out 
using two formulations of ZnO NPs including; surfactant-treated (well dispersed) 
and untreated (aggregated), ranging from 30 to 200 nm in size. Various inorganic 
metal oxide NPs were examined; ZnO and TiO2 NPs and, various cell types were 
 vii
studied including immune and epithelial cells, adherent and non-adherent cells, 
and cancer and non-cancerous cells. 
 
The ZnO and TiO2 NP-induced cytotoxicity to mast cells (P815, RBL-2H3, BMMCs) 
and lung epithelial cells (LA4, A549) was dependent on cell type and particle size, 
dispersion, composition, concentration, time and growth media.  Small ZnO NPs 
(30 nm) caused more cytotoxicity than bulk ZnO (200 nm) particles. ZnO NPs 
displayed cytotoxic effects on all cancer cell types (P815, RBL-2H3 and A549), but 
did not induce cytotoxicity in primary BMMC cells. Surfactant-treated small ZnO 
NPs demonstrated strong cytotoxicity in all cell types (cancerous and primary 
cells). Surfactant-treated ZnO NPs showed greater toxicity to RBL-2H3 cells than 
their untreated NP counterparts, but had equitoxic effects to P815 and A549 cells. 
LA4 cells generally were more susceptible to ZnO NPs than other cell types. P815 
mast cells grown in RPMI-1640 media were more sensitive to ZnO NPs than those 
grown in DMEM media. The solubility of ZnO NPs in cell culture was very low and 
soluble extra-cellular zinc alone was not sufficient to induce cytotoxicity. Whereas, 
the intracellular concentration of Zn ions was very high after exposure of the cells 
to ZnO NPs. Therefore, the cytotoxicity of ZnO NPs may be due to direct contact of 
the NPs with cells, leading to dissolution intracellularly, and then causing cell 
damage via induction of oxidative stress. Investigation of cell death pathways 
indicated that ZnO NPs caused cell death through apoptosis and necrosis. Overall, 
TiO2 NPs exhibited relatively low cytotoxicity in all tested cell types. 
 
The immune effects of ZnO and TiO2 NPs were evaluated via cytokine profiles and 
mast cell degranulation markers. ZnO NPs caused more inhibition of IL-4 cytokine 
release than bulk ZnO in PMA and ionomycin-stimulated mouse P815 mast cells. 
 viii
The rat RBL-2H3 and BMMC mast cells were sensitized with TIB-142 IgE mAb in 
the presence or absence of ZnO, TiO2 NPs and zinc chloride (ZnCl2) and then 
challenged with TNP-BSA hapten to stimulate mast degranulation. The release of 
degranulation products, β-hexosaminidase and histamine, was markedly inhibited 
by ZnO NPs, but only very weakly inhibited by bulk ZnO particulates. Interestingly, 
surfactant-treated ZnO NPs (30 nm) had the highest inhibitory effects, while TiO2 
NPs did not demonstrate any inhibition of immune modulators, but instead caused 
a slight but significant (p < 0.05) increase in β-hexosaminidase release from mast 
cells. However, ZnO NPs increased the release of the proinflammatory cytokine IL-
8 from A549 lung epithelial cells.  
 
Pristine organic chitosan nanocapsules were found to be highly biocompatible, 
showing negligible cytotoxicity. The drug delivery efficiency using chitosan 
capsules of varying particle size, wall thickness and porosity loaded with curcumin 
was examined with P815 mouse mastocytoma cells. The size of the nanocapsules 
played the most important role in dictating their chemotherapeutic efficiency. 
Furthermore, these chitosan nanocapsules displayed inhibitory effects on IL-4 
release by non-stimulated and ionomycin-stimulated P815 mast cells. 
 
This study has provided valuable information on how size and dispersion of NPs 
can play major roles in cytotoxicity and immune responses. These discoveries will 
also provide useful information which will contribute to the development of new 
nanomaterials with lower cytotoxicity, immunogenicity and greater therapeutic 
potential. 
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P815 Mouse mastocytoma cell line 
PBS Phosphate buffered saline 
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RBL-2H3 Rat basophilic leukemia 
 xi
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
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TEM Transmission electron microscopy 
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TNF-α Tumor necrosis factor-α 
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UV Ultraviolet 
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Chapter 1: Introduction and Literature Review 
1.1 Introduction 
Modern science enables the manufacture of new materials made of particles of 
very small size; these particles are less than thousands of a millimetre in diameter 
and the science of building these tiny particles is called Nanotechnology. These 
materials not only have industrial uses but also have found their way into 
commonly used materials, such as sunscreens. The small size and unique 
properties of nanoparticles (NPs) enables novel applications and improvements in 
many areas, such as drug delivery, medical contrast agents and chemical 
catalysis. 
 
Nanomaterials (NMs) in consumer products have been increased dramatically 
around the world. Zinc oxide (ZnO) and titania (titanium dioxide, TiO2) inorganic 
NPs are used in sunscreens due to their broad UV absorption characteristics, 
which protect the skin from sunburn and skin cancer.  Biodegradable chitosan 
organic NPs have been assembled to carry medical compounds and genes as a 
vaccine delivery. However, there is currently limited understanding of how these 
NMs interact with immune cellular systems and what the potential impact on 
human health may be. 
 
This introductory chapter and literature review will provide an overview on the types 
of NMs and current uses of NPs for human health. It will mainly focus on inorganic 
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NPs that are commonly applied in sunscreens, such as ZnO and TiO2 NPs, as well 
as organic chitosan NPs, as a model for drug delivery. 
 
1.2 The nanotechnology industry 
Nanotechnology includes all techniques, materials and devices that deal with the 
manufacture of particles on a nanometre size scale (Maynard, 2006). It represents 
one of the biggest engineering technologies of the 21st century, and has been 
considered to be a new industrial revolution (Nohynek et al., 2008). The global 
market of engineered NMs is estimated to be more than $1 trillion within the next 
decade (Maynard et al., 2006). The major products of nanotechnology are NPs, 
which are considered to be a subset of NMs and are defined as a single particle 
with a diameter below 100 nm (Nohynek et al., 2008). Recently the International 
Organization for Standardization (ISO) has established a universal set of definitions 
related to nanotechnology that include nano-structured materials and nano-objects 
(i.e. nanoparticle, nanoplate, nanofibre, nanotube, nanorod, nanowire and quantum 
dot), as illustrated in Figure 1.1. An NP is defined as being a nano-object with all 
three external dimensions in the nanoscale (i.e. the size range from 1 to 100 nm). 
Whereas, a particle is known as a small piece of material that is larger than the 
nanoscale (ISO, 2010). 
 
Nanomaterials can be divided into three categories: Firstly, ultrafine particles that 
are naturally occurring, such as NPs arising from volcanic ash, ocean spray and 
mineral components. Secondly, anthropogenic ultrafine particles that have been 
made by human daily activity, for instance, diesel exhaust particulates (DEP) and 
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tobacco smoke. Thirdly, engineered NPs which have been designed for specific 
applications (Chang, 2010). 
 
There are many methods to make engineered NPs – the two common approaches 
for synthesising engineered NPs are through breaking bulk materials down to NMs 
by milling, grinding, etching and pyrolysis; or through integrating atomic substances 
together until they are large enough to form NPs. 
 
Engineered NPs can be classified according to their composition into: organic NPs 
(polymers, polymeric micelles, dendrimers), organic-inorganic hybrids 
(nanocomposites), carbon-rich NPs (carbon nanotubes (CNTs), fullerene (C60)), 
liposome NPs, biological NPs (proteins, lipids, carbohydrates) and inorganic NPs 
including silver (Ag), gold (Au), (Platinum) Pt, iron (Fe), TiO2, ZnO, calcium 
carbonate (CaCO3), quantum dots (QDs) and silica (Teow et al., 2011). 
 
These new engineered NPs have different physicochemical properties from their 
bulk material counterparts (Hsiao & Huang, 2011), thus it is unknown whether 
these new unique properties of NPs may be toxic to cells in biological systems and 
cause health diverse effects. Moreover, it is important to consider that NPs are 
usually present in aggregated and agglomerated forms when suspended in liquids. 
Aggregation occurs when the NPs combine together through strong bonds, while 
agglomeration occurs when NPs or aggregates join together with loose bonds. 
Aggregates and agglomerates contain clusters of NPs larger than single NPs; 
these clusters sometimes reach up to 1 micron in size (Schulling et al., 2010). A 
criticism of some published studies on the safety of NPs is that risk assessments 
have been performed on aggregate forms. As these different NP forms are likely to 
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have different biological properties, it is important to investigate the cytotoxic and 
immunological responses to both dispersed and aggregated forms of NPs. 
 
 
 
Figure 1.1: Overview of standard definitions and terms in ISO related to 
nanotechnology (adapted from ISO, 2010 and Fruijtir-Polloth, 2012). 
 
 
 
Nanotechnology 
Application of scientific knowledge to manipulate and control 
matter in the nanoscale  
Nanoscale 
Size range from approximately 1–100 nm 
Nanomaterial 
Material with any external dimension in the 
nanoscale or having internal structure or 
surface structure in the nanoscale 
Nano-objects 
Objects with any dimension 
in the nanoscale 
Nanostructured material 
Materials with internal 
structure or surface structure 
in the nanoscale 
Nanoparticle 
Nanoplate 
Nanofibre 
Nanotube 
Nanorod 
Nanowire 
Quantum dot 
Nanocomposite 
Material with 
nano-structured 
surfaces 
Assembled  
nanomaterial 
Nanoshell 
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The use of NMs has increased dramatically in recent years; they have been used 
in sporting goods, tyres, catalysts, electronic components, window sprays, paints, 
varnishes, coatings, foods, sunscreens, cosmetics and antimicrobial agents. Other 
applications, including vaccine trials, drug delivery and medical imaging, are still 
under development. The increased use of NMs may pose potential new risks to 
human health and the environment (Nohynek et al., 2007). 
 
1.3 Nanoparticles in sunscreens and cosmetics 
Australia has the highest rate of skin cancer in the world, and application of 
sunscreens is recommended to protect the skin from ultraviolet light (UV light), 
which damages the skin and causes skin cancer (Haywood et al., 2003). More than 
twelve hundred sunscreens are authorised to be used in Australia by the Australian 
Therapeutic Goods Administration (TGA). Approximately half of these sunscreens 
contain ZnO NPs or TiO2 NPs, or both. These metal oxide NPs are used in 
sunscreens because of their ability to filter a broad spectrum of UV light 
(particularly UVA) from sunlight, giving better protection, particularly at the longer 
wavelengths, than other organic sunscreen materials (TGA, 2006). 
 
Traditional sunscreens contained large (bulk) ZnO and TiO2 particles, which did not 
spread well, leaving a white film on the skin, and so they were not considered to be 
cosmetically attractive. Recently, various sunscreen formulations containing ZnO 
and TiO2 NPs have been made commercially available; these materials are clear or 
transparent when applied on the skin, and are more effective at filtering UV light 
from sunlight (Nohynek et al., 2007). This new formulation of sunscreens has 
solved the problem of the undesirable appearance of traditional sunscreens. 
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However, the possible toxic and immune (including allergic) consequences of 
exposure to these NPs are poorly characterised. 
 
Furthermore, recent sunscreen preparations contain surfactant materials that 
prevent ZnO and TiO2 NPs from aggregating, to ensure that the NPs are dispersed 
to spread well on the skin and give a more desirable transparent appearance. 
Therefore, it is recommended to repeat the health risk assessment of such metal 
oxide UV filters when used in nanosunscreen preparations (Faunce, 2010). 
 
The production of engineered NPs in sunscreen products has spread around the 
world and has been estimated to be up to 100 kilotonnes during 2003 alone (Borm 
et al., 2006). Today the rapid expansion of NP production may bring about new 
risks to human health and the environment. However, there is conflicting data 
regarding the risks associated with application of these NPs in sunscreens, and 
whether skin penetration occurs (Nohynek et al., 2008). There is also concern 
about the possible risk from ingestion or inhalation of NPs during the application of 
sunscreens, especially in the case of children. There is a need to address whether 
there are risks from the application of NMs in sunscreens, so that new NMs can be 
engineered with minimal toxicity and the greatest therapeutic potential. 
 
1.4 Chitosan nanoparticles 
During the past few decades, there has been growing interest towards the design 
of suitable polymer-based drug delivery carriers for controlled delivery of 
therapeutic molecules to disease sites in the body. The choice of the carrier 
material plays an important role in the development of these drug delivery vehicles, 
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especially as the carrier comes into direct contact with the body and its immune 
system, which plays a major role not only in determining the therapeutic potential of 
the carrier-drug conjugate system, but also in its clearance from the body post-drug 
action. 
 
Chitosan [(1,4)-2-amino-2-deoxy-β-D-glucan] is one such preferred carrier system 
with a broad range of proven biomedical applications due to its low 
immunogenicity, toxicity, and good mechanical properties (Zeng & Ruckenstein, 
1996). Chitosan possesses most of the above properties, due to it being a 
polysaccharide and not a polypeptide, which are typically immunogenic. 
Furthermore, the chitosan polymer can be broken down in the body by lysosomes 
to harmless N-acetyl glucosamine (Gan & Wang, 2007), making it a highly 
desirable biodegradable material in designing carrier vehicles for drug delivery. 
 
Different approaches have been undertaken in the past to prepare chitosan-based 
nanoparticulate systems, including chitosan nanospheres and beads, by way of 
emulsion cross-linking (Al-Helw et al., 1998; Kumbar et al., 2002), spray-drying 
(Conti et al., 1998; He et al., 1999), coacervation/precipitation (Nishimura et al., 
1986), ionic gelation, (Aydin & Akbuǧa, 1996; Shu & Zhu, 2000) the emulsion-
droplet coalescence method (Tokumitsu et al., 1999), the reverse micellar method 
(Mitra et al., 2001), and the sieving method (Agnihotri & Aminabhavi, 2004). 
Although these particles represent very promising drug delivery platforms, most of 
these methods produce solid chitosan particles, thereby restricting their capacity as 
a drug loading and carrier system. Moreover, it is extremely difficult to control the 
monodispersity of the chitosan particles synthesized via these routes, thus limiting 
their ability to control the drug payload during administration. In contrast, the use of 
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a template onto which a polymer layer is deposited, followed by subsequent 
removal of the template matrix, can result in a polymer capsule with a hollow 
interior. This interior can then be utilized for further drug loading, in addition to the 
surface, enabling substantially increased drug capacity per carrier (Wang et al., 
2007). Therefore, well-controlled synthesis of chitosan nanocapsules via a 
templating method provides an obvious advantage over previously reported solid 
chitosan nanospheres for drug-delivery applications. 
 
1.5 Exposure to nanoparticles 
There are several possible ways by which the body can be exposed to NPs; these 
include environmental pollution, workplace incidents, during transportation of NMs, 
and by consumption of products containing NMs. These NMs can interact with the 
body through common entry routes, including inhalation, ingestion and skin 
absorption. 
 
1.5.1 Inhalation 
It is well established that particulate air pollution is associated with adverse health 
effects, including respiratory disorders that result in coughing, sneezing and 
breathing difficulties. Ultrafine particles can cause greater toxicity and respiratory 
damage than larger particles in test animals (Zhu et al., 2008). In addition, size and 
shape of NPs are very crucial for particle distribution in the airways, for instance 
smaller particles were found to enter deeper inside the respiratory tract than larger 
particles (Oberdorster et al., 2005). Access to the alveoli further facilitates the 
distribution of NPs, which may be capable of crossing the epithelial layer, to enter 
the blood circulation where they can deposit in various organs in the body 
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(Semmler-Behnke et al., 2008; Furuyama et al., 2008). Thus, very small NPs have 
a high chance of crossing through and damaging lung epithelial cells, and 
interacting with mast cells, which could induce respiratory disorders such as 
asthma and other allergic responses. 
 
1.5.2 Skin penetration 
The skin is a very important barrier that protects the body from attack by both 
biological and non-biological substances. However, NPs may enter through 
damaged or weak skin. Some studies have reported that ZnO and TiO2 NPs do not 
pass through the stratum corneum, and that the possibility of skin penetration is 
very limited or negligible over short periods of time (Gulson et al., 2010; Filipe et 
al., 2009). Although no specific adverse health risks associated with the use of 
metal oxide NPs in sunscreens have been demonstrated, it has been suggested 
that some factors, such as damaged skin and the thinner skin of infants and elderly 
people, might lead to a greater likelihood of transdermal penetration, especially 
with chronic exposure over several years (Gulson et al., 2010; Monteiro-Riviere et 
al., 2009). It has also been reported that TiO2 NPs are capable of penetrating the 
epidermis and dermis after removing the horny layer (Lademann et al., 1999). 
 
1.5.3 Ingestion 
Nanoparticles have been introduced into food and medical applications, such as 
molecular imaging, site-specific targeted drug delivery, anticancer therapy and 
gene therapy (Gwinn & Vallyathan, 2006). Nanoparticles can be orally taken up in 
food additives or drug delivery vectors, and absorbed into the body through the 
cells of the digestive system, including the specialized epithelial microfold (M) cells. 
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A recent study showed that 15 nm silver NPs had greater penetration through the 
intestine than larger 198 nm particles in a rat model (Sonavane et al., 2008). 
Sunscreens containing NPs such ZnO and TiO2 may be swallowed by children 
during application on the face or lips (Nohynek et al., 2007). 
 
1.6 Cellular uptake of nanoparticles 
It is very important to understand the interaction between engineered NPs and 
cells.  Studying cellular uptake mechanisms are useful for nano-medicines, which 
are required to ensure that the NPs enter the cells to provide better diagnosis or 
treatment. For example, chitosan NPs have been successfully used as a model for 
drug-delivery applications (Oyarzun-Ampuero et al., 2009). Another essential 
concern is to know the undesirable cytotoxic effects of engineered NPs and their 
biological fate inside the cells. 
 
There are many methods that have been established to investigate NP 
internalization inside cells, including flow cytometry and confocal microscopy 
(Faklaris et al., 2008; Thurn et al., 2010). However, labelling of NPs is necessary in 
these techniques to visualise the NPs inside the cells. However, the addition of 
labelling materials to the NPs may cause a major problems through changing their 
physicochemical properties, including size, shape and surface chemistry, 
subsequently altering cellular uptake pathways and subcellular localization of the 
NPs (Al-Rawi et al., 2011; Gupta and Gupta, 2005; Nativo et al., 2008; Win and 
Feng, 2005). Chitosan nanocapsules used in this study are autofluorescent in 
nature and did not require additional fluorescent labelling. 
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Transmission electron microscopy (TEM) is also a good technique to visualise NP 
internalization (Oberdörster et al., 2005), but it is difficult with this technique to 
determine the quantity of specific elements due to intact NPs, especially if they 
contain essential metal elements, such as for ZnO NPs inside the cells. 
Synchrotron x-ray fluorescence microscopy (SXFM) has recently been used to 
quantitatively estimate elements inside the cells (Carmona et al., 2008). Thus, it 
can be applied to investigate metal oxide NP internalization in cells. 
 
Engineered NPs may enter cells by various mechanisms such as 
macropinocytosis, lipid raft-dependent endocytosis (caveolin-dependent and 
clathrin-dependent endocytosis), clathrin- and caveolin-independent endocytosis, 
and phagocytosis, as illustrated in Figure 1.2 (Geiser, 2010; Hu et al., 2009; 
Dawson et al., 2009; Conner & Schmid, 2003); whereas ions (e.g. Zn2+ ions 
release from ZnO NPs) enter the cells through ion channels in the cell membrane 
(Canton & Battaglia, 2012). 
 
Phagocytosis occurs mainly in some immune cells, such as the major antigen-
presenting cell (APC) types, being the dendritic cells (DCs) and macrophages, as 
well as neutrophils and mast cells. It is characterised by the engulfing of large 
foreign antigens (e.g. large particles, bacteria, yeast or large cellular debris) that 
can reach up to multiple micrometers in size, by the fusion of the cell’s membrane 
around the particles to form phagosomes. Phagosomes then bind to lysosomes 
and form phagolysosomes, in which the particles are digested (Champion et al., 
2008). 
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Figure 1.2: Nanoparticles may enter the cells through different mechanisms 
including macropinocytosis, lipid raft-dependent endocytosis (caveolin-dependent, 
clathrin-dependent), clathrin- and caveolin-independent endocytosis, and 
phagocytosis (adapted from Conner & Schmid, 2003; Dawson et al., 2009). 
 
Macropinocytosis and pinocytosis occur in all mammalian cells, by which small 
particles approximately several hundreds of nanometres in size can enter the cells. 
The pinocytic pathways are directed by the type of cargo molecule and its receptor 
(Conner & Schmid, 2003). 
 
Both caveolae-mediated endocytosis (Wang et al., 2009; Contreras et al., 2010) 
and clathrin-mediated endocytosis are essential mechanisms for NP uptake (Zhang 
et al., 2009). These endocytosis pathways form small vesicles less than 100 nm 
that fuse with endosomes (Rappoport, 2008). Clathrin- and caveolin-independent 
endocytosis may play a major role in the uptake of negatively charge NPs 
(Dausend et al., 2008). For instance, polyethylene glycol-coated gold NPs (with a 
negatively-charged surface) have been shown to pass through cell membranes via 
clathrin- and caveolin-independent endocytosis, but did not enter the cells via 
clathrin- or caveolin-dependent endocytosis (Brandenberger et al., 2010). Very 
small NPs less than 40 nm can penetrate into cells and enter the nucleus (Dawson 
et al., 2009), and also translocate between cells (Wang et al., 2009). Therefore, 
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engineered NPs that are capable of crossing into the nucleus may potentially 
damage DNA and result in cell death or cause DNA mutation in surviving cells. 
 
Stolle et al. (2009) suggested that TiO2 NPs (39 nm) were engulfed by the cells 
through endocytosis and that the NPs were localized within lysosomes, the 
cytoplasm and a few of the mitochondria, which may alter mitochondrial function. 
Another study by Geiser et al. (2005) reported that TiO2 NPs (41 nm) passed into 
the nucleus and organelles, which may enhance their toxicity. They also observed 
that these TiO2 NPs were not taken up by the endocytic pathway because particles 
within the cells were not bound to membranes. In contrast, some other studies 
found that TiO2 NPs were up taken by various endocytic pathways such as 
macropinocytosis, clathrin-mediated endocytosis, or caveolae-mediated 
endocytosis (Faklaris et al., 2009; Saxena et al., 2008; Singh et al., 2007; Thurn et 
al., 2010, Belade et al., 2012). Consequently, the exact mechanism of TiO2 NP cell 
uptake is not completely known (dos Santos et al., 2011). 
 
Cellular uptake mechanisms are also dependent on many factors, including 
physicochemical properties of NPs, such as size, shape, solubility, crystal structure 
and electrostatic charge, chemical composition, surface area, surfactant coating, 
particle size distribution (i.e. agglomeration state, dispersion factor and zeta 
potential in the system), protein adsorption, time of incubation and differences 
between cell lines (Belade et al., 2012; Dawson et al., 2009). 
 
A recent study by Belade et al. (2012) examined particle size effects using 
fluorescent carboxyl-modified polystyrene particles (ranging from 40 nm to 2 µm) 
on several different cell lines, including human HeLa and A549 epithelial cells, 
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human 1321N1 astrocytes, human HCMEC D3 endothelial cells, and murine RAW 
264.7 macrophages. They reported that NP uptake was highly dependent on their 
size; the greatest cell uptake occurred with smaller particle sizes in all of these cell 
lines. However, there are conflicting studies concerning the relationship between 
the cellular uptake pathways and size of NPs. For example, 500 nm NPs enter the 
cells via caveolin-dependent endocytosis (Rejman et al., 2004), whereas other 
studies demonstrated that caveolin-dependent endocytosis is a major uptake 
pathway for NPs less than 100 nm (Wang et al., 2009; Nishikawa et al., 2009). 
 
Surface modification or surfactant-coating of NPs may alter the major cell uptake 
pathway from that used for their pristine NP counterparts. For instance, amino-
functionalized polystyrene NPs mainly entered the cells via the clathrin-dependent 
pathway, but pristine polystyrene NPs were up taken through clathrin-independent 
endocytosis (Jiang et al., 2010). Therefore, surfactant-coated materials may be 
useful to re-engineer new safer NMs that are not able to enter specific organelles 
within the cell to cause cell death, such as the mitochondria and nucleus. 
 
Surface charge of NPs also plays another important key role in determining their 
major cellular uptake pathway. Positively-charged NPs enter cells at a greater rate 
through clathrin-mediated endocytosis than negatively-charged NPs (Mailander & 
Landfester, 2009). The enhanced ability of positive-charged NPs to enter cells 
could be due to their ionic interaction to the negatively charged cell membrane 
(Dobrovolskaia & McNeil, 2007). 
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1.7 Cytotoxicity effects of nanoparticles in mammalian 
cells 
Numerous studies have confirmed that NPs can induce cytotoxic effects in a 
variety of mammalian cells, as illustrated in the following reviews (Landsiedel et al. 
2010; Nohynek et al. 2007; Nohynek and Dufour 2008; Schilling et al. 2010; 
Nohynek et al. 2012). It has also been observed that even NPs originating from 
nontoxic bulk materials can cause toxic effects in cells and organs (Donaldson et 
al. 2005). 
 
Toxic dose responses have been shown in several different cell lines, including: 
human BEAS-2B bronchial epithelial cells (Huang et al., 2010), human A549 lung 
epithelial cells (Lin et al., 2009; Karlsson et al., 2008; Horie et al., 2009), human 
HaCaT keratinocyte cells (Horie et al., 2009), human A431 epidermal cells 
(Sharma et al., 2009), rat L2 lung epithelial cells and rat alveolar macrophages 
(Sayes et al., 2007, 2009), mouse RAW 264.7 macrophages (Xia et al., 2008), 
human MSTO-211H mesothelioma cells and rodent 3T3 fibroblast cells (Brunner et 
al., 2006), primary mouse embryo fibroblasts (PMEF) (Yang et al., 2009), human 
embryonic lung fibroblasts (HELF) (Yuan et al., 2010), mouse neural stem cells 
(NSC, C17.2) (Deng et al., 2009), human U87 astrocytoma cells (Lai et al., 2008), 
human T lymphocytes (Reddy et al., 2007; Hanley et al., 2008), and human aortic 
endothelial cells (HAEC) (Gojova et al., 2007). However, the cytotoxic mechanisms 
induced by NPs are still not understood (Nohynek et al. 2007), and generalizations 
are inappropriate as one needs to also consider the specific physicochemical 
characteristics of the NPs and the innate toxic potential of the constituent material. 
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There are some possible factors that have been correlated to the toxicity of NPs 
such as generation of reactive oxygen species (ROS), release of metal ions, and 
mechanical injury. Accumulation of NPs inside cells leads to excessive generation 
of ROS that damage the cell membrane and organelles, and causes cell death. 
This can be happen with numerous NP types, such as TiO2, carbon black, silica, 
Ag, magnetite, CeO2 and WCo-Co (Xia et al. 2006; Hussain et al. 2009; Eom & 
Choi, 2009; Kim et al. 2009; Park et al. 2008; Park et al. 2009; Hsin et al. 2008; 
Ding et al. 2009). 
 
Furthermore, metal oxide NPs such as NiO, ZnO, Fe2O3, Mn3O4, Co3O4 and Al2O3, 
are able to release metal ions in cell culture media or inside the cells. The 
dissolved metal ions from metal oxide NPs appear to play a critical role in cell 
toxicity (Brunner et al., 2006). For example, a recent study by Buerki-Thurnherr et 
al. (2012) showed that ZnO NP toxicity is mainly due to the release of Zn2+ ions. 
Therefore, measurements of intracellular and extracellular metal ion release are 
necessary when investigating the cytotoxicity of soluble metal oxide NPs. 
 
Another important issue is penetration and translocation of NPs through vital 
components of the cells, such as the nucleus, mitochondria and other organelles, 
which may cause mechanical damage and kill the cells. An in vitro study has 
shown that CNTs can enter the nucleus of human cells, resulting in cell toxicity in a 
dose-dependent manner (Porter et al., 2007). Titanium ultrafine particles (<0.1 µm) 
could also be found in the organelles and nucleus of the cells, which may be the 
reason for their cytotoxic effects (Geiser et al., 2005). 
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1.8 Nanoparticles and their impact on the immune system 
1.8.1 The immune system 
The immune response consists of two interconnected arms: innate immunity and 
adaptive immunity. Innate immunity is the first-line of defence against an antigen, in 
which microorganism recognition is mediated through pathogen-associated 
molecular patterns (PAMPs) on the surface of microorganisms that are recognized 
by pathogen recognition receptors (PRRs) on phagocytic cells, such as neutrophils, 
eosinophils, mast cells, macrophages and natural killer cells. This response is 
associated with a number of mechanisms such as opsonization, complement 
activation, acute inflammation, host-derived antimicrobial compounds, or 
phagocytosis (Look et al., 2010). 
 
The adaptive immune response acts as a second-line of defence against 
pathogens. Unlike innate immunity, it is characterised by powerful antigen-specific 
memory responses (Kuby, 1992). The APCs, such as macrophage and DCs, 
process and present the antigen through class II major histocompatibility complex 
(MHC) molecules to CD4 T helper cells. The T helper cells may activate B cells to 
produce antibodies (humoral immunity), or in cell-mediated responses, CD4 T 
helper cells respond to APCs and produce cytokines that activate CD8 cytotoxic T 
lymphocytes (CTLs), which mediate the killing of infected cells (Romangnani, 
1999).  Mast cells have features of both innate and adaptive immunity and can also 
express MHC class II (Sayes et al., 2008), thus mast cells play a role in the 
processing and presenting of antigen to T cells similar to that of APCs. 
 
The APCs can activate naïve CD4 T cells which are then differentiated into Th1, 
Th2, Th17 and T regulatory (Treg) cells (Figure 1.3). T cells of all types produce 
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many cytokines. Th1 cells produce interferon-γ (IFN-γ) and tumour necrosis factor-
α (TNF-α) cytokines, while Th2 cells produce IL-4, IL-5, and IL-13 cytokines. Th17 
cells are characterized by the production of the proinflammatory cytokine IL-17, 
while Treg cells are responsible for control of immune tolerance to self-antigens 
through production of the immunosuppressant cytokine, IL-10 (Look et al., 2010). 
Measurement of cytokine profiles can be used to monitor changes in immune 
responses. Table 1.1 shows some important cytokines of the innate and adaptive 
immune responses. 
 
1.8.1.1 Mast cells 
Mast cells are derived from haematopoietic stem cells and circulate in the blood in 
an immature form; when these cells reach the tissue they differentiate into mature 
mast cells. Mast cells are very widespread throughout the body, especially at the 
surface of the skin, as well as throughout the airways and gastrointestinal tract 
where microorganisms invade the tissue. Mast cells generally are among the first 
immune cells that are exposed to pathogens, along with DCs and macrophages 
(Galli et al., 2008). 
 
Mast cells are phenotypically very close to the basophils in blood, and both share 
many similar features, including the presence of basophilic granules in the 
cytoplasm, the surface expression of high-affinity IgE receptor FcεRI, and the 
release of chemical mediators during stimulation, such as histamine (Mukai et al., 
2009). 
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Figure 1.3: T helper cell subsets – naïve CD4 T cells can be activated by APCs; 
subsequently, these activated CD4 T cells can differentiate into a Th1, Th2, Th17 
or T regulatory (Treg) phenotype. Th1 cells can produce IFN-γ and TNF-α 
cytokines, which are important in defence against intracellular pathogens, while 
Th2 cells produce IL-4, IL-5, and IL-13 cytokines, which are associated with allergy, 
extracellular and helminthic infections. Th17 cells produce the proinflammatory 
cytokine IL-17, whereas Treg cells are responsible in maintaining tolerance for self-
antigen. Adapted from Look et al., 2010. 
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Table 1.1: Examples of cytokines of innate immunity and adaptive immunity 
(reproduced from Kuby, 1992). 
 
Some cytokines mainly involved in innate immunity 
Cytokine Secreted by Targets and effects 
Interleukin 1 (IL-1) Monocytes, 
macrophages, 
endothelial 
cells, epithelial 
cells 
Vasculature (inflammation); 
hypothalamus (fever); liver 
(induction of acute phase proteins) 
Tumor Necrosis 
Factor α (TNF-α) 
Macrophages Vasculature (inflammation); liver 
(induction of acute phase proteins); 
loss of muscle, body fat (cachexia); 
induction of death in many cell 
types; neutrophil activation 
Interleukin 12 (IL-12) Macrophages, 
dendritic cells 
NK cells; influences adaptive 
immunity (promotes TH1 subset) 
Interleukin 6 (IL-6) Macrophages, 
endothelial 
cells 
Liver (induces acute phase 
proteins); influences adaptive 
immunity (proliferation and antibody 
secretion of B cell lineage) 
Interferon α (IFN-α) 
(This is a family of 
molecules) 
Macrophages Induces an antiviral state in most 
nucleated cells; increases MHC 
class I expression; activates NK 
cells 
Interferon β (IFN-β) Fibroblasts Induces an antiviral state in most 
nucleated cells; increases MHC 
class I expression; activates NK 
cells 
Some cytokines mainly involved in adaptive immunity 
Cytokine Secreted by Targets and effects 
Interleukin 2 (IL-2) T cells T-cell proliferation; can promote 
activation-induced cell death 
(AICD); NK cell activation and 
proliferation; B-cell proliferation 
Interleukin 4 (IL-4) TH2 cells; 
mast cells 
Promotes TH2 differentiation; 
isotype switch to IgE 
Interleukin 5 (IL-5) TH2 cells Eosinophil activation and generation 
Interleukin 25 (IL-25) Unknown Induces secretion of TH2 cytokine 
profile 
Transforming growth 
Factor β (TGF-β) 
T cells, 
macrophages, 
other cell 
types 
Inhibits T-cell proliferation and 
effector functions; inhibits B-cell 
proliferation; promotes isotype 
switch to IgE; inhibits macrophages 
Interferon γ (IFN-γ) TH1 cells; 
CD8+ cells; 
NK cells 
Activates macrophages; increases 
expression of MHC class I and class 
II molecules; increases antigen 
presentation 
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1.8.1.2 Role of mast cells in innate and adaptive immune responses 
Mast cells play important roles in innate and adaptive immunity, including the killing 
of pathogens, especially parasites, and controlling the immune system through 
regulating immune stimulation (Galli et al., 2010). Mast cells control immune 
stimulation by three ways. Firstly, by stimulating the migration, maturation, 
differentiation and function of immune cells, through secretion of factors such as 
TNF, chemokines, histamine, leukotriene B4 (LTB4) and proteases. Secondly, by 
presenting antigen to T cells through MHC class I or II molecules, or activating 
antigen presentation by capturing IgE-bound-antigen through FcεRI and then dying 
through apoptosis. Thirdly, mast cells stimulate B cells to produce IgE through IL-4, 
IL-13 and CD40L (Galli et al., 2008). Moreover, mast cells stimulate expression of 
thymic stromal lymphopoietin (TSLP) on epithelial cells by the production of cell 
mediators such as TNF, IL-4 and IL-13, and also increase the recruitment of 
immune cells by production of TNF and other mediators that up-regulate adhesion 
molecule expression on vascular endothelial cells. Mast cells are also able to 
stimulate TH2 responses through action of prostaglandin D2 on DC maturation.  
Finally, mast cells produce TNF, IL-4 and IL-13 that stimulate airway smooth 
muscle production of other inflammatory chemokines and cytokines (Galli et al., 
2010; Tsai et al., 2011). 
 
Conversely, mast cells can also induce immune suppression through production of 
IL-10, which suppresses cytokine production by T cells and monocytes, reduces 
the production of proinflammatory cytokines and chemokines by keratinocytes, 
suppresses sensitization for contact hypersensitivity, and enhances the ability of 
DCs to decrease T cell proliferation and cytokine production (Galli et al., 2008) 
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The interaction between mast cells and the adaptive immune response is initiated 
following the stimulation of Th2 cells, via mast cells’ APC function, these cells then 
secrete IL-4 that in turn activates B lymphocytes to produce IgE and IgG, and these 
antibodies bind to FcεRI and FcγRI receptors on mast cells, respectively (Figure 
1.4). Activation of mast cells occurs when specific antigens bind to antibodies 
attached to these receptors, leading to mast cell degranulation and the release of 
cytokines or chemokines and other mediators, such as granulocyte macrophage 
colony-stimulating factor (GM-CSF), monocyte chemoattractant protein (MCP), 
macrophage inflammatory protein (MIP), “regulated upon activation, normal T cell 
expressed, and secreted” (RANTES), histamine and β-hexosaminidase (Tkaczyk et 
al., 2006). Mast cells are especially recognised for their role in IgE-associated 
allergic disorders, including hypersensitivity (Galli et al., 2010). 
 
Activation of mast cells can also occur directly through many other signals, 
including physical and chemical injuries, exposure directly to pathogens, or some 
signals that are generated during innate or adaptive immune responses (Sharma et 
al., 2002; Tsai et al., 2011). These signals can activate the intracellular signalling 
cascade, which leads to the secretion of many mediators that control immune 
responses. Tumour mast cell lines, such as rat RBL-2H3 basophilic leukemia cells 
and mouse bone marrow-derived mast cells (BMMCs, primary cells that are 
cultured in vitro from mice bone marrow), have been widely used as models to 
study the IgE-mediated responses of mast cells in vitro. Primary mast cells have an 
advantage over tumour mast cells, by which BMMCs can be engrafted to mast cell-
deficient c-kit-mutant mice (mast cell knock-in mice) to study the specific mast cell 
mediators and their diverse immunological responses in vivo (Kalesnikoff & Galli, 
2011). In contrast, the P815 mouse mastocytoma cell line can be activated by 
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chemical substances, such as the calcium ionophore ionomycin, but cross-linking 
of high-affinity IgE (FcεRI) receptors by multivalent antigens does not stimulate 
degranulation in an IgE-sensitized P815 mouse cell line (Ohno et al., 1990). 
 
 
 
 
Figure 1.4: The role of adaptive immune responses in regulating mast cell 
activation. Activation of mast cells occurs when specific antigens bind to antibodies 
attached to the receptors, leading to mast cell degranulation and release of 
cytokines or chemokines, such as GM-CSF, MCP, MIP and RANTES (reproduced 
from Tkaczyk et al., 2006). 
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1.8.2 Effect of nanoparticles on the immune system 
Many studies have found that engineered NPs at high concentrations can cause a 
cytotoxic effect in immune cells, but recently researchers have also started to 
realize that NPs may also impact on immune system regulation (Hussain et al., 
2012). Due to these potential immune interactions and the poor understanding of 
the novel chemistry of NMs, all engineered NPs should be investigated for their 
potential interactions with the immune system before introducing them for 
commercial use. There are two potential primary impacts resulting from interaction 
between NPs and immune systems: immunostimulation and immunosuppression. 
 
Immunostimulatory NPs are defined as NPs that enable the triggering of 
stimulatory immune responses that may be either desirable or undesirable. 
Desirable immunostimulatory effects of NPs may include vaccine and antitumor 
effects, while undesirable immunostimulation by NPs may include hypersensitivity 
reactions, inflammation and anaphylaxis. Immunosuppressive NPs (NPs that 
down-regulate immune responses) may also be either desirable or undesirable. 
Desirable immunosuppression may be useful in the treatment of inflammatory 
disorders, autoimmune disease, prevention of allergic responses or to promote 
transplant acceptance, while undesirable immunosuppressive effects may cause 
reduced immune responses to infection and cancerous cells, myelosuppression 
and thymic suppression (Zolnik et al., 2010). 
 
Some immunostimulatory reactions generated by NPs have been investigated. A 
number of studies have reported that NPs are capable of inducing cytokine 
production, both in vitro and in vivo (Fifis et al., 2004; Mottram et al., 2007; Scholer 
et al., 2002; Vallhov et al., 2006). NPs are also able to improve the antigenicity of a 
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weak antigen, and therefore act as an adjuvant that can be applied in vaccine 
development (Manolova et al., 2008; Fifis et al., 2004). On the other hand, NPs can 
trigger undesirable immune responses that are responsible for allergic reactions. 
Some studies have argued that NPs cause allergic immune responses in animals 
and humans (Nygaard et al., 2009; Toyama et al., 2008). For instance, a study in 
mice has shown that CNTs promote allergic responses to the known allergen 
ovalbumin (OVA) (Nygaard et al., 2009). 
 
There are several studies showing that NPs are capable of beneficially suppressing 
immune responses. For example, poly(D,L-lactic/glycolic acid) (PLGA) NPs loaded 
with betamethasone sodium phosphate have been applied to treat inflamed joints 
(arthritis) in a mouse model (Higaki et al., 2005). Some NPs have toxic effects on 
immune cells, which can result in the lowering of immune responses, e.g. inhaled 
multi-walled carbon nanotubes (MWCNT) caused systemic immune suppression in 
a mouse model (Mitchell et al., 2009). To date, there has been a dramatic increase 
in the quantity of manufactured NPs, however, few studies have been undertaken 
to investigate the specific immune inhibitory effects of NPs. More studies are 
urgently needed to evaluate such risks from the use of these NPs. 
 
1.8.2.1 Immunotoxicity of nanoparticles 
Nanoparticles initially interact with epithelial cells that are the first line of defence in 
the body, which are likely to be located in the skin, respiratory and digestive 
systems. Once NPs damage and invade the epithelial cells, inflammation is 
triggered and NPs are engulfed by tissue-resident immune cells. During this 
process a variety of inflammatory, cytotoxic and immune responses occur. Several 
studies have established using in vivo and in vitro models that NPs can induce 
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inflammatory responses, as well as cytotoxicity via necrosis and apoptosis of cells 
(Sayes et al. 2006; Sayes & Warheit, 2008). There are many possible ways in 
which NPs cause immunotoxic effects, for instance, the toxicity of NPs depend on 
various factors such as the physicochemical properties of NPs, interaction with 
medium components, the specific cell types encountered, and the way by which 
NPs enter cells. Once inside cells, NPs can cause a variety of effects, such as 
generation of ROS, apoptosis, necrosis and activation of cell signalling (Marano et 
al., 2011). 
 
The physicochemical properties of NPs play a critical role for inducing 
immunological responses and cytotoxicity. A number of studies have confirmed 
that the toxicity of engineered NPs (like cellular uptake) is due to physicochemical 
properties such as size, shape, solubility, crystal structure and electrostatic charge, 
chemical composition, and surface area, as well as particle size distribution 
(agglomeration state, dispersion factor and zeta potential) and the innate toxic 
potential of the constituent material (Padmavathy & Vijayaraghavan, 2008; Nair et 
al., 2008; Nel et al., 2006; Yang et al., 2008; Jiang et al., 2009). 
 
1.8.2.2 Biological investigation of zinc ion and ZnO nanoparticles 
Zinc is an essential trace element and the second most abundant transition metal 
ion found in mammals. However, zinc deficiency is widespread in human 
populations, causing harmful impacts on growth, nerve cell development, and 
immune system function (Tapiero & Tew, 2003; Plum et al., 2010). Rather than 
being a common toxic metal, zinc deficiency is a far greater risk to human health 
than its excess. However, many studies have reported that exposure to high levels 
of ZnO oxide particle inhalation in workers has lead to metal fume fever that is 
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characterized by airway irritation and lung inflammation (Antonini et al., 2003; 
Warheit et al., 2009). Therefore, safety concerns have been raised about the 
potential toxic effects of direct and long term skin contact to the ZnO NPs 
increasingly used as a broad-spectrum, UV absorber in sunscreens and personal 
care products (Stern & McNeil, 2010; Epstein, 2011). 
 
Several studies on the toxicological impact of ZnO NPs in vitro have shown a toxic 
dose response in a number of different cell types. It has been suggested that high 
levels of dissolved Zn2+ are a contributor to overall ZnO NP toxicity, with the 
induction of oxidative stress as the major factor in cytotoxicity (Deng et al., 2009; 
De Berardis et al., 2010). Brunner et al. (2006) also demonstrated that the severe 
cytotoxic effects of ZnO NPs on human MSTO mesothelioma or rat 3T3 fibroblast 
cells may be related to the release of Zn2+ ions in the media or inside the cells. 
ZnO NP dissolution could occur in culture medium and reach approximately 80% 
saturation of dissolved Zn2+ ions within 3 hours. It was expected that until Zn 
saturation was reached, the cells are mainly exposed to aqueous Zn2+ ions, but 
when particle concentrations are used that exceed the maximum Zn solubility, 
which is around 225 µM in complete Dulbecco's Modified Eagle's Medium (DMEM), 
cells will be exposed to non-dissolved NPs (Xia et al., 2008). At this stage, the 
multiple pathways for cellular toxicity of ZnO NPs in vitro have yet to be fully 
elucidated, and their relevance to long-term dermal or inhalational exposures is not 
known. For these reasons, it is important that the biological interactions of ZnO 
NPs be more comprehensively assessed. 
 
Similarities in cytotoxicity between ZnCl2 and ZnO NPs, have led to the suggestion 
that Zn dissolved from these NPs is the main contributor to their cytotoxicity (Song 
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et al., 2010), other research has indicated that direct ZnO NP-to-cell contact is 
required for cytotoxicity (Moos et al., 2010). Whilst a definitive answer on the 
relative contributions to cytotoxicity between ZnO NPs and “soluble” Zn remains 
unresolved to date, no studies have been carried out which explain why “soluble” 
Zn gives varied results, or even if it is present as Zn2+ in the cell culture systems 
typically used. 
 
The cell culture media widely employed usually consists of a complex mixture of 
amino acids and inorganic salts, designed to mimic the electrolytic, osmotic and pH 
properties of blood plasma, together with the addition of a source of serum (e.g. 
foetal bovine serum, FBS) to provide proteins, predominately albumin, which will 
coat NPs introduced into the system (Vippola et al., 2009). In many studies a 
simple water-soluble, ionic form of Zn (e.g. ZnCl2 or ZnSO4) has been employed to 
serve as a control, to distinguish the activity of “soluble” Zn from that of ZnO NPs. 
However, Zn2+ ions are well known to afford a range of poorly soluble carbonate 
(Chen et al., 1998; Ghose, 1964) and phosphate phases (Ziemniak & Opalka, 
1994; Frost, 2004). 
 
Examination of the solubility and physicochemical speciation of Zn2+ in cell culture 
media may impact on Zn bioavailability in cell studies. Common cell culture media 
types (RPMI-1640, DMEM, Hank’s Balanced Salt Solution - ‘HBSS’, etc.) have 
relatively high concentrations of both phosphate and carbonate anions. As the Zn 
salts of phosphate and carbonate anions are known to be insoluble in aqueous 
solutions, it is reasonable to expect that the addition of Zn2+ ions to cell culture 
media may also result in the formation of insoluble Zn species. Some very recent 
work has suggested that the solubility of ZnO NPs in various media solutions is 
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quite variable, and that reactions and precipitations indeed do appear to form in 
some of these solutions (Reed et al., 2012). Thus for in vitro cell studies, the 
speciation of Zn will complicate the comparison of the relative cytotoxicity of ZnO 
NPs compared to that of a soluble Zn control. 
 
Numerous of studies have been conducted to investigate the effect of 
physicochemical properties of ZnO NPs on cytotoxicity and inflammatory 
responses in different mammalian cells. A recent research study has been 
published by our research group (Feltis et al., 2012) that investigated the effect of 
size and dispersion of ZnO NPs (ZnO NPs, 30 & 200 nm, and surfactant-coated 
ZnO NPs, 30 & 200 nm) on immune cell function and cytotoxicity of human THP-1 
monocytes and macrophages. They reported that cytotoxicity was higher in 
macrophages than monocytes, suggesting that active phagocytosis by 
macrophages may be important in NP cytotoxicity. Consequently, increased ZnO 
NP uptake led to increased Zn2+ level inside the cells. In addition, the smallest NPs 
were more cytotoxic than bulk particles. Surfactant-dispersed ZnO NPs were also 
more toxic than their pristine counterparts. However, ZnCl2 showed equivalent 
cytotoxicity to the smallest ZnO NPs in both macrophages and monocytes. 
Cytokine profiles showed that IL-8 was induced by all ZnO NPs, with the smaller 
NPs inducing a higher amount of IL-8 release, regardless of cytotoxicity or dose. 
However, ZnO NPs did not stimulate type 1 (i.e. IL-2, IL-12, TNF-β and IFN-γ) or 
type 2 (i.e. IL-4, IL-5, IL-6 and IL-10) cytokine responses. Our research group is 
currently investigating the possible mechanism of Zn2+-induced cytotoxicity and 
immune responses upon the addition of ZnCl2. 
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Another study by Hanley et al. (2009) reported that ZnO NP-induced cytotoxicity 
and immunoregulatory cytokine release were dependent on cell type, size of NPs 
and ROS generation. They also reported that ZnO NPs are capable of increasing 
the production of IFN-γ, TNF-α, and IL-12 in primary human peripheral blood cells. 
In addition, a study by Hsiao et al. (2011) provided detailed information about the 
interaction of ZnO NPs with human A549 lung epithelium cells. They reported that 
physicochemical properties of NPs including size, shape, surface area, phase, and 
composition have a marked effect on cell toxicity and production of IL-8 from A549 
cells. 
 
In contrast, other studies have reported that ZnO NPs did not cause size-
dependent cytotoxic effects on mouse neural stem cells. This suggested that firstly, 
ZnO NPs might aggregate and form large particles with similar cytotoxicity, and 
secondly, that the cytotoxicity of ZnO NPs could be due to Zn2+ ions released into 
the medium (Deng et al., 2009). 
 
A number of studies have reported that particle surface area is a major determinant 
of cytotoxicity. Smaller particles have a larger surface area to volume ratio than 
larger particles, resulting in increased NP exposure and uptake in cells and more 
cytotoxic effects (Karakoti et al., 2006). However, others have observed that the 
higher surface area might not relate to higher cytotoxicity for some NP types such 
as TiO2 NPs (Sayes et al., 2006; Gojova et al., 2007). 
 
Many studies have tried to illustrate the effect of ZnO NPs on the mechanism of 
cell death but the research data are contradictory. On one hand, some studies 
have showed that the apoptosis pathway is induced in cells that are exposed to 
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ZnO NP (De Berardis et al., 2010; Lai et al., 2008), while on the other hand, other 
studies have reported that ZnO NPs induced cell death by necrosis (Hackenberg et 
al., 2010). This discrepancy may be related to differences in exposure and 
sampling periods and the dose-range investigated – as many toxic substances can 
induce apoptosis at lower concentrations, but higher concentrations can 
overwhelm the energy-dependent apoptotic processes to cause cell death by 
necrosis. 
 
1.8.2.3 Biological investigation of titania nanoparticles 
Zinc oxide and TiO2 NPs both consist of inorganic metal oxides, but cause different 
biological interactivities. For instance, TiO2 NPs are insoluble, whilst ZnO NPs are 
capable of releasing Zn2+ ions that play a crucial role in ZnO NP-induced 
cytotoxicity (Brunner et al., 2006). Therefore metal ion release from NPs may 
contribute in the cytotoxicity and immune response effects of some soluble NPs, 
but other insoluble NPs have different mechanisms for inducing toxicity and other 
biological effects. 
 
The significantly different cytotoxic effects seen between ZnO and TiO2 NPs have 
been confirmed in numerous studies (Lin et al., 2009; Yang et al., 2009; Hsiao et 
al., 2011). Moreover, both of these inorganic metal oxide NPs generate ROS 
(Hussain et al., 2009). 
 
A number of studies have been conducted to compare the cytotoxicity and 
inflammatory properties of TiO2 NPs to their bulk counterpart. Many studies have 
found that ultrafine TiO2 particles (20 nm) induce higher inflammatory responses in 
the rat lungs compared to fine TiO2 particles (250 nm) (Oberdörster et al., 1994).  
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In addition, ultrafine TiO2 particles (140 nm) caused greater cytotoxicity than fine 
TiO2 particles (380 and 250 nm) in human A549 and rat L2 lung epithelial cells 
(Sayes & Warheit, 2008). Very small nanoscale (10 and 20 nm) TiO2 particles can 
elicit oxidative damage, while larger particles (200 and >200 nm) do not induce 
oxidative damage (Gurr et al., 2005). Other studies have argued that there are no 
biological differences between ultrafine and fine particles (Sayes et al., 2006; Kim 
et al., 2009). 
 
Sayes et al. (2006) illustrated that the dose of TiO2 NPs required to observe 
cytotoxicity and change biological function in human dermal fibroblasts (HDF) cells 
was around 1.5 mg/mL. Caution must be used in interpreting this result, as this is a 
very high concentration that may have impacted directly on colourimetric readings 
(due to light scattering by the NPs present in the multi-well plate), as well as the 
potential for direct binding of NPs to assay components. 
 
There are different forms of TiO2, such as anatase, rutile, brookite, ilmenite, 
leucoxene, perovskite and sphene. Rutile and anatase TiO2 are the most common 
forms used. A number of studies have shown that the crystal composition has an 
impact on cytotoxic and inflammatory responses. The cytotoxicity of TiO2 NPs to 
A549 cells was greater for a mixture of anatase/rutile TiO2, than for amorphous 
NPs (Hsiao et al., 2011). Anatase TiO2 NPs have also been shown to be 100 times 
more cytotoxic than an equivalent sample of rutile TiO2 NPs (Sayes et al., 2006). 
The mixture of two crystal forms together has also elicited a much higher level of 
cytotoxicity than those of pure rutile or anatase forms (Gurr et al., 2005). Therefore, 
it is very important to know the purity and composition of TiO2 NPs before 
investigating their cytotoxic and inflammatory effects. 
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One of the major concerns with TiO2, as with ZnO NPs, is that there is relatively 
little specific data regarding interaction of these NPs with the immune system. 
Schanen et al. (2009) found that TiO2 NPs induced immune responses through 
increased production of proinflammatory cytokines, such as IL-1α, IL-1β, IL-6, IL-8, 
IFN-γ and TNF-α, from monocyte-derived DCs, which induced proliferation in CD4+ 
T cells. However, the TiO2 bulk counterpart did not induce any responses and 
remained inert. Moreover, TiO2 NPs also stimulated A549 cells to produce IL-8 
(Sayes et al., 2006). In contrast, Hsiao et al. (2011) did not observe an increase in 
IL-8 production from A549 after exposure to TiO2 NPs. 
 
A study has observed the immunogenicity of TiO2 and ZnO NPs. Palomaki et al. 
(2010) reported that in the murine RAW 264.7 macrophage cell line, TiO2 NPs 
induced expression of TNF-α and macrophage inflammatory protein (MIP-1α), 
whereas ZnO NPs stimulated the expression of IL-1β, and the neutrophil 
chemoattractant chemokine (C-X-C motif) ligand 9 (CXCL-9). Both ZnO and TiO2 
NPs induced the production of IL-6. Only ZnO elicited the expression of IL-1β, IL-6, 
TNF-α, CXCL-5, CXCL-9 and CXCL-10 in bone marrow-derived dendritic cells 
(bmDCs). TiO2 and ZnO NPs were both able to stimulate the expression of a 
maturation marker (CD11c) and various activation markers, such as MHC II, CD1d, 
CD86 and CD40 in RAW 264.7 cells. However, no significant differences were 
observed in these markers for bmDCs exposed under the same conditions 
(Palomaki et al., 2010). 
 
A study by Warheit et al. (2007) provided detailed information about the toxicity and 
inflammatory affects of rutile and anatase ultrafine and rutile fine TiO2 particles in 
rats. They reported that rutile ultrafine and fine particles produced pulmonary 
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inflammation, histopathological changes, and fibrogenic and cytotoxic effects at a 
lower concentration than anatase ultrafine TiO2 particles. Size distribution was 
measured by dynamic light scattering (DLS) which showed particle sizes of 382 nm 
for fine rutile, 136 nm for ultrafine rutile and 129.4 nm for ultrafine anatase 
particles. However, high resolution scanning electron micrographs (HR-SEM) 
images demonstrated that the size of the ultrafine rutile was larger than the 
anatase, which might explain the different results from rutile ultrafine particles. 
 
As illustrated above, TiO2 in its bulk form seems to be quite inert or less bioactive.  
The nanoparticulate form is associated with cytotoxic and inflammatory effects, and 
any novel changes to the characteristics of NPs, such as shape, coating and size, 
will possibly create new health risks and should be tested extensively. 
 
In addition to the different factors discussed above, the binding of proteins to NPs 
(protein corona) is an important consideration when investigating the effect of NPs 
on toxicity and immune responses, in both in vitro and in vivo studies. A number of 
studies have reported that protein binding to NPs can cause changes to the 
physicochemical properties of NPs (Moghimi et al., 2001; Chithrani et al., 2006; 
Nagayama et al., 2007; Lynch et al., 2009; Deng et al., 2011; Monopoli et al., 
2011). These changes may have an impact on cytotoxicity, immune responses and 
other biological functions. It has been shown that binding of albumin to single-
walled CNTs increased their uptake by RAW 264.7 cells (Dutta et al., 2007). 
 
1.8.2.4 The effect of nanoparticles on mast cells 
Mast cells, which are present at all the tissue sites where NPs are likely to first 
encounter, play a significant role in both activation and inhibition of innate 
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immunity, adaptive immunity and allergic responses, as described previously in the 
section 1.7.1.1. Therefore, mast cells provide a very good model for studying the 
interaction between NPs and cells of immunity, and how this interaction might alter 
the regulation of allergic immune responses. However, to date, very few studies 
have looked at the impact of NPs on mast cells. 
 
A recent study by Chen et al. (2012) examined rat RBL-2H3 mast cells exposed to 
a mixture of anatase and rutile forms of TiO2 NPs (<100 nm to 100, at 750 µg/mL) 
and measured histamine release. They observed that TiO2 NPs can directly 
stimulate histamine release from mast cells via a Ca2+ dependent pathway. They 
did not, however, investigate the effect of TiO2 NPs on IgE-activated RBL-2H3 rat 
mast cells, which is considered to be a more relevant model. 
 
A study by Yamaki et al. (2009) investigated the β-hexosaminidase inhibitory 
effects of ultrafine (21 nm) and fine (<5 µm) ZnO particulates on IgE-induced mast 
cell activation. They reported that ZnO inhibited the release of β-hexosaminidase 
from rat RBL-2H3 mast cells activated with anti-OVA IgE and its antigen, through 
inhibition of FcεRI-mediated PI3K and protein tyrosine kinase activation, without 
affecting calcium mobilization. Also, they demonstrated that ultrafine ZnO and 
ZnSO4 inhibited FcεRI-mediated degranulation more efficiently than fine ZnO; this 
could be explained by the higher surface area and therefore greater release of Zn2+  
from ZnO, thus causing the more inhibition. Similarly, Marone et al. (1981) argued 
that ZnCl2 inhibits histamine release from IgE-activated human basophils. 
Unfortunately, Yamaki et al. (2009) did not describe the cytotoxic effects of ultrafine 
and fine ZnO particulates, and only studied the β-hexosaminidase inhibitory of ZnO 
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NPs in their aggregated state, but not the dispersed state which may give stronger 
inhibitory effects. To date no study has been conducted to evaluate ZnO NPs on 
normal primary mast cells and their potential immunomodulatory effects. 
 
In contrast to the finding of Yamaki and coworkers, Hide and Beaven (1991) found 
that Zn2+ inhibited IgE-activated mast cell degranulation through inhibition of 
calcium influx. In addition, Musset et al. (2008) reported that the Ca2+ influx 
stimulated by anti-IgE in human basophils may also be inhibited by Zn2+. Thus, 
increasing the intracellular level of Zn2+ might play a potential role in inhibiting Ca2+ 
influx. 
 
Another study examined the effect of carbon NPs on allergic responses. Ryan et 
al., (2007) reported that fullerene NM derivatives (polyhydroxy-C60, N-ethyl-
polyamino C60) were able to inhibit allergic responses in human primary mast cells 
and peripheral blood basophils in vitro and anaphylaxis in vivo. They suggested 
that the IgE-dependent allergic inhibitory responses might be due to inhibition of 
oxidative stress and syk tyrosine phosphorylation. 
 
Nanoparticles can also inhibit inflammatory responses; Ag NPs inhibited the IL-5 
and TNF-α inflammatory cytokines produced by phytohaemagglutinin (PHA) 
stimulated peripheral blood mononuclear cells (Shin et al., 2007). However, 
Wingard et al. (2011) recently reported that 8 nm cerium oxide (CeO2) NPs 
activated mouse BMMCs to produce proinflammatory mediators, such as TNF-α 
and IL-6, suggesting that mast cells may have an essential role in recruitment of 
inflammatory cells in response to NP exposures. 
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Organic NPs can act as negative regulatory agents for IgE-mediated allergic 
responses. For example, chitosan and dendrosome NPs loaded with peanut 
allergen inhibited IgE allergic responses in mice (Balenga et al., 2006; Roy et al., 
1999). Moreover, Tahara et al. (2012) recently conducted a comprehensive study 
on the effect of chitosan-PLGA NPs on the allergic response of RBL-2H3 mast 
cells in vitro and also used the same NPs in an in vivo mouse model. They 
observed that chitosan-PLGA NPs were capable of inhibiting histamine allergic 
responses mediated by IgE-activated mast cells, both in vitro and in vivo. In 
contrast, another study did not observe any inhibitory effects or histamine release 
for chitosan-hyaluronic acid NPs loaded with heparin and stimulated with 
compound 48/80 in RBL-2H3 cells (Ampuero et al., 2009). A criticism of this work is 
that the chitosan NPs were made by Ampuero and co-workers using an ionotropic 
gelation method, which is not an ideal method for drug delivery. 
 
Anthropogenic ultrafine particles can induce allergic responses, e.g. DEPs, which 
are a major source of atmospheric pollution. Devouassoux et al. (2002) 
demonstrated that DEPs can greatly stimulate IL-4 production from non IgE-
activated human basophils (i.e. IL-4 production via the IgE-independent basophil 
cytokine pathway) – consequently DEPs can shift the adaptive immune response 
toward an undesirable Th2 allergic inflammatory response. Similar effects of DEPs 
on IgE-activated murine mast cells have been reported by Sanchez et al. (2000). 
Therefore, DEPs can stimulate IL-4 production from basophils via both IgE-
independent and IgE-dependent pathways. 
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1.8.2.5 The effects of nanoparticles on lung epithelial cells 
The human A549 cell line has been used in well established in vitro models to 
study lung epithelium responses (Don Porto Carero et al., 2001; Aufderheide et al., 
2003; Schwerdtle & Hartwig, 2006). The lung is a primary area for direct exposure 
to NPs, or accumulation of NPs in the respiratory tract, through inhalational 
exposure. Inhalation is one of the most likely risks of exposure to dry powders or 
aerosols containing NPs, and also allows direct contact with the NPs to living cells 
and potential access to the body’s circulation. 
 
Numerous studies have provided detailed information about the cytotoxic effects of 
ZnO and TiO2 NPs in A549 cells. They report that the physicochemical properties 
of NPs, including size, shape, surface area, phase, composition and 
agglomeration, have a crucial impact on cytotoxicity (Hsiao et al., 2011; Sayes & 
Warheit, 2008). However, these studies investigated the cytotoxic and 
proinflammatory effects of these metal oxide NPs in an aggregated state and not in 
a dispersed form, which may induce different cytotoxicity and immune responses. 
 
ZnO NPs display more cytotoxicity than TiO2 NPs in A549 cells (Hsiao et al., 2011). 
TiO2 NP cytotoxicity often gives contradictory results in different studies, but the 
general view is that TiO2 NPs do not induce severe cytotoxicity (Johnston et al., 
2010). This could be due to the purity of the titanium component (rutile, anatase, 
amorphous or crystalline mixtures), physicochemical properties (such as the lack of 
solubility) and concentration of TiO2 NPs. 
 
Recently, Lankoff et al. (2012) reported studies of the cytotoxic effects of TiO2 and 
Ag NPs in three different cell lines, i.e. the human HepG2 liver cell line, A549 and 
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THP-1 monocytic cell lines. They observed that the NP cytotoxicity was not directly 
dependent on particle size only, but that there was a “complex relationship” 
between particle and cell properties. 
 
Production of the inflammatory cytokine IL-8 from A549 cells has been stimulated 
by both ZnO NPs (Hsiao et al., 2011) and TiO2 NPs (Sayes et al., 2006). In 
contrast, Hsiao et al. (2011) did not observe an increase in IL-8 production from 
A549 cells after exposure to TiO2 NPs. These contradictory results suggest that 
there is insufficient data regarding the effect of ZnO and TiO2 NPs on cytokine 
production from A549 cells. 
 
1.9 Project objectives 
Nanoparticles are increasingly being used in drug delivery and skin care products. 
ZnO and TiO2 NPs are used in sunscreens due to their broad UV absorption 
characteristics and transparency to visible light. Most sunscreen preparations also 
contain surfactant materials that prevent NP aggregation and ensure NP 
dispersion. Therefore, it is very important to expand the health risk assessment for 
these preparations (Faunce, 2010). Mast cells are very important in many immune 
responses, especially in the skin and respiratory tract, due to their role in 
inflammatory and allergic reactions. However, to date, very few studies have 
looked at the direct impact of NPs on mast cells. 
 
There is currently a limited understanding of how these NMs interact with cellular 
systems and what the potential impact on human health may be. To address the 
risks from the increasing application of NMs, the cytotoxicity and inflammatory 
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responses to NMs will be assessed with in vitro studies. This study aims to provide 
useful information to contribute to the development of new NMs with lower toxicity 
and greater therapeutic potential, and to help identify biomarkers that may predict 
the potential health hazards of NMs. 
 
In this present study, I will examine how the size and dispersion of ZnO NPs, along 
with two different crystalline forms of TiO2 NPs, can affect both the cytotoxicity and 
inflammatory profiles of mast cells and lung epithelial cells. I will investigate several 
NP sizes that are typical of those present in current sunscreen formulations, in both 
well and poorly dispersed forms. In the case of ZnO, I will also compare these NPs 
with both bulk and dissolved ion controls. 
 
The study will also investigate the role of different structural properties (particle 
size, wall thickness and porosity) of chitosan nanocapsules used in drug delivery. 
Capsules will be infiltrated with curcumin, a hydrophobic anticancer molecule 
naturally found in the yellow curry spice turmeric. The effects of curcumin-loaded 
chitosan nanocapsules on cellular uptake, cell viability and allergic responses in 
mouse P815 mast cells will be studied. 
 
Specifically, the aims of this study are: 
 
• To assess the mechanism of cytotoxicity and the cytokine profiles induced 
by zinc oxide and titanium dioxide nanoparticles in the mouse P815 mast 
cell line; 
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• To assess the effects of zinc oxide and titanium dioxide nanoparticles on 
mast cell degranulation in rat RBL-2H3 and bone-marrow derived mouse 
mast cells; 
 
• To assess the inflammatory and cytotoxic responses of lung epithelial cell 
lines (human A549 and mouse LA4) exposed to zinc oxide and titanium 
nanoparticles; and 
 
• To assess the potential of chitosan nanocapsules as a nontoxic and non-
allergenic drug delivery vector in vitro using mouse P815 mast cells. 
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Chapter 2: Investigation of the mechanism of 
cytotoxicity and cytokine profile response to zinc 
oxide and titanium dioxide nanoparticles in the 
P815 mouse mast cell line 
 
2.1 Introduction  
Nanotechnology represents one of the most promising technologies of the 21st 
century. The applications of nano-materials have increased dramatically in recent 
years; they have been used in many commercial products such as sunscreens, 
cosmetics and antimicrobial agents (Choksi et al., 2010).   
 
To date, a variety of sunscreen and cosmetic formulations containing ZnO and 
TiO2 NPs have been made commercially available; these recent sunscreens are 
effective at filtering a broad spectrum of UV light from sunlight (Nohynek et al., 
2007). However, the possible toxic, immune and allergic consequences of 
exposure to these NPs are poorly characterised.  
 
Mast cells are essential in the regulation of immune responses, especially those at 
the surface of the skin and the respiratory system, due to their role in inflammatory 
and allergic reactions (Galli et al., 2008). Activation of mast cells through the cross-
linking of high-affinity IgE (FcεRI) receptors by multivalent antigens, or indirectly by 
chemical substances such as the calcium ionophore ionomycin, causes the 
activation of an intracellular signalling cascade, which leads to the release of 
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cytokines, chemokines and other inflammatory mediators that can result in an 
allergic response (Tkaczyk et al., 2006). Mast cells and basophils can act at many 
levels, some of which have undesirable outcomes; they produce Th2 type 
cytokines, such as IL-4, which can shift immune responses toward allergy (Galli et 
al., 2010). Investigation of the cytokine profiles produced in mast cells when they 
are stimulated in specific ways, may be a useful tool for predicting an allergic 
immune response.  
 
Several studies have been conducted on the toxicological impact of ZnO and TiO2 
NPs in vitro. They have reported that the cytotoxicity of these NPs was dependent 
on their physicochemical properties, such as particle size, shape, solubility, crystal 
structure, electrostatic charge, chemical composition, and surface area, as well as 
particle size distribution (agglomeration state and zeta potential) (Nel et al., 2006; 
Nair et al., 2008; Padmavathy & Vijayaraghavan, 2008; Yang et al., 2008; Jiang et 
al., 2009).  
 
Many studies have investigated the effect of particle size on cytotoxicity, but the 
research data are contradictory. Some researchers have found that smaller ZnO 
NPs caused greater cytotoxicity than larger particulates (Hanley et al., 2009; Feltis 
et al., 2011). In contrast, Deng and coworkers reported that ZnO NPs did not cause 
size dependent cytotoxicity (Deng et al., 2009). Likewise, other studies have found 
no prominent biological difference between TiO2 ultrafine and fine particles (Sayes 
et al., 2006; Kim et al., 2009). Consequently, the size dependency of cytotoxic 
responses is still unclear. 
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Both ZnO NPs and TiO2 NPs are metal oxide nanoparticulates, but ZnO NPs are 
known to have greater cytotoxicity than TiO2 NPs (Lin et al., 2009; Yang et al., 
2009; Hsiao et al., 2011).  The greater cytotoxicity of ZnO NPs could be related to 
solubility of ZnO and release of Zn2+ ions into cell culture media, whereas TiO2 NPs 
are insoluble (Burner et al., 2006: Deng et al., 2009; De Berardis et al., 2010). 
Interestingly, both of these NPs are able to generate ROS, which can induce cell 
death (Hussain et al., 2009). 
 
Nanoparticles in a biological matrix are always present in aggregates and 
agglomerates that are larger than single NPs (Schulling et al., 2010). There is 
some debate about the risk assessments of NPs, which are often done on 
aggregate forms (Nohynek et al., 2007; Hsiao et al., 2011; Taccola et al., 2011). It 
is therefore relevant to investigate the cytotoxic and immunological responses to 
both dispersed and aggregated forms of NPs. In addition, ZnO and TiO2 NPs in 
many sunscreen formulations are coated with surfactant materials, which keep NPs 
very well dispersed without aggregation in order to improve the UV filtering and 
transparent appearance on the skin. Therefore, NP risk assessments should take 
into account both aggregated and dispersed forms of these preparations (Faunce, 
2010). 
 
ZnCl2 or ZnSO4 has been used as a control for in vitro test systems for soluble Zn 
ions coming from ZnO NPs. Both ZnCl2 and ZnO NPs have similar cytotoxicity, 
which suggests that Zn2+ ions release from these NPs are responsible for cell 
death (Song et al., 2010). To date, there has been no clear definitive answer on the 
relative contributions to ZnO NP-induced cytotoxicity of the original ZnO NP form 
and subsequent “soluble” Zn2+.  
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Mast cells provide a good model for studying the allergic immune reactions induced 
by NP/immune cell interaction. However, few studies have looked at the potential 
effects of NPs on the cytokine release profiles of mast cells in vitro (Devouassoux 
et al., 2002; Sanchez et al., 2000). Furthermore, the specific effects of ZnO and 
TiO2 NPs on cytokine production from mast cells in vitro have not been 
investigated. 
 
The aims of the studies described in this chapter were to evaluate the effects of the 
size and dispersion state of ZnO NPs (using ZnCl2 as a control for Zn2+ ions), 
compared to two different crystalline forms of TiO2 NPs, on both the mode of action 
of cell toxicity and cytokine production, in non-activated and activated P815 mouse 
mast cells.   
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2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
Assay kits utilized CellTiter 96® AQueous Solution (MTS) (Promega, Madison, WI, 
USA), Annexin V / propidium iodide kit (Beckman-Coulter, Marseille, France), 
FlowCytomix Mouse Th1/Th2 10plex cytokine kit (Bender Medsystems, 
Butlingame, CA, USA) and IL-4 BD OptEIA ELISA Sets (BD OptEIA kit -BD 
Systems, Franklin Lakes, NJ, USA). Biochemicals included lipopolysaccharide 
(LPS), zinquin-ethyl ester and ionomycin calcium salt from Streptomyces 
conglobatus (Sigma-Aldrich, St Louis, USA), Flou-4 AM and 2,7-dichlorofluorescein 
diacetate (DCFDA) (Invitrogen, Carlsbad, CA, USA), phorbol myristate acetate 
(PMA) (Sapphire Bioscience, Redfern, NSW, Australia), and phosphate buffered 
saline. 
 
Cell culture media included RPMI-1640 with HEPES modification (Sigma-Aldrich, 
St Louis, USA), DMEM (Invitrogen, Carlsbad, CA, USA), glucose and 2-
mercaptoethanol (BDH, Merck, Kilsythe, VIC, Australia), pyruvate, L-glutamine, 
gentamycin and fetal bovine serum (FBS), (Sigma- Aldrich, St. Louis, MO, USA). 
 
2.2.2 Nanoparticles 
The nanoparticles and particulates (bulk form), with and without surfactant 
dispersant (polyacrylate copolymer, Orotan 731 DP), used in this study included: 
pristine zinc oxide at 30 nm, 80 nm and 200 nm (ZnO 30, ZnO 80, ZnO 200); 
surfactant-treated ZnO at 30 nm, 80 nm and 200 nm (sZnO 30, sZnO 80, sZnO 
200) (Micronisers Pty. Ltd. Melbourne, Australia); 34 nm rutile (TiO2 R) and 25 nm 
 47 
rutile/anatase (P25) titania (TiO2 P25) (Evonik Industries, Dandenong, VIC, 
Australia). 
2.2.3 Nanoparticle characterization  
2.2.3.1 Nanoparticle size analysis 
Nanoparticle size analysis was performed on a DC1800 disc centrifuge (CPS 
instruments, Stuart, FL, USA), with an RPMI-1640 media and sucrose gradient. 
Size distribution and agglomeration of nanoparticle suspensions were measured in 
RPMI-1640 media and RPMI-1640 media plus FBS. 
 
2.2.3.2 Electron Microscopy.  
Room temperature transmission electron microscopy (TEM) images were obtained 
on a Philips CM20 microscope at 200kv using a LaB6 filament. The samples were 
prepared by suspending the solid material in ethanol and placing a drop on a 
copper grid containing holey carbon film and then air dried.  
 
Cryo-TEM samples were examined using a Gatan 626 cryoholder (Gatan, 
Pleasanton, CA, USA) and Tecnai 12 Transmission Electron Microscope (FEI, 
Eindhoven, The Netherlands) at an operating voltage of 120 kV. At all times, low 
dose procedures were followed, using an electron dose of 8-10 electrons/A2 for all 
imaging. Samples were prepared on 300-mesh copper grids coated with lacy 
formvar-carbon film (ProSciTech, Townsville, QLD, Australia) that were glow 
discharged in nitrogen for 15 s prior to use. A laboratory built humidity-controlled 
vitrification system was used to prepare the samples for cryo-TEM. Humidity was 
kept close to 80% for all experiments and ambient temperature was 22°C. Aliquots 
(4 µL) of each sample were pipetted onto a grid. After 30 s adsorption time, the grid 
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was blotted manually using Whatman 541 filter paper, for between 2 and 10 s. 
Blotting time was optimized for each sample. The grid was then plunged into liquid 
ethane cooled by liquid nitrogen. Frozen grids were stored in liquid nitrogen until 
required. Images were recorded using a Megaview III CCD camera and analysis 
camera control software (Olympus, Munster, Germany) at magnifications between 
70,000x and 110,000x. 
 
2.2.4 Preparation of nanoparticles 
Each of the nanoparticles (ZnO30, sZnO30, ZnO80, sZnO80, ZnO200, sZnO200, 
TiO2 R, TiO2 P25) were weighed into pre-weighed sterile vials. Sterile water was 
then added to make a NP stock solution with a concentration of 20 mg/mL. The NP 
suspension was ultra-sonicated for 15 min and left to stand for 24 h, once the stock 
solution dropped below 1 mL volume, its use was discontinued. The stock solution 
was vortexed for 30 s and inverted 10-20 times, and then resuspended by pipetting 
up and down 3-5 times, before the desired volume of stock solution was added to 
the media to make the working solution. Dilutions were made by inverting the 
working solution 3-5 times, or until no particles were stuck to the bottom of the 
tube, and pipetting up and down 5 times, before the desired volume of the work 
solution was added to the media. A 100 µL volume of the dilutions (500, 200, 100, 
60, 20 and 2 µg/mL) was added to the 100 µL in control and cell-containing wells 
for a total volume of 200 µL/well. 
 
2.2.5 Cell culture 
All cell culture techniques were performed under sterile conditions in a class II 
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biohazard hood. Mouse P815 mast cells (American Type Culture Collection, 
Manassas, VA, USA) were cultured in RPMI-1640 media containing 10% v/v FBS 
with gentamycin, glucose, pyruvate, 2 mercaptoethanol and L-glutamine 
supplementation, and maintained in a humidified incubator at 37°C and 5% CO2. 
The cells had been frozen in FBS and 10% DMSO and stored in liquid nitrogen, 
prior to thawing at 37°C and culturing in cell growth media. Cells were maintained 
in 75 cm2 culture flasks containing media at 37°C and 5% CO2 in a Heraeus 
Instruments BB16 incubator. When cultures reached 8 x 105 cells/mL, a 1/10 
dilution of cells to media was added to a new 75 cm2 culture flask. 
 
2.2.5.1 Cells for NP exposure experiments 
Cells were centrifuged at 200 g for 5 min using a Heraeus benchtop centrifuge and 
re-suspended in fresh media to obtain a working cell suspension of 106 cells/mL. 
The working suspension was then added to the media in 96-well plates for a final 
concentration of 105 cells/well. 
 
2. 2.6 Cytotoxicity assays 
2.2.6.1 Cytotoxicity of ZnO and TiO2 NPs in RPMI-1640 complete media 
The P815 mast cells were centrifuged (200 g, 5 min) and re-suspended in fresh 
RPMI-1640 media plus 10% FBS before seeding in 96-well plates at 105 cells/well. 
These cells were incubated in quadruplicate wells of 96-well plates with a 
concentration range of NPs at 0, 10, 20, 30, 60, 100, 150 and 200 µg/mL in a 
humidified incubator (at 37°C and CO2). Cytotoxicity was measured at 24 h, and for 
kinetic study at 4, 8, 12 and 24 h, by adding a soluble tetrazolium salt (MTS, 
Promega, USA) to the wells 4 h prior to the measurement of the optical absorbance 
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(490 nm) using a microplate reader (Perkin Elmer EnSpire, Waltham, MA, USA). 
MTS was used to evaluate the mitochondrial function of cells and its reduction to a 
chromophore is proportional to the number of viable cells present in the wells. ZnO 
and TiO2 NPs, in the presence of MTS reagent alone, were measured to control for 
any optical density effects from the NPs; these values were subtracted from the 
experimental readings. Each experiment was repeated in triplicate and the average 
viability results with standard error of mean, calculated. The supernatant at the 20 
h time point was collected before adding MTS, and stored at -80°C for cytokine 
analysis. 
 
2.2.6.2 Cytotoxicity of ZnO and TiO2 NPs in DMEM complete media 
Mouse P815 cells were cultured and incubated with NPs in DMEM media plus 10% 
FBS. Cytotoxicity was measured as previously described in section 2.6.1. (all other 
experiments described in this thesis were performed in RPMI-1640 media plus 
10% FBS). 
 
2.2.7 Cytotoxicity of zinc dialysate from ZnO NPs 
2.2.7.1 ZnO NP solubility 
ZnO NPs were added to 5 mL of RPMI-1640 media in cellulose dialysis tubing 
(10,000 MW cut-off; Sigma-Aldrich, St Louis, USA) and dialysed for 24 h at 37°C 
into 30 mL of fresh RPMI-1640 media without FBS. Dialysates were collected and 
analysed for zinc ion content by inductively-coupled plasma atomic absorption 
spectroscopy (IPC-AAS) using a Perkin Elmer Model 1100 Atomic Absorption 
Spectrometer (Perkin-Elmer, Waltham, MA, USA). Calibration standards were 
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made from a zinc stock solution (1 mg/mL Zn, Spectrosol, VWR, Radnor, PA, 
USA). 
 
2.2.7.2 Cytotoxicity of Zn dialysate 
P815 cells were incubated with the dialysate of Zn (section 2.7.1) for 24 h in a 
humidified incubator (at 37°C and CO2). Cytotoxicity was measured as previous 
described in the section 2.6.1. 
 
2.2.8 Cytotoxicity of the Zinc precipitates. 
2.2.8.1 ZnCl2 precipitates in cell culture media.  
A solution of anhydrous ZnCl2 (2 g, 14.7 mmol) in water (3 mL) was thoroughly 
mixed with RPMI-1640 media (500 mL) or with media + 10 v/v% FBS giving a 
nominal [Zn] = 29.4 mM. Fluffy white precipitates formed rapidly. The mixtures 
were stirred briefly and the precipitates allowed to settle overnight. Most of the 
supernatant was carefully decanted and the remaining liquid containing precipitate 
was centrifuged, washed 3 times with water and dried in a vacuum oven at 40°C 
for 48 h. 
 
2.2.8.2 Cytotoxicity of the zinc precipitates  
P815 cells were incubated in quadruplicate wells and each of the following were 
added to separate wells: 1) ZnCl2 at 1-200 µg Zn/mL (from a [Zn] = 0.31 M stock 
solution); 2) washed and vacuum-dried Zn precipitate from RPMI-1640 plus 10% 
FBS; 3) freshly prepared Zn precipitate from RPMI-1640 plus 10% FBS; or 4) ZnO 
39 nm nanoparticles suspended in RPMI-1640; for a final concentration of 
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particulate/precipitate of 1-200 µg Zn/mL. Cytotoxicity was measured as previous 
described in the section 2.2.8.1. 
 
2.2.9 Measurement of intracellular level of zinc ions 
The intracellular level of zinc ions was estimated using the zinc-selective 
fluorophore, zinquin ethyl ester. P815 mast cells were incubated in triplicate wells 
of 96-well plates with a concentration range of ZnO NPs at 30 and 100 µg/mL, in a 
humidified incubator (at 37°C and CO2). Intracellular levels of Zn2+ ions were 
measured at the specific time points of 1, 4, 8 and 24 h by adding zinquin ethyl 
ester (25 µM) and the cells incubated for a further 30 min prior to analysis. Finally, 
the cells were washed twice in PBS and the fluorescence intensity measured at 
excitation/emission wavelengths of 364/485 nm, respectively, using flow cytometry 
(FACS Canto II, Becton Dickinson, Franklin Lakes, NJ, USA).The qualitative 
analysis of intracellular zinc ions was performed by fluorescence microscope 
(Olympus Optical Co. Ltd., Japan). 
 
2.2.10 Measurement of intracellular reactive oxygen species (ROS)  
The level of intracellular ROS generation was detected by the method of Wilson et 
al. (2002) using 2,7-dichlorofluorescein diacetate (DCFDA) dye. P815 mast cells 
were centrifuged (200 g, 5 min) and washed with PBS and resuspended in PBS. A 
100 µM of DCFDA was then added to the cells and incubated for 30 min in a 
humidified incubator (at 37°C and CO2). The cells were washed twice with PBS 
and resuspended in RPMI-1640 (phenol red free version; Sigma-Aldrich, St Louis, 
USA) plus 10% FBS and seeded in 96-well black opaque plates (Corning Life 
Sciences, USA) at 5 x 105 cells/well. A range of NP dilutions in RPMI-1640 (phenol 
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red free) medium were added to the cells in separate quadruplicate wells and 
incubated for 24 h. Fluorescence intensity was measured using a microplate reader 
and luminol chemiluminescence (Pierce Biotechnology, Rockford, IL, USA) at 
excitation and emission wavelengths of 485 and 528 nm, respectively. ZnO and 
TiO2 NP background in RPMI media was measured as to control for any optical 
density effects from the NPs; these values were subtracted from the experimental 
readings. Hydrogen peroxide was used as a positive control at concentration (400 
µM).The qualitative analysis of intracellular ROS generation was performed using 
confocal laser scanning microscopy (CLSM; Nikon, A1 Confocal Microscope, 
Tokyo, Japan). 
 
2.2.11 Mechanism of cell death 
Apoptotic and necrotic cell death mechanisms were detected using the Annexin 
V/propidium iodide kit (Invitrogen, Carlsbad, CA, USA). In brief, the cells were 
washed with PBS (centrifuged for 5 min at 500 g, 4°C) and the cell pellets 
resuspended in ice-cold 1x Binding Buffer to between 5 x 105 and 5 x 106 cells/mL. 
The positive control for necrosis was performed by growing the cells without FBS, 
while the apoptosis positive control was done by incubating the cells with 3% 
formaldehyde-containing PBS for 30 minutes on ice and then washed. Finally, 
Annexin V-FITC solution and propidium iodide were added to the cells. Following a 
15 min incubation period, the cells were analysed in triplicate wells using flow 
cytometry (FACS Canto II, Becton Dickinson, Franklin Lakes, NJ, USA). 
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2.2.12 Determination of ZnO and TiO2 NP cell uptake by 
synchrotron x-ray fluorescence microscopy 
P815 mast cells were seeded at 5 x 105 cells/well in 24 well plates containing a 
silicon grid in each well. The cells were incubated for 24 h with 30 µg/mL of ZnO 
NPs doped with 5% (w/w) cobalt (Co), TiO2 NPs or ZnCl2. 
 
P815 cells attached to the grid were taken from the culture and fixed with 2.5% 
glutaraldehyde in 0.1 M sodium cacodylate containing 2 mM CaCl2. These cells 
were then washed in 2 mM CaCl2 and 0.1 M sodium cacodylate in distilled water 
for 10 min. Postfixation was performed by immersion for 20 min in 1:1 osmium 
tetroxide (1% w/v) in 0.1 M sodium cacodylate with 2 mM CaCl2. The cells were 
washed in 0.1 M sodium cacodylate in distilled water for 10 min to remove residual 
osmium tetroxide from the surface of the cells. The cells were then dried and 
stored until synchrotron x-ray fluorescence microscopy (XFM) analysis. Intracellular 
ZnO and TiO2 NPs imaging were mapped at 300 nm resolution using x-ray 
fluorescent microscopy at the Australian Synchrotron, Victoria. 
 
2.2.13 Cytokine Profiling 
2.2.13.1 FlowCytomix Mouse Th1/Th2 10plex 
The frozen supernatant samples from culture medium of P815 cells exposed to 
NPs (section 2.6.1) were analysed by flow cytometry for levels of ten different 
cytokines using a FlowCytomix Mouse Th1/Th2 10plex kit (GM-CSF, IFN-γ, IL-1a, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, TNF-α; Bender MedSystems, Vienna, Austria). 
Samples were analysed in triplicate for two experiments. 
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2.2.13.2 IL-4 ELISA measurement 
P815 cells were seeded onto 96-well plates at 105 cells/well, and various 
concentrations of NPs (0, 10, 30 and 60 µg/mL) were added to the cells which 
were then stimulated with ionomycin (1 µM) plus PMA (20 nM) by co-incubation for 
24 h at 37°C. The supernatant from the 20 h time point was collected before 
adding MTS, and stored at -80 °C for IL-4 cytokine analysis. Enzyme-linked 
immunosorbant assay (BD OptEIA kit, BD Systems, Franklin Lakes, NJ, USA) was 
used to measure IL-4 in thawed cell supernatants. The absorbance at 450 nm was 
obtained using a microplate reader (Perkin Elmer EnSpire, Waltham, MA, USA), 
as per the manufacturer’s instructions. The spontaneous release of IL-4 (without 
the addition of the stimulants; ionomycin plus PMA) was also measured after 
incubating the P815 cells with range of NPs (0, 10, 30 and 60 µg/mL) for 24 h 
using the same procedure. 
 
NPs alone were titrated against IL-4 standard diluted in RPMI media, to investigate 
the possibility of IL-4 cytokine absorption or binding onto the NPs after the 24 h 
incubation. IL-4 standard in RPMI without NPs was used as the control. 
 
2.2.14 Statistical analysis 
All data in this study is expressed as the mean ± SEM of two to four experiments. 
Samples were analysed using three to four replicates within each experiment. 
Statistical analysis was performed using two-way ANOVA and Bonferroni post-hoc 
test by Graph Pad Prism for Windows version 5 (San Diego, CA, USA). Statistical 
significant differences were considered as having p values < 0.05. 
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2.3 Results 
2.3.1 Particle characterisation  
The ZnO NPs and TiO2 NPs used in this study were characterized by using TEM, 
cryo-TEM and disc centrifugation. Figure 2.1 shows TEM micrographs of ZnO 30 
and sZnO 30, TiO2 R and TiO2 P25. ZnO 30 and sZnO 30 displayed hexagonal 
particle morphology with an average particle size of approximately 30 nm. TiO2 R 
and TiO2 P25 were rectangular in shape and had average particle sizes of about 
40 nm and 20 nm, respectively.  
 
Figure 2.2 shows cryo-TEM micrographs of ZnO 30, ZnO 200, sZnO 30 in media 
(RPMI-1640) without serum after 24 h incubation. The ZnO 30 NPs formed 
agglomerates in media, whilst sZnO 30 NPs did not form strong agglomerates but 
stayed quite dispersed in media, as demonstrated in Figure 2.2 (A) and (B), 
respectively.  
 
It was difficult to evaluate the mean size and aggregation state of NPs based on 
TEM and cryo-TEM images alone. Therefore, a more accurate evaluation of the 
particle size distributions was attained using the disc centrifuge and dynamic light 
scattering (DLS) (Table 2.1). The disc centrifuge was used to characterise particles 
in media and serum after 24 h. Surfactant-treated NPs stayed well-dispersed (50-
100 nm), while pristine (untreated) NPs formed large agglomerations reaching up 
to 2 µm in size. These dispersion and agglomeration states of the NPs were further 
investigated for their cytotoxic and immunologic effects toward P815 mast cells. 
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Figure 2.1: TEM microscopy of (A) pristine ZnO 30, (B) surfactant-treated sZnO 
30, (C) titanium R, and (D) titanium P25. 
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Figure 2.2: Cryo-TEM micrograph of ZnO 30 (A), sZnO 30 (B) and ZnO 200 (C) in 
media (RPMI-1640) after 24 h incubation. 
A 
C 
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Table 2.1: Characterisation of ZnO NPs used in this study by disc centrifuge and 
DLS (adapted from Feltis et al., 2011).  
 
Particle  
Disc Centrifuge 
Agglomerate Size 
(mean [FWHM])  
Agglomerate 
Surface Area 
(m2/g)  
Primary 
Particle Size 
(nm)  
Primary 
Particle 
Surface Area 
(m2/g)  
ZnO 30  1.33 µm [0.68 – 1.98 µm]  0.80  DLS: 36 ± 6 nm  (TEM: 25 ± 7)  29.73  
ZnO 80  1.32 µm [0.65 – 1.32 µm]  0.81  DLS: 83 ± 8  12.90  
ZnO 200  1.29 µm [0.88 – 1.69 µm]  0.83  DLS: 200 – 500  3.06  
sZnO 30  75 nm [50 – 100 nm]  14.27  
 
 
sZnO 80  90 nm [50 – 130 nm]  11.89  
sZnO 200  460 nm [240 – 670 nm]  2.33  
FWHM = Peak full width at half maximum 
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2.3.2 ZnO NP solubility 
The dialysates collected after 24 h from ZnO NPs present at the highest 
concentration used for cytotoxicity testing (100 µg/mL), were analysed for zinc ion 
levels by ICP-AAS. Figure 2.3 shows that zinc ion release increased with time and 
was still ongoing after 24 hours (1440 min). The solubility of smaller ZnO NPs (ZnO 
30, 3.6 µg/mL; and sZnO 30, 2.8 µg/mL) were higher than for larger ZnO NPs (ZnO 
200, 1.9 µg/mL; and sZnO 200, 2.3 µg/mL). Surfactant-treated sZnO 30 NPs, 
which were very well dispersed in media, released more zinc ions (3.6 µg/mL) than 
untreated ZnO 30 NPs (2.8 µg/mL). This suggests that the surfactant coating 
around the ZnO 30 NPs may increase  zinc ion dissolution into the media.  
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
1 10 100 1000 10000
Time (min)
Zi
n
c 
io
n
 
re
le
as
e 
(µg
/ m
l)
ZnO 30
sZnO 30
ZnO 200
sZnO 200
 
Figure 2.3: Solubility of ZnO nanoparticles in RPMI-1640 media was measured 
over 24 h (1440 min) at 37 ºC with a concentration of 100 µg/mL. Dialysate 
collection was analysis using ICP-AAS (Mean ± SEM of two experiments in 
duplicate). 
 
 
 
1440 min 
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2.3.3 Cytotoxicity of ZnO and TiO2 NPs in RPMI-1640 and DMEM 
complete media 
MTS assays were used to assess the loss of cell viability by measuring the 
formation of a chromophore formazan product as an indicator for cellular 
mitochondrial dehydrogenase activity. Surfactant-treated ZnO NPs and untreated 
ZnO NPs and TiO2 NPs were tested for their effect on P815 mast cell viability, in 
either RPMI-1640 or DMEM media for 24 h. MTS data showed a dose-dependent 
cytotoxicity in all tested NPs (Figure 2.4). With concentrations up to 10 µg/mL, 
there was no cytotoxicity observed following exposure to any of the tested NPs, 
and therefore this concentration has been defined as a sub-toxic dose for all cell 
lines in this study. Cytotoxicity after exposure of mouse mast cells to ZnO NPs was 
dependent on particle size, surfactant coating, composition, concentration, 
exposure time and growth media (i.e. RPMI-1640 or DMEM).  
 
Mouse mast cells grown in RPMI-1640 media were more sensitive to ZnO NPs 
than those cells grown in DMEM media (Figure 2.5). The EC50 (effective 
concentration for 50% response) of ZnO 30 NPs and sZnO 30 NPs in RPMI-1640 
(EC50: 25 µg/mL and 28 µg/mL, respectively) were three to sixfold lower than for 
mouse mast cells that grown in DMEM media (EC50:168 µg/mL and 90 µg/mL) 
(Table 2.2).  
 
Smaller ZnO NPs caused more cytotoxicity than larger NPs. ZnO 200 particulates 
exhibited minimal cytotoxicity. In contrast, TiO2 NPs exhibited less cytotoxic effect 
than ZnO NPs in both RPMI-1640 and DMEM media (Figure 2.6 and Figure 2.7). 
Surfactant-treated NPs were equitoxic to untreated NPs on cells after 24h in RPMI-
1640. Interestingly, in cells cultured in DMEM, surfactant-treated NPs had 
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significantly increased cytotoxicity at 30 µg/mL of 70 ± 2% (p<0.01) when 
compared to untreated ZnO 30 NPs (EC50: sZnO 30, 90 µg/mL in RPMI media; 
and ZnO 30, 169 µg/mL in DMEM media).  
 
Cell viability was investigated over a time course in order to gather information on 
the kinetics of the ZnO NP-induced cytotoxicity. The mouse mast cells were 
incubated for 4, 8, 12 and 24 h with ZnO 30 and sZnO 30 NPs at concentrations of 
30 µg/mL and 100 µg/mL (Figure 2.8). These data illustrated that the cytotoxic 
effects became apparent at 12-24 h at the intermediate concentration of 30 µg/mL, 
but was earlier at between 8-24 h for the high concentration of 100 µg/mL. ZnO NP 
cytotoxicity in mouse mast cells increased over time, with surfactant-treated sZnO 
30 NPs causing slightly more cytotoxicity than ZnO 30 NPs at shorter exposure 
times (12 h) at a concentration of 100 µg/mL. This cytotoxic effect was not due to 
surfactant alone, which was confirmed to be not cytotoxic in the concentration 
range tested (Figure 2.6). 
 
 
In a parallel series of experiments to determine the potential role of “soluble” Zn 
species from ZnO NPs, each of the ZnO NPs samples were dialysed at a range of 
concentrations from the high toxic dose to a ten-fold higher dose (i.e. 100-1000 
µg/mL) and the dialysates examined for cytotoxicity. Interestingly, negligible 
dialysate cytotoxicity was observed from each of the ZnO NPs (Figure 2.9). 
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Figure 2.4: Cytotoxicity of untreated and surfactant-dispersed ZnO nanoparticles 
to P815 mouse mast cells in RPMI-1640 media after 24 exposure (Mean ± SEM of 
three experiments in quadruplicate).  
 
 
Figure 2.5: Cytotoxicity of untreated and surfactant-dispersed ZnO nanoparticles 
to P815 mouse mast cells in DMEM media after 24 exposure (Mean ± SEM of 
three experiments in quadruplicate). 
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Table 2.2: EC50 (µg/mL) of ZnO NPs over 24h in RPMI-1640 or DMEM cell culture 
media. 
 
EC50/24h ZnO 30 sZnO 30 ZnO 80 sZnO 80 ZnO 200 ZnCl2  
Mast cells grown 
in RPMI 
(Mean ± SEM) 
25 ± 2 28 ± 1 50 ± 2 65 ± 2 N/A 42 ± 3 
Mast cells grown 
in DMEM 
(Mean ± SEM) 
169 ± 2 90 ± 2 N/A N/A N/A 42 ± 5 
N/A = Non-cytotoxic.  
 
 
Figure 2.6: Cytotoxicity of TiO2 nanoparticles and the surfactant alone to P815 
mouse mast cells in RPMI-1640 media after 24 h exposure (Mean ± SEM of three 
experiments in quadruplicate). 
 
Figure 2.7: Cytotoxicity of TiO2 nanoparticles to P815 mouse mast cells in DMEM 
media after 24 h exposure (Mean ± SEM of three experiments in quadruplicate).  
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Figure 2.8: Cytotoxicity of untreated and surfactant-dispersed ZnO 30 nm 
nanoparticles to P815 mouse mast cells at different incubation times over 24 h, 
with a concentration of (A) 30 µg/ml and (B) 100 µg/mL (Mean ± SEM of three 
experiments in quadruplicate). 
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Figure 2.9: The viability of P815 mast cells exposed to Zn dialysate from ZnO NPs 
at a concentration range from 1-1000 µg/mL for 24 h exposure (Mean ± SEM of 
two experiments in quadruplicate). 
 
2.3.4 Reaction of ZnCl2 precipitates in cell culture media 
When solutions of ZnCl2 were added to RPMI-1640 media alone or to mixtures of 
media with 10% v/v FBS at a final Zn concentration of 30 mM, a flocculent white 
precipitate rapidly formed (a similar precipitate was also visible when the same 
concentration of Zn was added to DMEM, though we have not examined the 
DMEM precipitate in this study). Dialysis of these reaction mixtures showed that Zn 
was only minimally soluble in either media (2.8 ±1 µM) or pure FBS (12 ± 2 µM). 
Table 2.3 shows that the equilibrium concentration of Zn species in both the media 
and media/FBS, sufficiently small to pass through a 2 kDa membrane, was less 
than 0.5% of the corresponding [Zn] level in water alone. Based on the 
components present in RPMI-1640 media, the predominant anions present are 
carbonate (24 mM) and phosphate (5.6 mM), which will most likely form insoluble 
precipitates with added Zn2+.  
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Transmission electron micrographs of the cryo-vitrified amorphous precipitate 
obtained from the addition of ZnCl2 to RPMI-1640 cell culture media ([Zn] = 150 
µM) showed 10 - 50 nm sized clusters of featureless particles (Figure 2.10). Zinc-
containing nanoparticles of shell-like morphology (~40 nm) were  observed in dried 
samples isolated from RPMI cell culture media, both with or without added FBS, or 
in neat FBS, at an initial [Zn] of 30 µM (Figures 2.11 a and c) and fused 
nanometre-sized agglomerates at a higher [Zn] of 150 µM (Figure 2.11b). 
 
 
Table 2.3: Solubility of ZnCl2 in water, media and media + FBS using dialysis. 
Phase [Zn] (µM in dialysate) % Zn remaining in solution 
Water 2436 ± 20 ~95% 
RPMI-1640 2.8 ±1 0.11% 
RPMI-1640/FBS (10% v/v) 12 ± 2 0.47% 
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Figure 2.10: Cryo-TEM of amorphous precipitate obtained from RPMI-1640 cell 
culture media with ZnCl2 added, [Zn2+] = 150 µM. 
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Figure 2.11: TEM of the dried amorphous precipitates obtained from a) RPMI cell 
culture media with ZnCl2 added [Zn] = 29.5 mM , b) RPMI cell culture media with 
ZnCl2 added, [Zn] = 0.15mM, c) amorphous precipitate obtained from FBS with 
ZnCl2 added. 
 
 
 
B 
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2.3.5 Cytotoxicity of the zinc precipitates 
The following is an examination of the cytotoxicity of amorphous precipitate, (zinc-
containing NPs) that was obtained from the addition of ZnCl2 to RPMI-1640 media.  
 
P815 cells in RPMI-1640 + 10% v/v FBS, were exposed to the precipitate via 
increasing concentrations of (a) ZnCl2, (b) isolated and dried Zn precipitate or (c) 
an isolated form of the Zn precipitate that had been washed but not dried. This was 
compared to the cytotoxicity of 30 nm ZnO NPs. The cytotoxicity of the Zn species 
from the added ZnCl2 solution was slightly less than that seen for 30 nm ZnO NPs 
(EC50 of ZnCl2  (50 µg/mL), which was two-fold lower than the EC50 of ZnO 30 
NPs (25 µg/mL), whereas both the isolated/washed, and the washed and 
subsequently dried Zn precipitates were at least seven-fold  less cytotoxic (i.e. 
when comparing concentrations causing a 20% decrease in cell viability, i.e. the 
EC20 values) (Figure 2.12). 
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Figure 2.12: The viability of P815 mast cells exposed to 30 nm ZnO nanoparticles, 
zinc added directly as zinc chloride or the isolated non-dried and dried precipitates 
from media dosed with the equivalent concentration of zinc chloride for 24 h (Mean 
± SEM of three experiments in quadruplicate). 
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2.3.6 Intracellular level of Zinc ions 
The increase in intracellular Zn ion levels were measured after exposure of cells to 
ZnO NPs by the zinquin ethyl ester fluorescent probe. Fluorescence microscopy 
images showed increases in the intracellular concentration of zinc in P815 mast 
cells treated with ZnO NP and ZnCl2 for 24 h, compared to a negative control 
(Figure 2.13). Within any given ZnO NP-treated cell population, two sub-
populations were observed when cells were examined by flow cytometry (Figure 
2.14). These P1 and P2 populations (Figure 2.15 and Figure 2.16), had higher zinc 
levels than negative controls (cells not treated with NPs). The cells in population P1 
had higher intracellular zinc levels than the P2 population. This suggests that cells 
in population P1 were more sensitive to activation by the high level of ZnO NPs 
and had undergone apoptosis or necrosis, which led to the change in their position 
on the scatter plot. The P1 population showed a time-dependent (Figure 2.15) and 
dose-dependent (Figure 2.17) elevation in zinc ion levels when cells were exposed 
to ZnO NPs and ZnCl2. Surfactant-treated and untreated ZnO 30 NPs appeared to 
equally increase the intracellular zinc ion levels in the P1 population. Whereas, 
surfactant-treated sZnO 30 NPs had a greater intracellular zinc ions than untreated 
ZnO 30 in cells of the P2 population. Smaller ZnO NPs caused a greater increase 
in intracellular zinc ion levels than larger NPs in both cell populations (both P1 and 
P2). 
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 Figure 2.13: Photomicrographs showing the intracellular distribution of zinc using 
the Zinquin ethyl ester dye in P815 mast cells; control cells (“Cells”), cells exposed 
to ZnO 30, sZnO 30, ZnO 200, sZnO 200 and ZnCl2 at 30 µg/mL for 24 h. 
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Figure 2.14: Flow cytometry plot (Forward scatter (FSC) vs Side scatter (SSC)) of 
P815 mast cells after incubation with ZnO NPs at various times show two 
populations (in this case after 8 h); P1 and P2. Nanoparticles and cell debris in 
black colour were situated far from these cell populations.  
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Figure 2.15: Effect of ZnO NPs on intracellular zinc ion levels in P815 mast cells 
after exposure to 100 µg/mL NPs for 1, 4, 8 and 24 h (population P1). Data 
represented as mean ± SEM of two experiments in triplicate. 
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Figure 2.16: Effect of ZnO NPs on the intracellular zinc ion levels in P815 mast 
cells after exposure to 100 µg/mL NPs for 1, 4, 8 and 24 h (population P2). Data 
represented as mean ± SEM of two experiments in triplicate. 
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Figure 2.17: Effect of ZnO NPs on intracellular zinc ion levels in P815 mast cells 
after exposure to two different concentrations (30 and 100 µg/mL) of NPs at a 
specific time point (8 h, population P1). Data represented as mean ± SEM of two 
experiments in triplicate. 
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2.3.7 Intracellular reactive oxygen species (ROS) 
The production of intracellular ROS was estimated by using DCFDA, which is a 
non-fluorescent dye that is absorbed by cells and hydrolyzed by esterases to 
produce DCFH. DCFH is then oxidized to the fluorescent dichlorofluorescein (DCF) 
product by intracellular ROS; consequently, fluorescent intensity levels are 
proportional to the intracellular generation of ROS. 
  
The effects of surfactant-treated ZnO NPs, untreated ZnO NPs and TiO2 NPs on 
intracellular ROS production in P815 mast cells were investigated after a 24 h 
incubation. Confocal laser scanning microscopy (CSLM) images showed a rise in 
intracellular ROS in P815 mast cells treated with ZnO NP and ZnCl2 after 24 h, 
compared to the negative control (Figure 2.18). There was a dose-dependent ROS 
production seen with exposure of the cells to all tested ZnO NPs and ZnCl2 (Figure 
2.19). In contrast, TiO2 NPs did not induce ROS production. Smaller ZnO NPs 
caused more ROS production than the larger NPs. Even though surfactant-treated 
NPs were equitoxic to untreated NPs at concentrations of 10 and 60 µg/mL, 
untreated ZnO 30 NPs caused slightly more ROS generation at a concentration of 
30 µg/mL than the surfactant-treated sZnO 30.  
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Figure 2.18: Photomicrographs showing the generation of intracellular reactive 
oxygen species (ROS) using DCFDA dye in P815 mast cells, (A) control cells; (B-
H) cells exposed to ZnO 30, sZnO 30, ZnO 200, sZnO 200, ZnCl2, titanium R and 
titanium P25 respectively at 60 µg/mL for 24 h. 
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Figure 2.19: Effect of ZnO and titania NPs on the generation of intracellular ROS 
in P815 mast cells after exposure to 10, 30 and 60 µg/mL NPs for 24 h. The ROS 
generation of unexposed control cells was considered to be 100%. Data represents 
mean ± SEM of three experiments in quadruplicate. 
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2.3.8 Mechanism of cell death 
The mechanism of cell death was estimated by flow cytometry via the Annexin-V 
and propidium iodide fluorescence kit, which is capable of measuring early 
apoptosis and necrosis. This kit is not suitable in differentiating the late apoptosis 
stage from necrosis (which can result in inflammatory responses). The cell-death 
pathways for P815 mast cells exposed to sZnO 30 NPs, ZnO 30 and ZnCl2 showed 
an increase in both necrosis and apoptosis compared to control cells (unexposed 
cells alone). ZnO NPs also induced more cell death by necrosis or late apoptosis, 
than early apoptotic pathways (Figure 2.20). 
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Figure 2.20: Mechanism of cell death in P815 mouse mast cells after 24 h 
exposure to 30 µg/mL of untreated ZnO 30, surfactant-treated sZnO 30 NPs, and 
ZnCl2 NPS (Data represents mean ± SEM of two experiments in triplicate). 
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2.3.9 Synchrotron x-ray fluorescence microscopy cell imaging 
Synchrotron imaging was performed to measure the distribution of ZnO NPs doped 
with cobalt, and TiO2 NPs, into P815 mast cells. ZnO NPs were doped with cobalt 
to differentiate ZnO in the NP crystalline lattice from the endogenous Zn present 
inside the cells. As cells contain only tiny amounts of Ti, such dual-labelling is not 
necessary to confirm the detection of intact TiO2 NPs in intracellular compartments. 
Images are generated from the fluorescence signal produced by the excitation of 
the atoms in the sample with x-rays. As calcium was present throughout the entire 
cell, it was used as a cytoplasmic marker in the target cells. Elemental analysis and 
mapping of Zn and Co, or Ti, was then used to determine the presence and 
location of NPs within the cells. Figure 2.21 illustrates synchrotron images of ZnO 
NPs doped with Co, and TiO2 NPs, up taken by the P815 cells. However, in this 
study the positive control ZnCl2 did not increase the intracellular fluorescence 
intensity. 
 
2.3.10 Cytokine profiling 
The cytokine production profiles from P815 mast cells when exposed to NPs were 
screened using the FlowCytomix Mouse Th1/Th2 10plex kit. This kit contained 10 
cytokines including Th1 cytokines (IL-2, and IFN-γ), Th2 cytokines (IL-4, IL-5, IL-6 
and IL-10) and proinflammatory cytokines (GM-CSF, IL-1a, IL-17 and TNF-α). The 
cytokine profiles were measured at both a sub-cytotoxic dose (10 µg/mL) and a 
cytotoxic dose approximating the EC50 (30 µg/mL for ZnO 30 and sZnO 30).  
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Figure 2.21: Synchrotron imaging shows ZnO NPs doped with Co, and TiO2 NPs, 
internalized within P815 mast cells, (A) untreated cells, (B) ZnCl2 (positive control), 
(C) ZnO NPs doped with Co, (D) TiO2 NPs.  
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Figure 2.22 illustrates that ZnO and TiO2 NPs did not stimulate expression of any 
of these 10 cytokines, compared to the negative control (cells alone: measuring 
spontaneous release of cytokines). Whereas the positive control (PMA plus 
ionomycin) increased production of IL-4, IL-6, IL-5 and TNF-α. LPS was also used 
to simulate inflammatory cytokines, but it did not have a stimulatory effect in P815 
mast cells. The other six cytokines (GM-CSF, IFN-γ, IL-1α, IL-2, IL-10, IL-17) were 
not expressed by the NPs or the stimulatory agents (data not shown). Smaller ZnO 
NPs at a concentration of 30 µg/mL caused greater IL-4 and IL-6 suppression (200 
pg/mL and 400 pg/mL, respectively) when compared to control cells (IL-4: 900 
pg/mL and IL-6: 1200 pg/mL).  
 
To confirm that the observed effect of ZnO NPs on IL-4 suppression was not due to 
NPs binding to assay components or cell death, a more sensitive IL-4 ELISA assay 
was performed at a sub toxic dose that did not alter the assay by binding IL-4 (10 
µg/mL). This was confirmed by incubation of NPs alone with IL-4 standard dilution 
in RPMI-1640 cell culture media and compared to control (without NPs) - all NPs at 
a concentration of 10 µg/mL did not cause any alterations in the IL-4 standard 
curves. Surfactant-treated ZnO NPs had greater binding or adsorption to IL-4 at a 
concentration of 60 µg/mL, compared to the pristine NPs (Figure 2.23). 
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Figure 2.22: Multiplex cytokine profile of unstimulated mast cells exposed to ZnO 
and TiO2 nanoparticles, (A) small ZnO NPs induced IL-4 and (B) IL-6 inhibition, (C 
and D) TNF-α and IL-5 were only seen in the positive control . Data represents 
mean ± SEM of two experiments in triplicate. 
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Figure 2.23: Shows possible ZnO and TiO2 NPs binding or adsorption to the IL-4 
standard after incubation for 24 hr at 37°C (Data represents mean ± SEM of two 
experiments in triplicate). 
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The inhibitory effect of ZnO NPs on IL-4 release was investigated in both 
unstimulated P815 mast (i.e. spontaneous release of IL-4) and PMA+ionomycin-
activated P815 cells after a 24 h exposure to NPs. The sZnO30, ZnO30 and 
ZnO200 particulates had significant inhibitory effects (p<0.05) on IL-4 release in 
PMA plus ionomycin-stimulated P815 mast cells, while TiO2 NPs did not 
demonstrate any inhibition of IL-4 response (Figure 2.24). There were no 
significant inhibitory effects on IL-4 release from inactivated mast cells after 
exposure to both ZnO and TiO2 NPs (Figure 2.25). 
 
 
Figure 2.24: Inhibitory effects of ZnO NPs on IL-4 release from PMA+ ionomycin-
activated P815 cells after 24 h of exposure to sub-toxic doses of ZnO and TiO2 
NPs (cell viability was 100% of control). Data represents mean ± SEM of two 
experiments in triplicate. 
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Figure 2.25: Inhibitory effect of ZnO NPs on IL-4 release from unstimulated P815 
cells after 24 h of exposure to NPs. Data represents mean ± SEM of two 
experiments in triplicate. 
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2.4 Discussion 
To the best of my knowledge, there are no published investigations of following 
studies: 
• Cytotoxic effects of ZnO and TiO2 NPs in P815 mast cells; 
• Comparing the cytotoxicity of ZnO NPs in two different states (agglomerated 
and dispersed) in P815 mast cells; 
• Comparing the cytotoxicity of ZnO NPs in two different types of cell culture 
media (DMEM and RPMI-1640);  
• Precipitation of ZnCl2 in RPMI-1640 culture media forming Zn nanoparticles;   
• Using synchrotron x-ray fluorescence microscopy to determine cellular 
uptake of ZnO and TiO2 NPs; and 
• ZnO NP inhibition of IL-4 production from activated P815 mast cells. 
 
In this study the possible modes of action of ZnO and TiO2 NPs were investigated. 
Figure 2.26 illustrates some of the possible mechanisms by which ZnO NPs may 
induce cytotoxicity. This mode of cell death may be related directly to the size, 
composition and dispersion of ZnO NPs, which may be taken up by cells via 
different pathways, for instance phagocytosis and endocytosis. Indirect cytotoxicity 
can occur through Zn ion release from ZnO NPs into the culture media outside the 
cells (extracellular) or alternately, ZnO NPs may be taken up and then dissolved 
inside the cells (intracellular) – both of these mechanisms would result in a high Zn 
ion concentration that can then damage the cells. The other possible mechanism is 
due to Zn ion interaction with carbonate and phosphate anions in the media to form 
insoluble precipitates, which may directly result in cell toxicity. ZnO NPs or Zn ions 
may also induce ROS generation which can result in cell death. Furthermore, the 
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ZnO cytotoxicity profile may be dependent on the cell type (e.g. immune or 
epithelial cells, adherent or non-adherent cells, cancer or non-cancerous cells), 
which is explored further in chapters three and four. 
 
In this study, P815 mouse mastocytoma cells were chosen because they represent 
a good model to investigate immunotoxic effects. For instance, these cells are non-
adherent cells, which make them easy to manipulate and analyse by flow 
cytometry, and these cells are also known to produce Th1 and Th2 cytokines, 
including IL-4 and IFN-γ. However, in this study P815 mast cells did not respond 
like primary mast cells to stimulation by IgE, and then challenge with multivalent 
antigens or the chemical substance ionomycin, to enable measurement of mast cell 
activation and degranulation, e.g. using as β-hexosaminidase and histamine 
release.  
 
2.4.1 Cytotoxicity of ZnO and TiO2 nanoparticles 
Several studies in mammalian cells have confirmed that ZnO NPs caused 
cytotoxicity in a variety of epithelial and immune cell types, such as human BEAS-
2B bronchial epithelial cells (Huang et al., 2010), human A549 lung epithelial cells 
(Karlsson et al., 2008; Lin et al., 2009; Horie et al., 2009), mouse RAW 264.7 
macrophages (Xia et al., 2008) and human T lymphocytes (Reddy et al., 2007; 
Hanley et al., 2008). A cytotoxic dose response was observed in each of these cell 
lines, with ZnO NPs exhibiting a more significant cytotoxicity profile than TiO2 NPs 
(Lin et al., 2009; Yang et al., 2009; Hsiao et al., 2011). Surprising, there are no 
published reports of cytotoxicity studies of ZnO and TiO2 NPs in mast cells.  
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Figure 2.26: Schematic outline of zinc oxide nanoparticle-induced cytotoxicity.  
 
 
 
 
 
 
 89 
The present study investigated the cytotoxicity, ROS, apoptosis and cytokine 
profiles in the P815 mouse mast cells of pristine and surfactant-treated ZnO at 30, 
80 and 200 nm, ZnCl2, titania rutile at 34 nm and rutile/anatase at 25 nm.  
 
The cytotoxicity experiments showed that a dose-dependent cytotoxicity was 
observed for all tested NPs (Figure 2.4 and 2.5). Mouse mast cells grown in RPMI-
1640 media were more sensitive to ZnO NPs than those grown in DMEM media 
(Table 2.2). Surfactant-treated ZnO 30 NPs were equitoxic to uncoated NPs in the 
P815 cells after 24 hr in RPMI-1640 media. However, surfactant-treated ZnO 30 
NPs had higher cytotoxicity in P815 cells than untreated ZnO 30 NPs in DMEM 
media. This difference can be assigned to the increased permeability of surfactant-
treated ZnO NPs into the P815 cells with slow growth log phase in DMEM, 
whereas the P815 cell in RPMI media with fast growth rate, may be able to uptake 
equally high amount of both surfactant treated and untreated ZnO 30 NPs which 
caused equitoxic effects. Similar conclusions have been reach in previous studies, 
for example, Taccola et al. (2011) found that the mechanism of ZnO NPs 
cytotoxicity might relate to the cell proliferation rate. Another possibility is that the 
different concentration of carbonate and phosphate anions present in RPMI-1640 
and DMEM media have an effect on the state of the particles in media. Sodium 
bicarbonate and sodium phosphate concentrations in RPMI-1640 are 200 and 80 
mg/L, respectively, while their concentrations in DMEM are 3700 and 125 mg/L, 
respectively. These differences may have differing effects on the solubility of ZnO 
NPs altering their cytotoxicity.  
 
Cytotoxicity of ZnO NPs was also dependent on the size of the NPs. Smaller ZnO 
NPs (30 nm) caused more cytotoxicity than the larger particulates (200 nm). This 
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study clearly confirmed that altering the size of ZnO particles has a great impact on 
their cytotoxicity. Figure 2.5 showed that the cytotoxicity of ZnO NPs were 
increased in the following order; 30 nm > 80 nm > 200 nm. This can result from 
increased uptake of smaller NPs by mast cells in comparison to larger particles, 
increasing the exposure of cells to the smallest nanoparticles with a larger surface 
area relative to mass and greater dissolution rate.  These results were in 
agreement with previous studies (Reddy et al., 2007; Hanley et al., 2008; Nair et 
al., 2009) that revealed ZnO NPs had greater cytotoxicity than ZnO microparticles. 
However, Lin et al. (2009) and Deng et al. (2009) found that small and large NPs 
had similar cytotoxicity, suggesting that small NPs formed aggregates that had 
similar sizes to larger particles and therefore caused similar cytotoxicity. To 
eliminate the effect of aggregation, well-dispersed surfactant-treated ZnO NPs 
were employed in this study (Table 2.1), and the cytotoxicity of these surfactant-
treated ZnO particles have shown a clear size dependency in the following order: 
sZnO 30 nm > sZnO 80 nm > sZnO 200 nm, confirming that ZnO nanoparticles are 
more cytotoxic as they decrease in size.  
 
Overall, TiO2 NPs (1-250 µg/mL) exhibited low cytotoxicity in both RPMI-1640 and 
DMEM culture media (Figure 2.6 and Figure 2.7). TiO2 NPs are insoluble and may 
require a very high dose to initiate cell biological change. Sayes et al. (2006) 
illustrated that the dose of TiO2 NP required for observing cytotoxicity and change 
in the biological function of human dermal fibroblasts cells is around 1500 µg/mL. 
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2.4.2 The role of dissolved zinc ion in the cytotoxicity of ZnO 
nanoparticles 
To investigate the role of extracellular zinc ions in the cytotoxicity of ZnO NPs, 
each of the ZnO NPs samples were dialysed at a range of concentrations from a 
high toxic dose to an above toxic dose (100 -1000 µg/mL) for 24 h at 37°C. Cells 
were then exposed to the dialysates for 24 h and examined for cytotoxicity. 
Negligible dialysate cytotoxicity was observed from each of the ZnO NPs (Figure 
2.9). This suggests that the solubility of ZnO NPs in cell culture was very low and 
that the soluble Zn ions in solution were not at sufficient concentration to induce 
cytotoxicity. Therefore, the cytotoxicity of ZnO NPs may require direct contact of 
ZnO NPs with the cells. Moos et al. (2010) also reported that direct nanoparticle to 
cell contact was required for toxicity. However, Song et al. (2010) found that 
dissolved zinc ions in the supernatant severely inhibited cell viability. However, 
they isolated the ZnO NPs (10 nm) from supernatants by centrifuging the sample at 
20,000 rpm for 30 min, a speed that may still allow some of 10 nm NPs to remain in 
the supernatants, which may cause cytotoxicity.  
 
In the current study, the ZnO NPs cytotoxicity were compared to the direct 
cytotoxicity of a similar concentration of Zn2+ (ZnCl2). This was done to investigate 
if the mechanism of cytotoxicity may be attributed to solubilized Zn2+ ions in culture 
media. Small ZnO NPs (30 nm) had higher cytotoxicity that was closer to that of 
zinc ions (EC 50: ZnO 30, 25 µg/ mL; and Zn2+ ions, 42 µg/ mL) in RPMI-1640. 
Therefore, Zn2+ ions are highly likely to contribute to the cytotoxic response of ZnO 
NPs. The cytotoxicity caused by ZnCl2 and ZnO NPs is reported as very similar, 
which has lead to the suggestion that Zn dissolved from these nanoparticles is the 
main contributor to their cytotoxicity (Song et al., 2010). 
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The addition of Zn2+ ions to cell culture media may also result in the formation of 
insoluble Zn species. Some very recent work has suggested that the solubility of 
ZnO NPs varies with different media solutions, and that precipitates do indeed form 
in some of these solutions (Reed et al., 2012). Most cell culture media used in 
biological studies (e.g. RPMI-1640) contain large concentrations of carbonate and 
phosphate anions, which are known to form insoluble precipitates with Zn2+. 
Interestingly, when ZnCl2 was used as a control for a ZnO solubility experiment in 
RPMI-1640, only a minute fraction (2.8 µM) of the Zn passed through a dialysis 
membrane. This initial finding then led to studying the precipitation of Zn under 
biological conditions. Examination of these precipitates showed them to consist of 
amorphous ~30 nm nanoparticles (Figure 2.11). However, both the 
isolated/washed and the washed and subsequently dried Zn precipitates were at 
least seven-fold less cytotoxic than ZnO 30 nm (Figure 2.12). It may be that Zn2+ 
interacts with carbonate and phosphate anions in culture media, which then forms 
an insoluble precipitate that protects the cells from Zn ion damage.  
 
Further information can be gained on how this precipitate interacts with cells by 
investigating the effect of the Zn precipitate on intracellular Zn ion levels. 
It is also very important to know that the cytotoxicity of ZnO NPs is due to 
intracellular release of Zn ions. Therefore, the contribution of intracellular zinc ions 
to the cytotoxicity of ZnO NPs was investigated by exposing the cells to ZnO NPs 
or ZnCl2 and measuring the signal from the zinquin ethyl ester fluorescence probe. 
In this study, for all ZnO NP-treated cells, higher zinc levels relative to the negative 
control were observed (Figure 2.15 and Figure 2.17). Moreover, the increased level 
of zinc ions was dependent on NP size, the concentration of ZnO NPs, and time 
period of incubation. These three factors were correlated to MTS data for 
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cytotoxicity effects of ZnO NPs. The study indicated that the increase in 
intracellular solubilized zinc ion concentration may be an important factor in cell 
death. Therefore, the finding of this study suggested that small ZnO NPs are 
readily taken up by the cells, and inside the lysosomes (with their low pH), the ZnO 
NPs are easily dissolved to Zn ions that damage cell membranes and other cell 
components. Some of these ZnO NPs may also escape into the cytoplasm and 
cause further damage to cell organelles, mitochondria and the nucleus. Similar 
results have been reported by Taccola et al. (2012) who found that the hydrolysis 
of ZnO NPs to zinc ions within the lysosomes and their release into the cytosol 
resulted in cell damage. Further techniques are required to visualise the ZnO NP 
distribution inside the cells. 
 
2.4.3 Generation of intracellular reactive oxygen species (ROS) 
It has been suggested that the mechanism of cytotoxicity at high concentrations of 
ZnO NPs is their dissolution into soluble Zn2+ and the subsequent induction of 
direct or indirect oxidative stress via killing the cells (De Berardis et al., 2010; 
Sharma et al., 2011; Taccola et al., 2011). TiO2 NPs also generate free radicals 
(Hirakawa et al., 2004), which may damage DNA by oxidation, nitration, 
methylation or deamination reactions (Schins and Knaapen, 2007). The 
intracellular ROS data in the present study demonstrated that a dose-dependent 
ROS production was observed in all tested ZnO NPs and ZnCl2 (Figure 2.19). In 
contrast, TiO2 NPs did not induce ROS production, suggesting that the dose or 
crystalline form of the TiO2 NPs used in this study may not be sufficient to induce 
ROS. Smaller ZnO NPs caused more ROS production than larger NPs. Correlation 
of the ROS, intracellular Zn ions and MTS data showed that ZnO NPs caused an 
increase of ROS generation, combined with an increase of intracellular Zn ions and 
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a decrease in cell viability. This suggests that ZnO NPs entering the cell leads to 
increasing intracellular Zn ion levels, as well as some ZnO NPs escaping in 
cytoplasm. Both the increase of intracellular Zn ions and movement of ZnO NPs 
into the cytoplasm, stresses the cells to generate ROS, as well as damage the 
mitochondrial, which can result in cell death. Thus, intracellular ROS may be 
generated as a consequence of cell death, but not from ZnO NPs directly.  
 
2.4.4 Mechanism of cell death  
Cell death occurs through apoptosis or necrosis. Apoptotic mechanism 
(programmed cell death) involves cell degradation without inflammation, whereas 
necrosis occurs through the release of pro-inflammatory factors that attract other 
immune cells and causes inflammation.   
 
The effect of ZnO NPs on cell membrane damage (necrosis) was measured via 
permeability of cells to propidium iodide. Annexin V-FITC binds to the membrane 
phosphatidylserine (PS) that is expressed on the surface of the apoptotic cells. 
Therefore, the Annexin V-FITC flow cytometric assay was performed to assess cell 
death via apoptosis.  
 
In this study, the sZnO 30 NPs, ZnO 30 NPs and ZnCl2 showed an increase in 
necrosis and apoptosis compared to the controls (cells alone). ZnO NPs induced 
higher levels of necrosis than apoptosis (Figure 2.20).  This could be the result of 
either: the late apoptotic cells, which could not be differentiated from necrotic cells; 
or high doses of ZnO NPs overwhelming apoptotic processes and thereby inducing 
a greater degree of necrosis than apoptosis. In addition, the incubation of the cells 
with ZnO NPs for 24 h may result in the early apoptotic signal being missed if the 
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cells began apoptosis relatively early after exposure. Therefore, kinetic 
investigation at earlier incubation time points for ZnO NP exposure of cells (for 1, 2, 
4, 8 and 24 h) can give a better understanding of the relationship between cell 
death by apoptosis and necrosis. There are conflicting results from different studies 
regarding the mechanism of cell death induced by ZnO NPs. On one hand, De 
Berardis et al. (2010) and Lai et al. (2008) found that the apoptotic pathway was 
predominant. On the other hand, Hackenberg et al. (2010) reported that ZnO NPs 
induce cell death primarily by necrosis.  
 
2.4.5 Visualisation of ZnO and TiO2 NPs by synchrotron X-ray 
fluorescence microscopy 
Synchrotron x-ray fluorescence was used to detect the distribution of intracellular 
ZnO and TiO2 NPs in P815 mast cells. Whilst this was a preliminary result, ZnO 
and TiO2 NPs appeared to be taken up by the cells and distributed in the cytoplasm 
(Figure 2.21). However, this technique alone cannot confirm that the NPs are not 
merely attached to the cell surface. Therefore to confirm this result, further study 
will be required, employing x-ray tomography or focussed ion-beam ablation to 
confirm that the NPs are within the cytoplasm. 
  
2.4.6 Effects of ZnO and TiO2 NPs on the cytokine profiles of P815 
mast cells 
Studying the cytokine profiles provides very important information about the 
changes in the immune responses when a stimulus is applied to a cell system 
(immune stimulation and/or inhibition). Some reports suggested that NPs are 
capable of inducing cytokine production in vitro (Scholer et al., 2002; Fifis et al., 
2004; Vallhov et al., 2006; Mottram et al., 2007). For instance, carbon nanotubes 
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(CNTs) can promote allergic responses (Nygaard et al., 2009). In contrast, inhaled 
multiwalled carbon nanotubes (MWCNT) caused systemic immune suppression in 
a mice model (Mitchell et al., 2009). 
 
The multiplex cytokine profiles in the present study (Figure 2.22) showed that ZnO 
and TiO2 NPs did not provoke immunological responses for the ten cytokines 
investigated. However, inhibition of IL-4 and IL-6 by ZnO NPs was detected. The 
IL-4 cytokine is one of the main cytokines that is responsible for Th2 responses 
(Devouassoux et al., 2002). Therefore, more sensitive IL-4 ELISA assays were 
performed at a sub-toxic and sub-binding dose (10 µg/mL) of ZnO NPs (Figure 
2.24) to confirm our findings about the immuno-inhibitory effects of ZnO NPs. The 
results demonstrated that sZnO30, ZnO30 and ZnO200 particulates had significant 
inhibitory effects on IL-4 release in the PMA plus ionomycin-stimulated P815 mast 
cells. This could be a result of increased intracellular zinc ions, which could lead to 
competitive inhibition along with calcium influx. Thus, ZnO NPs may have an 
essential role to inhibit undesirable Th2 allergic inflammatory response, and may 
be applied for treatment of allergic diseases such as asthma. Zinc oxide ointments 
are well known for their applications for different types of dermatitis (Heimall et al., 
2012). 
 
Other types of NPs may have diverse immunological reactions. For example, 
Devouassoux et al. (2002) found that diesel exhaust particulates (DEPs) increased 
IL-4 production from mast cells. Consequently, these NPs can shift the adaptive 
immune response toward an undesirable Th2 allergic inflammatory response. 
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In conclusion, the results in this chapter indicate that NP size, composition, 
concentration, time of exposure and growth media are critical in determining the 
degree of cytotoxicity of NPs. The solubility of ZnO NPs in cell culture media is not 
sufficient to induce cytotoxicity. Release of intracellular zinc ions from ZnO NPs 
that have been taken up by the cells, maybe represent a very important factor in 
cell death. ZnO NPs also demonstrated immune inhibitory effects in PMA- and 
ionomycin-activated P815 mouse mast cells. Finally, we observed only a very little 
biological reactivity with the TiO2 NPs, which exhibited minimal cytotoxicity and did 
not cause immune inhibition in mast cells. 
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Chapter 3: Effects of zinc oxide and titanium 
dioxide nanoparticles on cytotoxicity and 
degranulation in RBL-2H3 rat mast cells and mouse 
bone marrow-derived mast cells 
 
3.1 Introduction 
Metal oxide ZnO and TiO2 NPs are currently used in various commercial products, 
such as sunscreens and cosmetics. Many studies have investigated the cytotoxicity 
of ZnO and TiO2 NPs in cancer cell lines, the details of which have been reviewed 
in section 1.5. However, there have been few studies conducted in primary (non-
cancerous) cells. Aktar et al. (2012) studied the cytotoxicity of ZnO NPs in three 
types of cancer cells (HepG2 human hepatocellular carcinoma, A549 human lung 
adenocarcinoma, and BEAS-2B human bronchial epithelial cells) and two primary 
rat cell types (astrocytes and hepatocytes). They reported that ZnO NPs induced 
death of cancerous cells, whilst not causing cytotoxicity in primary cells. Similarly, 
Taccola et al. (2011) demonstrated that ZnO NPs induced cell death in proliferating 
pluripotent mesenchymal stem cells, but did not exhibit cytotoxic effects to non-
proliferating osteogenically-differentiated mesenchymal stem cells. In addition, it 
has been observed that ZnO NPs and Zn2+ increased the cellular uptake of 
anticancer drugs by a leukaemia cell line (Guo et al., 2008). Thus, cell type is 
clearly important when considering the cytotoxicity of ZnO NPs. However, the 
selective sensitivity of TiO2 NPs toward cancer cells has not been investigated in 
the literature. Moreover, there are no published studies on the effects of ZnO and 
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TiO2 NPs related to their potential cytotoxic and immunomodulatory effects in 
primary mast cells. 
 
The RBL-2H3 rat basophilic leukemia cancer cell line and primary mouse bone 
marrow-derived mast cells (BMMCs) have both been widely used as models of 
IgE-mediated responses in mast cells (Kalesnikoff & Galli, 2011; Elbaz et al., 
2012). Degranulation assays have been carried out to quantify the biological 
activity of sensitized mast cells with a recombinant IgE monoclonal antibody (mIgE) 
and challenged with multivalent antigen (Yamaki et al., 2009). The β-
hexosaminidase is stored in the mast cell granules and is released parallel to 
histamine when mast cells are activated by cross-linking IgE with antigens 
(Tkaczyk et al., 2006). Therefore, β-hexosaminidase release in cell culture media is 
a very useful marker for assessing mast cell degranulation to evaluate mast cell 
activity. However, the role of β-hexosaminidase in allergic diseases is not well 
understood (Tomasiak et al., 2008). Histamine is another mast cell degranulation 
mediator that is essential for inducing the major symptoms of type I allergic 
responses, such as vasodilation and mucous secretion, itching, and 
bronchoconstriction in allergic rhinitis, atopic dermatitis and asthma, respectively 
(Huang et al., 2009; Yamaki et al. 2009). Figure 3.1 illustrates the mechanism of 
mast degranulation via mIgE. 
 
A study by Yamaki et al. (2009) found that ZnO NPs inhibited the release of β-
hexosaminidase from an anti-ovalbumin IgE + antigen-activated RBL-2H3 mast cell 
line, but they did not study the cytotoxic effects of ultrafine ZnO and fine ZnO 
particulates in these cells. Another recent study conducted by Chen et al. (2012) 
observed that TiO2 NPs can directly stimulate histamine release from RBL-2H3 
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mast cells via a Ca2+ dependent pathway, but they did not investigate the effects of 
TiO2 NPs on IgE-activated RBL-2H3 rat mast cells. Neither of these studies took 
into consideration the effect of dispersed ZnO NPs on mast cell degranulation. 
 
Multivalent antigen
IgE
Degranulation
γ
γ
Inflammatory mediators
Symptoms: rashes, wheezing, vomiting
Mast cells 
IgE recepter
Granules; containing 
Eg. Histamine and 
β-hexosaminidase
 
 
Figure 3.1: Mast cell degranulation; multivalent antigen binds to IgE antibodies that 
are attached to the IgE receptors leading to mast cell degranulation and the 
release of various mediators, which are responsible for allergic responses. Adapted 
from Kuby, 1992. 
 
The mechanism of ZnO NP inhibitory effects on mast cells is still unclear; with 
some studies demonstrating that these are related to Ca2+ ion inhibition. For 
example, Hide and Beaven (1991) found that zinc inhibited IgE-activated mast cell 
degranulation through inhibition of Ca2+ influx. However, there are conflicting 
reports about the interaction between ZnO NPs and Ca2+ ions, e.g. Yamaki et al. 
(2009) explained that ZnO NP inhibitory effects were not due to Ca2+ ion inhibition, 
but were a result of the inhibition of protein phosphorylation. 
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The purpose of the study described in this chapter was to investigate the effects of 
size and dispersion state of ZnO NPs, ZnCl2 (as a control for Zn2+ ions), and two 
different crystalline forms of TiO2 NPs, on cytotoxicity and degranulation in both the 
RBL-2H3 cancer cells and the non-cancerous mouse BMMCs. 
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3.2 Materials and Methods 
3.2.1 Chemicals and Reagents 
This study used the following: 0.05% trypsin-EDTA (Invitrogen, Carlsbad, CA, 
USA); TIB-142 IgE monoclonal antibody (mIgE) – a gift of Dr Graham Mackay, The 
University of Melbourne; release buffer (1×Hanks buffer, 0.14% NaHCO3, 10 mM 
HEPES, 5.5 mM glucose, 0.05% BSA, 0.73 mM MgSO4, 1.8 mM CaCl2, pH 7.3); 
2,4,6-trinitrophenyl hapten conjugated to Bovine Serum Albumin protein (TNP-
BSA) (BioSearch technology, USA); Triton-X 100, p-nitrophenyl N-acetyl-β-D-
glucosaminide, and glycine (Sigma Aldrich, USA); Fluo-4, AM fluorescence probe 
(Invitrogen) and histamine-ELISA kit (Life Science Format, Oxford Biomedical 
Research, USA). 
 
Protein gel reagents included (details shown in Appendix 1): a separating gel 
(12.5%), stacking gel (4%), 5x SDS sample buffer, 10x SDS electrophoresis buffer 
(Tris – glycine), Coomassie stain (0.1% w/v), destaining solution (10% v/v ethanol 
and 10% v/v acetic acid), Bradford reagent, and x10 Tris Buffer Saline (TBS). 
 
Western blot items included: the blocking solution of 5% (w/v) skim milk (Bonlac 
Foods Limited, Australia) in TBS; western blot primary antibodies of anti-phospho-
Akt (Thr308) mouse mAb, phospho-Akt (Ser473) mouse mAb and Akt (pan) mouse 
mAb; western blot secondary antibody of anti-mouse IgG (whole molecule) – 
peroxidase antibody produced in rabbit (Sigma-Aldrich); protein standard of 
“Precision plus” prestained standard (Biorad), stored at -20°C; wash buffer of 25 
mM Tris, pH 8.0, 0.5 M NaCl, 80 mM imidazole (Sigma), pH 8.0; extraction reagent 
of PhosphosafeTM extraction reagent (Novagen, USA); iBlot® Dry Blotting System 
(Invitrogen); western blot developing solution using chemiluminescence substrate 
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(Sigma-Aldrich); the developer and fixer (Kodak, USA); and the photosensitive 
films (Amersham Bioscience, Germany). 
 
3.2.2 Nanoparticle characterization and preparation  
The methodology used is described previously in section 2.2.3. 
 
3.2.3 Cell culture 
In the present study, two different types of mast cells were used, i.e. the cancerous 
RBL-2H3 cells and the non-cancerous (primary cells) BMMCs. 
   
3.2.3.1 Culture of RBL-2H3 mast cells 
The RBL-2H3 cells (American Type Culture Collection, Manassas, VA, USA) were 
cultured in RPMI-1640 media containing 10% v/v FBS with gentamycin, glucose, 
pyruvate, 2 mercaptoethanol and L-glutamine supplementation, maintained in a 
humidified incubator at 37°C and 5% CO2. Cells were maintained in 75 cm2 culture 
flasks containing media at 37°C in 5% CO2 incubator. When cultures reached 90% 
confluence, cells were detached by 0.05% trypsin-EDTA then neutralized with 
media. A small sample of cells was taken for counting cell number using trypan 
blue (Sigma-Aldrich, MO, USA) exclusion (to indicate cell viability) and a 
haemocytometer. Then a 1/10 dilution of cells to media was added to a new 75 cm2 
culture flask, and the sub-cultured cells were passaged every two days. 
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3.2.3.2 Preparation of BMMCs 
All mice were sacrificed by CO2 asphyxiation followed by cervical dislocation. Bone 
marrow cells from the C57Bl6 mice were flushed from the femurs using RPMI-1640 
and a 1 mL syringe and 20G needle (Terumo). Cells from each mouse were 
cultured independently in RPMI-1640 medium, supplemented with 10% v/v FBS, 
gentamycin, glucose, pyruvate, 2-mercaptoethanol, L-glutamine and IL-3 (5 
ng/mL). The cells were cultured in a 5% CO2 humidified atmosphere at 37°C. The 
cells in suspension were removed from the adherent cells in the flask, centrifuged 
and replenished with fresh media and transferred to a fresh flask every week. After 
5 weeks of culture, cells were phenotypically characterised via FACS analysis, by 
measuring CD117 and FcεRI expression. Experiments were conducted on wild-
type (WT) BMMCs that were age matched and cultured under identical conditions. 
Prior to all experiments, cell viability was assessed using trypan blue exclusion. 
Cultured cells with >90% viability were used in experiments. 
 
3.2.4 Cytotoxicity assays 
The RBL-2H3 cells were harvested via incubation with trypsin and EDTA, and then 
resuspended in medium. The RBL-2H3 and BMMCs mast cells were centrifuged 
(200 g, 5 min) and resuspended in fresh RPMI-1640 media before seeding in 96-
well plates at 105 cells/well. These cells were incubated in quadruplicate wells of 
96-well plates with a concentration range of ZnO and TiO2 NPs at 0, 10, 20, 30, 60, 
100, 150 and 200 µg/mL in a humidified incubator at 37°C and 5% CO2 
atmosphere. Cytotoxicity was measured at 24 h by adding a soluble tetrazolium 
salt (MTS, Promega, USA) to the wells 2 h prior to the optical absorbance 
measurement at 490 nm on a microplate reader (Perkin Elmer EnSpire, 
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Waltham, MA, USA). MTS was used to evaluate the mitochondrial function of cells, 
and its reduction to a chromophore is proportional to the number of viable cells in 
the well. The ZnO and TiO2 NPs were measured alone in the presence of MTS 
reagent, as a control for any optical density effects from the NPs. These values 
were subtracted from the experimental readings. Each experiment was repeated in 
in quadruplicate  and the average and standard error of mean of viability results 
calculated. 
 
3.2.5 Measurement of β-hexosaminidase 
The RBL-2H3 cells were treated in two different ways; the first by incubating the 
RBL-2H3 cells with a range of particulates (10, 30 or 60 µg/mL) and TIB-142 
mouse IgE (mIgE; 300 ng/mL) in 96 wells plates (105 cells/well) in a humidified 5% 
CO2  incubator at 37°C for 24 h. In the second method, RBL-2H3 cells were 
incubated with mIgE (300 ng/mL) solely in 96 wells plates (105 cells/well) for 20 h. 
The cells were then washed with media to remove mIgE and then incubated with a 
range of particles for 4 h. In both cases, the cells were washed twice in release 
buffer (1×Hanks buffer, 0.14% NaHCO3,10 mM HEPES, 5.5 mM glucose, 0.05% 
BSA, 0.73 mM MgSO4, 1.8 mM CaCl2, pH 7.3), and stimulated with 100 ng/mL 
2,4,6-trinitrophenyl hapten conjugated to bovine serum albumin protein (TNP-BSA) 
for 45 min at 37°C. The same procedure was followed, but without the addition of 
the stimulant (TNP-BSA), to investigate the effect of NPs on spontaneous release. 
 
The BMMCs were pre-incubated with mIgE in the tissue culture flask for 3 days 
because these cells required more time to sensitize with mIgE. The cells were then 
incubated with a range of particulates in 96 well plates (105 cells/well) for 24 h. The 
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cells were washed twice in release buffer, and stimulated with 10 ng/mL TNP-BSA 
for 45 min at 37°C. 
 
The β-hexosaminidase production was measured in both RBL-2H3 and BMMCs as 
follows: spontaneous levels of β-hexosaminidase release were measured in cells 
incubated with Hanks release buffer only, whereas total β-hexosaminidase release 
was determined through lysing cells with Triton-X 100 (0.1%) solution. After the 
cells were incubated with TNP-BSA in release buffer for 45 mins at 37°C, the plate 
was centrifuged (200 g, 5 mins). A 50 µL aliquot of the supernatant was stored at -
80°C for histamine analysis and another 50 µL transferred to a new 96-well flat-
bottom plate (BD Falcon) and 50 µL of p-nitrophenyl N-acetyl-β-D-glucosaminide 
(pNAG; 2 mM in phosphate/citrate buffer, pH 4.5) added and incubated for 90 min 
at 37°C. The enzymatic reaction was terminated by adding 100 µL of 0.2 M glycine 
solution (pH 10.7, Sigma). Absorbance was measured using a microplate reader 
(Perkin Elmer EnSpire, Waltham, MA, USA) at 405 nm. The percentage of β-
hexosaminidase release was calculated as: 
100
Total
Test(%) Release ×=  
Cytotoxicity in the remaining cells was measured after discarding the release buffer 
and adding 200 µL of pre-warmed media to the cells in the wells with soluble 
tetrazolium salt (MTS, Promega, USA), 2 h prior to the optical absorbance 
measurement at 490 nm using a microplate reader. The cells were washed twice 
with release buffer before adding TNP-BSA to remove non-binding mIgE as well as 
the NPs. The supernatants were also centrifuged after incubating the cells with 
TNP-BSA to remove any NPs remaining before measuring the β-hexosaminidase 
release. 
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A range of NPs alone were titrated against supernatant containing β-
hexosaminidase for 45 min (the time of β-hexosaminidase release experiment) at 
37°C, in order to measure whether any NPs bound to (or interfered with) the β-
hexosaminidase assay components. 
 
3.2.6 Histamine detection  
The -80°C stored supernatant was thawed and the level of histamine production 
was measured by using a histamine – ELISA kit, as per the manufacturer’s 
instructions (Life Science Format, Oxford Biomedical Research, USA). Optical 
absorbance was measured using a microplate reader at 450 nm. Triplicate 
samples were generated from two experiments for each treatment. 
 
Nanoparticles alone were titrated against the histamine-containing supernatant to 
investigate the possibility of histamine absorption or binding onto the NPs after the 
45 min incubation period. 
 
3.2.7 Measurement of intracellular level of zinc and calcium ions 
The levels of intracellular level of Zn2+ and Ca2+ ions were estimated by zinquin 
ethyl ester (Sigma-Aldrich) and Fluo-4 AM (Invitrogen) fluorescence probes, 
respectively. The RBL-2H3 mast cells were incubated in triplicate wells of 96-well 
plates with 300 ng/mL mIgE and 10 µg/mL ZnO NPs in a humidified 5% CO2 
incubator at 37°C for 24 h. The cells were then washed twice in release buffer and 
stimulated with 100 ng/mL TNP-BSA for 45 min at 37°C, except for wells used to 
measure the spontaneous release from cells alone.  
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Intracellular levels of Zn2+ and Ca2+ ions were measured by adding zinquin ethyl 
ester (25 µM) and Fluo-4, AM (5 µΜ) and incubating the cells for a further 30 min 
prior to analysis. Finally, the cells were washed twice in PBS and the fluorescence 
intensity was measured at excitation/emission wavelengths of 364/485 nm for 
zinquin, and 485/520 nm for Flou-4 Am, using flow cytometry (FACS Canto II, 
Becton, Dickinson and Co., Franklin Lakes, NJ, USA).  
 
3.2.8 Western blot analysis for Akt and tyrosine protein 
phosphorylation 
3.2.8.1 Cell culture  
The RBL-2H3 cells were seeded into 6-well culture plates at 1.5 x 106 cells/well for 
24 h in a humidified incubator (5% CO2 and 37°C). The cells were then washed in 
media and 30 µg/mL of ZnO and TiO2 NPs were added to the cells and incubated 
for a further 30 min period. 
 
3.2.8.2 Cell extraction 
The RBL-2H3 cells were washed twice with ice-cold PBS and lysed by 
phosphosafe extraction reagent (Novagen), as per the manufacturer’s instructions. 
The solution was then collected and centrifuged (4°C; 16,000 g; 5 min) and stored 
at -80°C. 
 
3.2.8.3 Determination of the protein concentration by Bradford Method 
Albumin standard solutions of 3, 6, 9, 12, 15, 18 and 21 µg/100 µL in 0.15 M NaCl 
were prepared. Twenty microlitres of each protein solution was put in the wells and 
diluted to 100 µL using 0.15 M NaCl. One millilitre of Coomassie Blue reagent was 
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added to each tube, mixed and left for 2 min at room temperature. The samples 
were aliquoted (200 µL) in duplicate into 96-well microtitre plates and read on a 
microplate reader at 600 nm. 
 
3.2.8.4 Western blot 
Equal amounts of extracted protein from the different samples were calculated and 
used in the western blots. The protein lysates were reduced in SDS sample buffer 
(0.05 M Tris-HCL, 0.1% w/v SDS, 10% v/v glycerol, and 50 mM dithiothreitol), and 
separated by SDS-polyacrylamide gel electrophoresis, and then the resolved 
proteins were transferred onto cellulose membranes (iBlot ® Dry Blotting System; 
Invitrogen). The membranes were blocked in 5% (w/v) skim milk in TBS/0.05% 
Tween 20 for 1 h and then coated with primary antibodies; anti-phospho-Akt 
(Thr308) mouse mAb, anti-phospho-Akt (Ser473) mouse mAb, anti-Akt (pan) 
mouse mAb and β-actin mouse mAb (Cell Signalling Technologies) overnight at 
4°C. Consequently, membranes were washed three times in TBS with 0.05% 
Tween 20 and incubated with the anti-mouse IgG peroxidase secondary antibodies 
(Sigma-Aldrich) at room temperature for 1 h, and then washed three times with 
TBS Tween 20. The membranes were incubated with chemiluminescence 
substrate (Sigma Aldrich). Immunoreactive protein phosphorylation was detected 
by the enhanced chemiluminescence technique (Lopata et al., 2005).  
 
3.2.9 Statistical analysis 
Statistics were performed using the same methods described in the section 2.2.13. 
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3.3 Results 
3.3.1 Cytotoxicity of ZnO and TiO2 NPs in RBL-2H3 and BMMC 
mast cells 
Surfactant-treated sZnO NPs, untreated ZnO NPs and TiO2 NPs were tested in cell 
culture for their effects on mast cell viability and proliferation. RBL-2H3 and BMMC 
mast cells were incubated with a range of NPs (1-250 µg/mL) in RPMI-1640 for 24 
h. In RBL-2H3 cells with NP concentrations up to 30 µg/mL, no cytotoxicity was 
seen with any of the tested ZnO and TiO2 NPs (i.e. sub-toxic dose). Small ZnO 
NPs (30 nm) had greater cytotoxic effects than large ZnO particulates (200 nm). 
Surfactant-treated ZnO 30 had more significant cytotoxicity at a concentration of 60 
µg/mL compared to untreated ZnO 30 (p<0.001). Surfactant-treated ZnO 30 had 
greater cytotoxic effects than all of the other ZnO NPs and ZnCl2 (Figure 3.2). In 
BMMC cells, with concentrations up to 60 µg/mL, cytotoxicity was not seen with 
any of the tested ZnO and TiO2 NPs (i.e. sub-toxic dose). Interestingly, all 
untreated ZnO NPs (including ZnO 30) did not have cytotoxic effects in BMMC 
mast cells, whilst surfactant-treated sZnO 30 showed significant cytotoxicity at a 
concentration 100 µg/mL (p<0.001) to BMMC cells. Moreover, sZnO 30 caused cell 
proliferation at a concentration of 60 µg/mL before inducing BMMC cell death 
(Figure 3.3).  
 
ZnO NPs had different cytotoxic effects between RBL-2H3 and BMMC cells. Table 
3.1 shows that RBL-2H3 cells were more sensitive to sZnO 30 NPs than BMMCs. 
The EC50 of sZnO 30 NPs in RBL-2H3 cells was 57 µg/mL, which was two-fold 
more sensitive than that of BMMC mast cells (EC50:122 µg/mL). The EC50 of 
untreated ZnO 30 NPs in RBL-2H3 cells was 187 µg/mL, but ZnO 30 NPs did not 
cause cytotoxicity to BMMCs.  ZnCl2 was cytotoxic to both RBL-2H3 and BMMC 
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cells and caused higher cytotoxicity to RBL-2H3 (EC50 = 114 µg/mL in RBL-2H3 
and 140 µg/mL in BMMCs). In contrast, large ZnO particulates (ZnO 200) were not 
cytotoxic to BMMCs and RBL-2H3 cells. Furthermore, TiO2 NPs did not induce 
cytotoxic effects toward RBL-2H3 or BMMCs cells (Figure 3.4 and Figure 3.5). 
 
 
Figure 3.2: Cytotoxicity of untreated and surfactant-treated ZnO NPs in cultured 
RBL-2H3 rat mast cells after 24h exposure (Mean ± SEM of three experiments in 
quadruplicate).  
 
 
Figure 3.3: Cytotoxicity of untreated and surfactant-treated ZnO NPs in BMMCs 
after 24 h exposure (Mean ± SEM of three experiments in quadruplicate). 
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Table 3.1: EC50 (µg/mL) of ZnO NPs in RBL-2H3 and BMMC cells after 24 h. 
 
EC50 at 24 h ZnO 30 sZnO 30 ZnO 200 sZnO 200 ZnCl2 
RBL-2H3 mast 
cells  
(Mean ± SEM) 
187 ± 4 57 ± 3 N/A N/A 114 ± 4 
BMMC mast cells  
(Mean ± SEM) N/A 122 ± 1 N/A N/A 142 ± 1 
N/A = Non-cytotoxic 
 
 
Figure 3.4: Effect on cell viability of TiO2 NPs in RBL-2H3 cells after 24 h exposure 
(Mean ± SEM of three experiments in quadruplicate). 
 
 
Figure 3.5: Effect on cell viability of TiO2 NPs on BMMCs cells after 24 h exposure 
(Mean ± SEM of three experiments in quadruplicate). 
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3.3.2 Effect of ZnO and TiO2 NPs on β-hexosaminidase release 
from RBL-2H3 and BMMCs mast cells 
Rat RBL-2H3 and BMMC mast cells were sensitized with TIB-142 IgE mAb in the 
presence or absence of ZnO particulates, TiO2 NPs or ZnCl2 for 24 h, and then 
challenged with TNP-BSA hapten to stimulate degranulation. Figure 3.6 and 3.7 
illustrate that the release of the degranulation product, β-hexosaminidase was 
inhibited by ZnO NPs in both RBL-2H3 and BMMC mast cells. At a concentration of 
30 µg/mL, both dispersed and pristine 30 nm ZnO NPs inhibited β-hexosaminidase 
release more than the bulk ZnO particulates; while sZnO30 was more inhibitory 
than ZnO 30 NPs to RBL-2H3 cells. In contrast, TiO2 NPs did not demonstrate any 
inhibition of degranulation, but instead caused a slight but significant increase 
(p<0.01) in β-hexosaminidase from mast cells.  
 
The RBL-2H3 cells were sensitized with mIgE mAb for 20 h, mIgE was then 
washed (to remove excess mIgE that might bind to NPs) and incubated with ZnO, 
TiO2 NPs and ZnCl2 for 4 h and challenged with TNP-BSA. Figure 3.8 shows that 
the inhibitory effects of ZnO NPs after a 4 h incubation were similar to the inhibitory 
effects of ZnO NPs after a 24 h incubation in RBL-2H3 cells.  
 
The effects of ZnO, TiO2 NPs and ZnCl2 on spontaneous β-hexosaminidase 
release from RBL-2H3 cells without the addition of the stimulant (TNP-BSA), 
confirmed that basal β-hexosaminidase was also inhibited by ZnO NPs, and again 
that TiO2 NPs caused a significant increase (p<0.01) (Figure 3.9). 
 
The cell viability was not affected in these experiments as the particulate 
concentrations used were sub-toxic (i.e. 10 and 30 µg/mL). Therefore, β-
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hexosaminidase inhibition was not induced by NP-induced cell death. Furthermore, 
a range of NPs alone were titrated against supernatant containing β-
hexosaminidase in order to account for NPs binding to β-hexosaminidase assay 
components. All NPs at concentrations of 10 and 30 µg/mL did not cause any 
alterations in the detection of β-hexosaminidase concentration levels (Figure 3.10).  
 
 
 
 
Figure 3.6: Inhibitory effects of ZnO NPs on β-hexosaminidase release from 
IgE/antigen-activated RBL-2H3 cells after 24 h of exposure to NPs (Mean ± SEM of 
two experiments in triplicate). 
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Figure 3.7: Inhibitory effects of ZnO NPs on β-hexosaminidase release from 
IgE/antigen-activated BMMC cells after 24 h of exposure to NPs (Mean ± SEM of 
two experiments in triplicate). 
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Figure 3.8: Inhibitory effects of ZnO NPs on β-hexosaminidase release from IgE-
activated RBL-2H3 cells after 4 h of exposure to NPs (Mean ± SEM of two 
experiments in triplicate). 
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Figure 3.9: Inhibitory effects of ZnO NPs on β-hexosaminidase release from non-
activated RBL-2H3 cells after 24 h of exposure to NPs (Mean ± SEM of two 
experiments in triplicate). 
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Figure 3.10: ZnO and TiO2 NPs did not bind to β-hexosaminidase or the assay 
components at concentrations of 10 and 30 µg/mL (Mean ± SEM of two 
experiments in triplicate). 
40 
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3.3.3 Effect of ZnO and TiO2 NPs on histamine release from RBL-
2H3 mast cells 
 
The RBL-2H3 rat mast cells were sensitized with mIgE mAb in the presence or 
absence of ZnO particulates, TiO2 NPs and ZnCl2 for 24 h and challenged with 
TNP-BSA to stimulate mast cell degranulation. The effect of NPs on histamine 
release was investigated by histamine ELISA kits. Small ZnO NPs strongly 
inhibited mIgE-mediated histamine release in a concentration-dependent manner 
(Figure 3.11). These small ZnO NPs caused more effective histamine inhibition 
than larger ZnO in triplicate when compared to the positive control. Surfactant-
treated sZnO 30 caused more a significant histamine inhibition at the concentration 
of 30 µg/mL (p<0.001) than untreated ZnO 30 NPs. Interestingly, ZnCl2 slightly 
increased histamine release at 30 µg/mL, and then strongly inhibited histamine at 
concentrations of 60 µg/mL. In contrast, TiO2 NPs did not demonstrate any 
inhibition of histamine release. 
 
The cell viability unaltered from control levels for all ZnO NPs doses (10, 30 and 60 
µg/mL) except sZnO 30, which at a concentration of 60 µg/mL displayed 
cytotoxicity, and therefore this concentration data point was excluded from the 
graph. In addition, a range of NPs alone were titrated against supernatant 
containing histamine in order to account for any NP binding to components of the 
histamine assay. All NPs across the experimental concentration range did not 
cause any alterations in the detection of histamine concentration levels (Figure 
3.12). This suggests that the inhibition of histamine release by ZnO NPs was not 
due to cell toxicity or NPs binding to histamine. 
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Figure 3.11: Inhibitory effects of ZnO NPs on histamine release from IgE/antigen-
activated RBL-2H3 cells after 24 h of exposure to NPs (Mean ± SEM of two 
experiments in triplicate). 
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Figure 3.12: ZnO and TiO2 NPs did not bind to histamine or assay components at 
concentrations of 10, 30 and 60 µg/mL (Mean ± SEM of two experiments in 
triplicate). 
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3.3.4 Intracellular level of zinc and calcium ions 
The intracellular Zn2+ and Ca2+ ion levels were measured after ZnO NP exposure 
of the RBL-2H3 cells that had been challenged with TNP-BSA. The Zn2+ and Ca2+ 
ions levels were detected using zinquin ethyl ester (Zn-specific) and Fluo-4 Am 
(Ca-specific) fluorescence probes that were analysed by flow cytometry (Figure 
3.13). All ZnO NP-exposed cells exhibited a strong increase in intracellular Zn2+ 
compared to control stimulated cells (Figure 3.14 and 3.15). Surfactant-treated and 
untreated ZnO 30 NPs had equal effect, with both causing an increase in 
intracellular Zn2+ ions. Smaller ZnO NPs caused a greater increase in intracellular 
Zn2+ ions than larger ZnO particulates. Figure 3.16 illustrates the effect of ZnO NPs 
on intracellular Ca2+ concentration; the histogram shows that the fluorescence 
intensity was decrease by ZnO NPs compared to the stimulated cells. The 
intracellular Ca2+ levels were significantly inhibited by small ZnO NPs, ZnO 200 
and ZnCl2 (p<0.05) (Figure 3.17). The 30 nm ZnO NPs caused a greater decrease 
of intracellular Ca2+ than the other ZnO particulates. 
 
 
 
Figure 3.13: Flow cytometry plot (Forward scatter (FSC) vs Side scatter (SSC)) of 
RBL-2H3 mast cells (A), and after incubation with ZnO NPs at 10 µg/mL for 24 h 
(B) and challenged with TNP-BSA. (P1; population 1 cells had two different 
phenotypic sizes which did not alter by the low exposure concentration of 10 µg/mL 
of ZnO NPs). 
A B 
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Figure 3.14: The effects of ZnO 30 (B), sZnO30 (C), ZnO 200 (D), sZnO200 (E) 
and ZnCl2 (F) on the intracellular Zn2+ concentration in RBL-2H3 cells, after 
challenge with TNP-BSA. Fluorescence intensity was increased by ZnO NPs 
compared to the stimulated cells (A).  
 
 
0
500
1000
1500
2000
2500
3000
3500
Cell Stimulated
cell
ZnO 30 sZnO30 ZnO 200 sZnO200 Zncl2
Dose of NPs 10 µg/mL
Fl
u
o
re
sc
en
ce
 
in
te
n
si
ty
 
(Zi
n
qu
in
)
 
 
Figure 3.15: Effects of ZnO NPs on intracellular Zn2+ ions in RBL-2H3 mast cells 
after exposure to 10 µg/mL NPs for 24 h and challenged with TNP-BSA. Data is 
represented as the mean ± SEM of two experiments in triplicate. 
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Figure 3.16: The effect of ZnO 30 (B), sZnO30 (C), ZnO 200 (D), sZO200 (E) and 
ZnCl2 (F) on the intracellular Ca2+ concentration in RBL-2H3 cells, after challenge 
with TNP-BSA. Fluorescence intensity was decreased by ZnO NPs compared to 
stimulated cells (A).  
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Figure 3.17: Effects of ZnO NPs on intracellular Ca2+ ions in RBL-2H3 mast cells 
after exposure to 10 µg/mL NPs for 24 h and challenge with TNP-BSA. Data is 
represented as the mean ± SEM of two experiments in triplicate. 
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3.3.5 The effect of ZnO and TiO2 nanoparticles on the level of Akt 
in RBL-2H3 cells. 
 
The effect of ZnO and TiO2 NPs on the common phosophorylation pathway 
through threonine and serine residues was investigated in this study using the 
western blot technique. The Akt enzyme is essential in regulating cell survival and 
apoptosis. Full activation of Akt occurs through the phosphorylation of its threonine 
308 and serine 473 residues. Figure 3.18 illustrates that a high level of Akt 
phosphorylation through serine 473 residues was induced by surfactant-treated 
and untreated ZnO 30 NPs in non-IgE/antigen-stimulated RBL-2H3 cells. More 
interestingly, surfactant-treated ZnO 30 NPs induced strong Akt phosphorylation at 
both serine 473 and threonine 308 residues. Both ZnCl2 and ZnO 200 caused a 
slight expression of pAkt Ser 473. In contrast, the surfactant-treated large ZnO 200 
particulates and TiO2 NPs did not exhibit an increase in Akt phosphorylation. A 50 
µM concentration of PI3 Kinase Inhibitor was used as an experimental control to 
inhibit the expression of pAkt phosphorylation that was induced by ZnO 30 NPs 
(Figure 3.19).  
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Figure 3.18: Effect of ZnO and TiO2 NPs on Akt phosphorylation. Non-antigen/IgE-
stimulated RBL2H3 cells were exposed to ZnO and TiO2 NPs for 30 min. 
Phosphorylated-Akt through serine (pAkt Ser) or through threonine amino acid, 
were determined by western blot. Both untreaed ZnO 30 and surfactant-treated 
sZnO 30 NPs increased the level of phosphorylation of pAkt Ser 473. Whereas, 
sZnO30 was the only particulate that increased the level of pAkt Thr 308. 
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Figure 3.19: The PI3 Kinase Inhibitor inhibited the phosphorylation of pAkt induced 
by ZnO 30 NPs, and was used here as an experimental control.  
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3.4 Discussion 
To the best of my knowledge, the current study is the first to compare the 
cytotoxicity and allergic immunological inhibitory effects of ZnO NPs in their 
agglomerated and dispersed states. The effects of these compounds were 
compared with two different crystalline forms of TiO2 NPs for their abilities to 
induce cell death and inhibit degranulation in both RBL-2H3 mast cells and primary 
BMMC mast cells.  
 
The present study demonstrated that untreated ZnO 30 nm NPs were cytotoxic to 
the RBL-2H3 cancer cells at concentrations ranging from 100 to 250 µg/mL (Figure 
3.2). However, untreated ZnO 30 nm NPs did not demonstrate cytotoxic effects in 
normal BMMCs at concentrations up to 250 µg/mL (Figure 3.3). Therefore, ZnO 
NPs may have a degree of selective cytotoxicity toward certain cancer cells over 
normal cells. A similar conclusion has been reached in previous studies. For 
instance, Aktar et al. (2012) and Hanley et al. (2008) found that ZnO NPs were 
cytotoxic to cancerous cells, but did not cause cytotoxicity in primary cells 
(astrocytes, hepatocytes and T cells). The cytotoxicity in RBL-2H3 cells is maybe 
due to the increased uptake of particles, because of their rapid growth compared to 
the slower growth of BMMC primary cells. This finding supports the previous 
results in section 2.4.1, in which P815 mast cells grown in DMEM culture media 
were more tolerant to ZnO NPs than the highly proliferating P815 mast cells grown 
in RPMI-1640 media. These results are in agreement with Hanley et al. (2008), 
who reported that ZnO NPs induced cytotoxicity in proliferating and activated T 
cells, while quiescent T cells displayed the most resistance to ZnO NPs. 
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Surfactant-treated sZnO 30 NPs were the only ZnO NPs showing significant 
cytotoxicity (p<0.01) toward BMMCs. The cytotoxicity level from treated sZnO NPs 
was increased in the adherent RBL-2H3 cancer cells in comparison to the 
untreated ZnO 30 NPs. This may suggest that the surfactant is increasing the 
permeability of the cell membrane toward ZnO 30 NPs, or that the surfactant’s 
ability to decrease the particulate aggregation is allowing the NPs to maintain their 
small size, and hence the more effective cellular uptake. However, surfactant-
treated sZnO 30 NPs were equitoxic to untreated ZnO 30 NPs in the non-adherent 
cancerous P815 mast cells when in the same RPMI-1640 growth media (section 
2.4.1). Thus, the cell type, i.e. adherent or non adherent cells, are another 
important factor that should be considered when studying NP cytotoxicity. 
Interestingly, ZnCl2 demonstrated strong cytotoxicity in both cell types (cancerous 
RBL-2H3 and normal BMMC cells); this could be due to the very high concentration 
of Zn2+ ions present in both the culture media and intracellularly, which can result in 
cellular damage.  
 
The RBL-2H3 and BMMC cells were also used to assess the effect of NPs on mast 
cell degranulation markers (β-hexosaminidase and histamine) in vitro, in order to 
study their potential to interact with allergic responses. Primary BMMC mast cells 
have an advantage over tumour mast cells, in which BMMCs can be transferred to 
mast cell-deficient c-kit-mutant mice (mast cell knock-in mice) to study the specific 
mast cell mediators in vivo for comparison with wild-type mice (Kalesnikoff & Galli, 
2011). Therefore, BMMC in vitro studies help enable correlation with future in vivo 
studies of NP actions on mast cells. 
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The current study demonstrated that β-hexosaminidase and histamine were highly 
inhibited by ZnO NPs from IgE-activated RBL-2H3 and BMMC mast cells after 24 h 
of incubation (Figure 3.6, 3.7 and 3.11). Small ZnO 30 NPs inhibited β-
hexosaminidase and histamine release more than bulk ZnO particulates. ZnO NPs 
also inhibited spontaneous β-hexosaminidase release from non-activated RBL-2H3 
cells. More interestingly, surfactant-treated sZnO 30 showed the greater inhibition 
of β-hexosaminidase and histamine than untreated ZnO 30 NPs in IgE-activated 
RBL-2H3 cells. Activation of mast cells via IgE/antigen cross-linking causes an 
increase in Ca2+ influx, which leads to an increase of free cytosolic Ca2+ that 
triggers mast cell degranulation. Therefore, it is very important to evaluate the 
effect of Zn2+ ions on Ca2+ ion influx after incubation of the mast cells with ZnO 
NPs.  
 
The impact of ZnO NPs on intracellular Zn2+ and Ca2+ levels in IgE-activated RBL-
2H3 cells were investigated. In this study, we found that there was an inverse 
correlation between Zn2+ and Ca2+ ions. For all tested ZnO NPs, intercellular Zn2+ 
levels were increased (Figure 3.15). In contrast, ZnO NPs diminished intercellular 
Ca2+ levels (Figure 3.17). In addition, these elevations in Zn2+ ions and reductions 
in Ca2+ ions were particle size-dependent, with small ZnO NPs having a more 
significant impact on intracellular Zn2+ and Ca2+ levels than larger particulates. This 
finding suggests that dissolved Zn2+ ions play an important role in the inhibition of 
mast cell immune mediators (β-hexosaminidase and histamine) via diminished 
Ca2+ influx, which inhibits mast cell degranulation. However, surfactant-treated 
sZnO 30 NPs induced the strongest inhibition, but had a lower Ca2+ inhibition 
(p<0.05) and equal intercellular Zn2+ levels to untreated ZnO 30 NPs. Therefore, 
there are other possible mechanisms causing surfactant-treated ZnO 30 NPs to 
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induce the strongest inhibition of mast cell degranulation. This could be due to 
surfactant-treated sZnO 30 NPs having a different impact on the cell signalling 
pathways. Moreover, surfactant-treated sZnO 30 NPs may escape from the 
cytoplasm and interact with organelle compartments such the endoplasmic 
reticulum, Golgi apparatus and secretory granules, and thereby interfere with the 
mast cell degranulation process.  
 
Herein, ZnCl2 exhibited a significant inhibitory effect on both β-hexosaminidase at 
30 µg/mL and histamine at a high dose of 60 µg/mL (p<0.05). This confirms that 
Zn2+ ions may have an inhibitory effect on mast cell degranulation. Similar results 
have reported that Zn2+ ions inhibited IgE-activated mast cell degranulation through 
inhibition of Ca2+ influx (Hide and Beaven, 1991: Musset et al., 2008).  
 
The TiO2 NPs did not demonstrate any inhibition of histamine, but instead caused a 
significant increase in β-hexosaminidase release (p <0.05) from IgE-activated and 
non-activated RBL-2H3 mast cells at 30 µg/mL. Chen et al. (2012) also observed 
that TiO2 NPs can directly stimulate histamine release from non-activated RBL-2H3 
mast cells at between 250 to 750 µg/mL. In this study the maximum concentration 
was 60 µg/mL, which might not be enough to induce histamine release. The β-
hexosaminidase release was elevated but histamine was unchanged could also be 
because the detection of β-hexosaminidase release as a marker for activation mast 
cells is more sensitive than the detection of histamine release. 
 
Another important finding in the present study was that surfactant-treated sZnO 30 
NPs had the strongest impact on the Akt signalling phosphorylation that regulates 
cell survival and apoptosis. A high level of Akt phosphorylation through serine 473 
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residues was induced by untreated ZnO 30 NPs in non-stimulated RBL-2H3 cells. 
Whereas, surfactant-treated sZnO 30 induced strong phosphorylation through both 
serine 473 and threonine 308 residues (Figure 3.18). This complete activation 
through serine and threonine residues at 30 min may be the trigger for apoptotic 
programmed cell death that is induced by the highly cytotoxic effects of sZnO 30 
NPs. As ZnO 30 NPs had less cytotoxicity than sZnO 30 NPs, the amount of 
phosphorylation was only partial and via serine 473 alone. Also, ZnCl2  slightly 
increased the expression of Akt phosphorylation. However, large ZnO particulates 
(200 nm) and TiO2 NPs did not express Akt phosphorylation because they were not 
cytotoxic. A recent study showed that PI3K/Akt pathway contributes in the ZnCl2-
induced increase in proliferation of mouse embryonic stem cells. However, this 
proliferative effect of Zn is reduced at higher doses of ZnCl2 (200 µM) (Ryu et al., 
2009). Further research is required to investigate the impact of ZnO NPs on cell 
signalling phosphorylation pathways in non-activated and IgE-activated mast cells.  
 
In conclusion, the experiments discussed in this chapter showed that ZnO NPs 
have selective cytotoxicity toward cancerous cells (RBL-2H3) but not to normal 
mast cells (BMMCs). Surfactant-treated sZnO 30 exhibited the highest cytotoxic 
effects to both cell types (RBL-2H3 and BMMCs). Furthermore, histamine and β-
hexosaminidase release from mast cells was also markedly inhibited by surfactant-
treated sZnO 30 NPs. ZnO NPs can inhibit IgE-activated mast cell degranulation 
through inhibition of calcium influx. It was also observed that TiO2 NPs had very 
low reactivity in this test system, in which they did not induce cytotoxicity or 
immune inhibition of mast cells, but only slightly increased β-hexosaminidase 
release. 
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Chapter 4: Inflammatory and cytotoxic responses 
of lung epithelial cell lines (A549 and LA4) to zinc 
oxide and titania nanoparticles 
 
4.1 Introduction  
Nanoparticulate ZnO and TiO2 are very important commercial nanomaterials. They 
have been widely used in many processes and products including rubber 
manufacture, sunscreens, cosmetics, pigments, food additives and medicines, as 
well as in the chemical fibre and electronics industries (Ji and Ye, 2008). 
Production of engineered ZnO and TiO2 NPs in sunscreen products alone was 
estimated to be up to 100 kilotonnes during 2003 (Borm et al., 2006). There are 
more than 1300 consumer products containing nanoparticles and the global market 
of engineered nanomaterials is estimated to be worth US$2.5 trillion by 2015 
(Lanone and Boczkowski, 2011). This rapid expansion in the use of nanomaterials 
has raised concerns about the potential health risks from NP exposure.  
 
Inhalation is one of the most likely exposure routes for NPs. Inhaled NPs includes 
ambient ultrafine particulates of many metals (such as Fe, Zn, V and Ni), and metal 
oxides (Fe2O3, ZnO, V2O5 and NiO), all of which can cause lung inflammation and 
respiratory irritation (Fond and Meyer 2006; Schaumann et al., 2004). Inhalation of 
very high doses of ZnO NPs in the workplace has been known to cause acute 
metal fume fever, which is characterized by fever, chills, nausea, headache, 
fatigue, and muscle aches (Gerberding, 2005; Warheit et al., 2009). Chronic 
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inhalation of TiO2 NPs is also commonly associated with development of 
inflammation, pulmonary damage and lung tumours in rats, most likely as result of 
overload of the particle clearance mechanisms (Hext, 1994; Warheit and Frame, 
2006). These inflammatory disorders might be due to the aggregation of NPs on 
the epithelial cell layer of the lung resulting in chronic inflammation, fibrosis, 
hyperplasia formation, and overall disruption of multiple biological systems. Non-
toxic and non-immunological surface coatings or treatments of NPs may reduce 
their health impacts (Mano et al., 2012). 
 
The A549 human lung epithelial cell line is a well-established model system that is 
commonly used to investigate the impact of NPs on the human lung epithelium 
(Don Porto Carero et al., 2001; Aufderheide et al., 2003; Schwerdtle and Hartwig, 
2006). Previous in vitro studies have provided detailed information about the 
cytotoxic effects of ZnO and TiO2 NPs toward A549 cells. These studies 
demonstrated that the physicochemical properties of NPs, including particle size, 
shape, surface area, phase, composition and agglomeration, have a crucial impact 
on cell toxicity and inflammatory responses (Hsiao et al., 2011; Sayes and Warheit, 
2008). However, these studies examined the cytotoxicity and proinflammatory 
effects of NPs in an aggregated state, but not in a dispersed form. Nanoparticles 
tend to clump together in culture media and forming big aggregates, sometimes 
reaching up to >1 micron in size (Schulling et al., 2010), while dispersed NPs are 
most likely remain closer to their corresponding nano-sized primary particle when 
suspended in culture media. Thus, the cells may interact differently with these 
various states of NPs to cause different cytotoxicity and immune responses. 
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In addition, there have been few studies examining the impact of ZnO NPs on LA4 
mouse lung epithelial cells. In one such study, Beyerle et al. (2009) demonstrated 
that 70 nm ZnO nanoparticles had greater cytotoxic effects in MH-S cells than in LA4 
cells. Currently, there are no published studies investigating the effect of TiO2 NPs on 
LA4 cells. 
 
The aim of the study described in this chapter was to evaluate the effects of the 
particle size and dispersion state ZnO NPs (pristine NPs in an aggregated state vs. 
surfactant-treated in a dispersed state), ZnCl2 (a control for Zn ions), along with two 
different crystalline forms of TiO2 NPs; and to compare these with the crystalline 
form of silica particles (Min-U-Sil 5), a well-known respiratory toxicant. For all these 
particulates, the cytotoxicity and inflammatory responses in human A549 lung 
epithelial cells and mouse LA4 lung epithelial cells were measured. 
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4.2 Materials and Methods 
4.2.1 Chemicals and Reagents 
Materials and assay kits utilized specifically in this chapter included: Cell 
dissociation solutions (Sigma-Aldrich); Ser-Leu-Ile-Gly-Arg-Leu-amide 
(SLIGRL−NH2) (Sigma); human Th1/Th2/Th9/Th17/Th22 13plex Kit FlowCytomix 
(Bender MedSystems, Vienna, Austria); and IL-6, IL-8 and TNF-α BD OptEIA 
ELISA Sets (Bioscience). 
 
4.2.2 Nanoparticle characterization and preparation 
The nanoparticle characterization and preparation was as per section 2.2. In 
addition, Min-U-Sil 5 particles (Fine Ground Silica, U.S. Silica Co., Berkeley 
Springs, WV, USA) were also used as a reference particle (positive control) in this 
chapter. Crystalline silica particles are well known for their lung toxicity and have 
been used as a benchmark substance to study toxicity and inflammatory responses 
in the lung (Beyerle et al., 2009). 
 
4.2.3 Cell culture 
Cell culture experiments were carried out using two adherent cancer cell lines; LA4 
mouse lung adenoma cell line and A549 human lung adenocarcinoma epithelial 
cell line. The cells were grown in RPMI-1640 medium containing 10% v/v FBS with 
gentamycin, glucose, pyruvate, 2-mercaptoethanol and L-glutamine. All cells were 
grown in 75 cm2 culture flasks containing media in a humidified incubator at 37°C 
and 5% CO2. At 90% confluence, cells were detached using the cell dissociation 
solution, and subsequently washed with media. A 1/10 dilution of cells to media 
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was then added to a new 75 cm2 culture flask. All cells were passaged every 2-3 
days. 
4.2.4 Cytotoxicity assay 
The A549 and LA4 cells were harvested by cell dissociation solutions instead of 
trypsin and EDTA, to avoid activation of cells via trypsin which increases the 
production of cytokines such as IL-8 and IL-6. The cells were resuspended in fresh 
RPMI-1640 medium, and centrifuged (200 g, 5 min) before seeding in 96-well 
plates at a cell density of 2 x 104 cells/well. After 24 h of cell attachment and 
culture, the media was discarded and replaced with fresh media; the cells were 
then exposed to various concentrations of NPs (ZnO or TiO2) and crystalline silica 
(Min-U-Sil 5) particles at 0, 10, 20, 30, 60, 100, 150 and 200 µg/mL for 24 h in a 
humidified incubator (at 37°C and 5% CO2). Cytotoxicity was measured by adding 
soluble tetrazolium salt (MTS, Promega, USA) to the wells. After 4 h, the optical 
absorbance was measured at 490 nm on a spectrophotometer (Perkin Elmer 
EnSpire, Waltham, MA, USA). Aliquots of supernatants were collected from wells 
before the addition of MTS and stored at -80°C for cytokine analysis. 
 
4.2.5 Cytokine profiling 
4.2.5.1 Quantification of human cytokines by multiplex flow cytometry 
Supernatants of A549 cells exposed to the various NP concentrations for 24 h 
were assessed for presence of 13 different cytokines (IFN-γ, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-10, IL-9, IL-12, IL-13, IL-17, IL-22 and TNF-α) with a multiplex kit 
(Th1/Th2/Th9/Th17/Th22 13plex FlowCytomix Kit, Bender MedSystems, Vienna, 
Austria) using flow cytometry. The peptide SLIGRL−NH2 (100 µM) was used as 
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positive control exposure for releasing IL-6 and IL-8. Samples from triplicate wells 
were analysed for each experiment. 
 
4.2.5.2 Quantification of IL-6 and IL-8 by ELISA 
The A549 cells were seeded in 96-well plates at a cell density of 2 x 104 cells/ well. 
After 24 h of cell attachment (70% confluence), various concentrations of ZnO or 
TiO2 NPs and Min-U-Sil 5 particles (at 10, 60 and 100 µg/mL) were added to the 
cells and incubated for 24 h. For kinetic studies, cells were exposed to 60 µg/mL of 
NPs for 4, 8, 12 and 24 h. The supernatant was then collected at different time 
points and IL-6 and IL-8 levels were analysed using enzyme-linked immunosorbant 
assay (ELISA, BD OptEIA kit; BD Systems, Franklin Lakes, NJ, USA). The 
absorbance at 450 nm was obtained using a microplate reader (Perkin Elmer 
EnSpire, Waltham, MA, USA) as per manufacturer’s instructions. The cytotoxicity 
was also measured by the MTS assay. 
 
To control for the possibility of particulates interfering with the ELISA assays, NPs 
without cells were titrated against IL-6 or IL-8 standard that was diluted in RPMI-
1640 media and incubated for 24 h at 37°C. The IL-6 or IL-8 standard in RPMI-
1640 without NPs was used as a negative control.  
 
4.2.6 Statistical analysis 
Statistics were performed using the same methods described in the section 2.2.13. 
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4.3 Results 
4.3.1 Cytotoxicity of ZnO and TiO2 NPs in A549 and LA4 cells 
The A549 human lung epithelial cells and LA4 mouse lung epithelial cells were 
incubated with surfactant-treated ZnO (dispersed, “sZnO”) NPs, untreated ZnO 
NPs, TiO2 NPs or Min-U-Sil 5 particles in RPMI-1640 plus 10% FBS for 24 h to 
evaluate cell viability. The cell viability data showed a dose-dependent cytotoxicity 
in A549 cells exposed to ZnO and sZnO NPs (Figure 4.1). At concentrations up to 
10 µg/mL, no cytotoxicity was observed for any of the tested ZnO and TiO2 NPs 
(“sub toxic” dose). At higher doses (>10 µg/mL), the smaller ZnO NPs (30 nm) 
caused more cytotoxicity than larger particulates. Small sZnO 30 NPs were 
equitoxic to untreated NPs on cells after the 24h exposure period. Large sZnO 200 
particulates demonstrated greater cytotoxicity than the large untreated NPs after 24 
h of exposure. The LA4 cells were more sensitive to all tested ZnO NPs than the 
A549 cells (Figure 4.2). The EC50 values of ZnO 30 and sZnO 30 NPs in LA4 cells 
were four-fold more sensitive than for A549 cells (Table 4.1). Interestingly, the 
large ZnO particulates (200 nm) were equitoxic to the small ZnO NPs (30 nm) in 
LA4 cells. In contrast, TiO2 NPs and the crystalline silica particles were not 
cytotoxic to either A549 or LA4 cells after 24 h of exposure (Figure 4.3 and 4.4). 
 
 
 
 
 
 
 
 
 137 
 
Figure 4.1: Cytotoxicity of untreated and surfactant-dispersed ZnO NPs in A549 
human lung epithelial cells after 24 h exposure (Mean ± SEM of three experiments 
in quadruplicate). 
 
 
Figure 4.2: Cytotoxicity of untreated and surfactant-dispersed ZnO NPs in LA4 
mouse lung epithelial cells after 24 hr exposure (Mean ± SEM of three experiments 
in quadruplicate). 
 
Table 4.1: EC50 (µg/mL) of ZnO NPs in A549 and LA4 cells after 24 h. 
 
EC50 at 24 h ZnO 30 sZnO 30 ZnO 200 sZnO 200 ZnCl2 
A549 cells  
(Mean ± SEM) 55 ± 2 56 ± 2 N/A N/A 90 ± 2 
LA4 cells  
(Mean ± SEM) 13 ± 1 13 ± 1 13 ± 1 25 ± 1 13 ± 0 
N/A = Non-cytotoxic 
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Figure 4.3: Cytotoxicity of TiO2 NPs and crystalline silica (Min-U-Sil 5) to A549 
human lung epithelial cells after 24 h exposure (Mean ± SEM of three experiments 
in quadruplicate).  
 
 
 
 
 
 
Figure 4.4: Cytotoxicity of TiO2 NPs and crystalline silica (Min-U-Sil 5) to LA4 
mouse lung epithelial cells after 24 h exposure (Mean ± SEM of three experiments 
in quadruplicate).  
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4.3.2 Cytokine profiling 
4.3.2.1 Multiplex cytokine profiling 
The effects of ZnO, TiO2 NPs and crystalline silica particles on cytokine expression 
in A549 lung epithelial cells were screened using a human 
Th1/Th2/Th9/Th17/Th22 13-plex flow cytometry bead-based kit.  This kit 
simultaneously quantifies 13 cytokines, including Th1 cytokines (IL-2, IL-12 and 
IFN-γ), Th2 cytokines (IL-4, IL-5, IL-13 and IL-10), a Th9 cytokine (IL-9), Th17 (IL-
17), Th22 (IL-22) and proinflammatory cytokines (IL-1α, TNF-α, IL-6). 
 
The cytokine profile was measured at both sub-cytotoxic (10 µg/mL) and cytotoxic 
doses at approximately the EC50 (60 µg/mL for ZnO 30 and sZnO 30) after a 20 h 
incubation. Figure 4.5 demonstrates that ZnO and TiO2 NPs and crystalline silica 
did not stimulate the expression of these 13 cytokines, except for the sZnO 200 
particulate and SLIGRL, which increased the expression of the IL-6 cytokine. 
However, as the important proinflammatory cytokine IL-8 was not part of the 
multiplex kit, it was measured by ELISA. 
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Figure 4.5: Multiplex cytokine profile of A549 cells exposed to ZnO or TiO2 NPs, 
crystalline silica (Min-U-Sil 5) particles or SLIGRL for 20 h. All NPs and ZnCl2 did 
not induce type 1 (cellular) or type 2 (humoral) inflammatory responses, except for 
sZnO 200 and SLIGRL, which caused an increase in IL-6 production. Responses 
below 9 pg/mL were considered to be below the level of detection for this assay. 
Note: this kit did not contain the inflammatory cytokine IL-8. 
 
 
 
 
 
 
 
Detection limit 
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4.3.2.2 Quantification of IL-6 and IL-8 release by ELISA 
Whilst the multiplex was used as an initial screening method for cytokine profiling, 
the more accurate ELISA method was carried out to accurately examine the 
differences in cytokine expression of IL-6 and IL-8. 
 
The A549 cells were exposed to three different concentrations of NPs, including 
sub toxic (10 µg/mL), cytotoxic (60 µg/mL) and highly cytotoxic (100 µg/mL) 
concentrations, to enable closer examination of the differences between cytokine 
profile expression among these closely-related ZnO particulates. All tested ZnO 
particulates and ZnCl2 at 60 µg/mL had greater IL-8 expression, relative to the 
negative control (i.e. spontaneous release of cytokine) (Figure 4.6). However, TiO2 
NPs and crystalline silica particles did not significantly increase IL-8. When IL-8 
release was normalized to cell viability, the smaller ZnO 30 NPs caused greater IL-
8 production than the larger ZnO (200 nm) particulates. Figure 4.7 illustrates that 
untreated ZnO 30 NPs caused greater IL-8 release than surfactant-treated sZnO30 
NPs, and then decreased in parallel with the loss of cell viability at 100 µg/mL. The 
kinetic IL-8 expression and cell viability data after 4, 8, 12 and 24 h showed that IL-
8 release increased in the following order: sZnO 30 > ZnO 30 > ZnCl2 > ZnO 200 > 
sZnO 200, respectively. The crystalline silica particles also caused a slightly 
increased expression of IL-8 (Figure 4.8). The peptide SLIGRL caused strong 
expression of both IL-8 and IL-6 cytokines and was therefore effective as a positive 
control for this test system. 
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Figure 4.6: The IL-8 release from A549 lung epithelial cells exposed to ZnO and 
TiO2 NPs or crystalline silica (Min-U-Sil 5) particles after 20 h of incubation, and 
their effects on cell viability (percentile number under x-axis). The IL-8 spontaneous 
release from non-stimulated cells was used as a negative control, whereas 
SLIGRL-stimulated cells were used as a positive control. (Mean ± SEM of two 
experiments in triplicate). 
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Figure 4.7: Category line graph showing the different correlations between IL-8 
expression (solid line) and cell viability (dashed line) in A549 lung epithelial cells 
exposed to sub-toxic, cytotoxic and highly cytotoxic doses of ZnO 30 or sZnO 30 
NPs. Untreated ZnO 30 NPs caused higher IL-8 production than surfactant-treated 
sZnO 30 NPs.  
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Figure 4.8: Time course of IL-8 release (A) and cell viability (B) in A549 lung 
epithelial cells exposed to 60 µg/mL of ZnO NPs or crystalline silica (Min-U-Sil 5) 
particles over 24 h (Mean ± SEM of two experiments in triplicate). 
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All tested ZnO particulates, ZnCl2, TiO2 NPs and crystalline silica particles did not 
elicit significant increases of IL-6 production, except for sZnO 200 which had a 
significant increase in IL-6 production at concentrations of 60 and 100 µg/mL, 
compared to negative controls after 20 h of incubation (Figure 4.9). The decrease 
in IL-6 levels at concentrations of 60 and 100 µg/mL for ZnO 30, sZnO 30 and 
ZnCl2 were due to the loss of cell viability at these toxic concentrations. The 
transient change in IL-6 over time was also examined after exposure the cells to 
NPs at different time points (4, 8, 12 and 24 h). Figure 4.10 demonstrates that 
sZnO 200 NPs was the only ZnO particulate that caused a sharp increase in IL-6 
release between 8 and 12 h, and then a slightly elevated IL-6 expression from 12 
to 24 h. Whereas, the crystalline silica particulate caused a significant increase in 
IL-6 expression throughout the duration. 
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Figure 4.9: The IL-6 release from A549 lung epithelial cells exposed to ZnO and 
TiO2 NPs or crystalline silica (Min-U-Sil 5) particles after 20 h of incubation, along 
with their effects on cell viability (percentile number under x-axis). The IL-6 
spontaneous release from non-stimulated cells was used as a negative control, 
whereas SLIGRL-stimulated cells were used as a positive control (Mean ± SEM of 
two experiments in triplicate). 
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Figure 4.10: Time course of IL-6 release (A) and cell viability (B) of A549 lung 
epithelial cells exposed to 60 µg/mL of ZnO NPs or crystalline silica (Min-U-Sil 5) 
particles over 24 h. IL-6 production was increased by exposure to sZnO 200 and 
silica particles. Cell viability was assessed by MTS assay over 24 h (B). Responses 
below 8 pg/mL were considered to be under the level of detection for this assay 
(Mean ± SEM of two experiments in triplicate). 
A 
B 
Detection limit 
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To control for the possibility of NPs interfering with the assays, NPs without cells 
were incubated for 24 h at 37°C with IL-8 or IL-6 standard dilutions in RPMI-1640 
cell culture media and compared to control standard curves (without NPs). All 
tested NPs at concentrations of 10, 60 and 100 µg/mL did not cause any 
alterations in the IL-8 and IL-6 standard curves, except sZnO 30 at 100 µg/mL, 
which appeared to slightly reduce IL-8 measurements but this was not significant 
(Figure 4.11 and 4.12). 
 
The effects of ZnO, TiO2 NPs and crystalline silica particles on IL-6 and TNF-α  
expression from LA4 mouse lung epithelial cells were examined after 24 h of 
incubation using the mouse IL-6 and TNF-α  BD OptEIA kit -BD Systems. 
However, the productions of these cytokines were not detected (data not shown). 
 
0
20
40
60
80
100
120
140
160
IL
-8
Z
nO
30
sZ
nO
30
Z
nO
200
sZ
nO
200
Z
nC
l2
Tita
niu
m
R
Tita
niu
m
P25
IL
-
8 
Pg
/m
l
10 µg/mL
60 µg/mL
100 µg/mL
 
 
Figure 4.11: Controls for the possibility of ZnO or TiO2 NPs binding or adsorbing 
IL-8 after incubation for 24 h at 37°C (Data represents mean ± SEM of two 
experiments in triplicate). 
 
 
 
 
 
 149 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
IL
-6
Z
nO
30
sZ
nO
30
Z
nO
200
sZ
nO
200
Z
nC
l2
Tita
niu
m
 R
Tita
niu
m
P25
IL
-
6 
Pg
/m
l
10 µg/mL
60 µg/mL
100 µg/mL
 
 
Figure 4.12: Controls for the possibility of ZnO or TiO2 NPs binding or adsorbing 
IL-6 after incubation for 24 h at 37°C (Data represents mean ± SEM of two 
experiments in triplicate). 
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4.4 Discussion  
In the present study, the in vitro cytotoxicity and immunomodulation of surfactant-
treated (dispersed) and untreated (aggregated) ZnO NPs were investigated, in a 
concentration range from sub-toxic to highly cytotoxic, to examine the differential 
effects of the NPs on human lung epithelial cells. These ZnO NPs were treated 
with an industrial dispersant mix containing a hydrophilic polyacrylate copolymer 
(Orotan 731 DP). This dispersant formulation is inert and does not elicit cytotoxic or 
immunological effects on biological systems (as described by Feltis et al., 2011). 
Crystalline silica particles (Min-U-Sil 5) were also used as a benchmark substance 
in this study. Crystalline silica was selected because it has well characterised in 
vivo respiratory and in vitro cytotoxicity and inflammatory effects (Sayes et al., 
2007). 
 
The MTS assay data (Figure 3.1 and 3.2) showed that a cytotoxic dose-response 
was observed for the ZnO NPs and ZnCl2 in both A549 and LA4 cells. This was in 
agreement with previous findings for ZnO NPs using lung epithelial cell lines, 
including A549 human lung epithelial cells (Lin et al., 2009; Karlsson et al., 2008; 
Horie et al., 2009), BEAS-2B human bronchial epithelial cells (Huang et al., 2010), 
and L2 rat lung epithelial cells (Sayes et al., 2007).  
 
The surfactant-treated sZnO 30 (30 nm) NPs were equitoxic to undispersed ZnO 
30 NPs in the A549 cells after 24 h. This result was in contrast to our previous 
findings with RBL-2H3 rat and BMMCs mast cells, which were more susceptible to 
sZnO 30 than untreated ZnO 30 (as described in section 3.3). Interestingly, not 
only were the LA4 cells four-fold more sensitive to the ZnO NPs than A549 cells, 
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but the LA4 cells were very sensitive to all ZnO particulates and ZnCl2, which were 
almost equitoxic in these cells (Table 4.1). 
 
The cell exposure systems used in this study have sought to specifically assess the 
cytotoxicity and immunomodulatory effects of NPs in the same culture media 
(RPMI-1640). This was firstly to avoid any differences in either composition or 
concentration of ingredients present in different culture media, such as phosphate 
and carbonate, which can result in different responses as previously illustrated in 
section 2.3, but secondly to also avoid changing the physical and chemical states 
and dispersion characteristics of the NPs.  
 
The cytotoxicity of ZnO NPs in different cell lines has shown significant variability, 
and clearly illustrates that cytotoxicity is not solely a function of the size of NPs but 
depends on a complex relationship between NPs and cellular properties. These 
results were in agreement with a previous study by Lankoff et al. (2012), which 
revealed that the NP-induced cytotoxicity was due to the interaction between cells 
and NPs, and not only due to the physical size of the NPs. TiO2 NPs and crystalline 
silica particles were less cytotoxic to both A549 and LA4 cells, which may also 
indicate that these particulates are less soluble than ZnO NPs (i.e. TiO2 NPs do not 
release metal ions intracellularly), and thus they would require extremely high 
doses to observe any cytotoxic effects. 
 
In the current study, cytokine secretion was evaluated in the supernatants of lung 
epithelial cells that were incubated with surfactant-dispersed and non-dispersed 
ZnO particulates, TiO2 NPs and crystalline silica. The transient release of cytokines 
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was monitored for non-cytotoxic, cytotoxic and highly cytotoxic concentrations of 
NPs at 4, 8, 12, 20 and 24 h after exposure. 
 
Cytokine profiling in A549 lung epithelial cells showed that IL-8 and IL-6 were the 
most prominent. No other specific type 1 or type 2 cytokine responses to the NPs 
were observed for the cytokines measured in this study. Both IL-8 and IL-6 are 
major proinflammatory cytokines in the lung. IL-8 is responsible for inflammatory 
cell recruitment, primarily neutrophils, to the site of inflammation. It is well 
established that when lung epithelial cells are exposed to particulates, IL-8 
secretion is increased, leading to an inflammatory response (Singh et al., 2007). IL-
6 is an essential trigger for the bone morrow, leading to synthesis and recruitment 
of leukocytes to the site of infection. It also stimulates the liver to synthesise acute 
phase proteins, such as C reactive protein or fibrinogen (van Eeden et al., 2001), 
which suggests it has a major role in lung fibrosis (Fries et al., 1994). The other 
important activities of the IL-6 cytokine are the induction of T cell proliferation and T 
and B cell differentiation, and shifting the innate immune responses to more 
prolonged  adaptive immune responses (Bacon et al., 1990). Also, IL-6 may 
contribute to the pathogenesis of lung diseases, such as asthma (Doganci et al., 
2005) and chronic obstructive pulmonary fibrosis (COPD) (Eddahibi et al., 2006).  
 
The benchmark substance of crystalline silica in this study showed a significant 
increase in IL-6 production, but not in IL-8 level (Figure 4.10). These results are in 
line with the findings of Cho et al. (2007), who demonstrated that intranasal 
instillation of mice with silica NPs increased the levels of IL-6 in the lung. It is well 
known that prolonged exposure to crystalline silica particles has been associated 
with lung fibrosis (Hetland et al., 2001). Therefore, it is suggested that IL-6 
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production induced by silica particles from lung epithelial cells may contribute to 
lung fibrosis. 
 
All tested ZnO NPs and ZnCl2 at 60 µg/mL caused a significant increase (p < 
0.005) in the proinflammatory cytokine IL-8, compared to untreated cells when 
normalized for cell viability. The elevation of IL-8 levels could be responsible for the 
transient fever (metal fume fever) observed in the workplace when workers are 
exposed to high levels of inhalable ZnO particles. More interestingly, the levels of 
IL-8 cytokine secretion varied with particle sizes. Small ZnO 30 NPs caused 
greater IL-8 release than large ZnO 200 particles. It may be that small ZnO 30 NPs 
in lysosomes release high levels of Zn2+ ions, which induce inflammation. The Zn2+ 
ions from ZnCl2 exhibited similar behaviour to ZnO NPs (30 nm), with virtually 
equal proinflammatory IL-8 production to the ZnO NPs. This supports the 
conclusion that Zn2+ ions contribute to the induction of inflammatory responses. 
This finding was consistent with a previous study, where Feltis et al. (2011) found 
that the size of ZnO NPs was one of the key factors that influenced IL-8 production 
in THP-1 human monocytic cells.  
 
The surfactant-treated sZnO 30 NPs had reduced IL-8 release when compared to 
their untreated ZnO 30 NPs counterparts at the studied concentrations of 10, 60 
and 100 µg/mL (Figure 4.7). This could be due to the possibility that surfactant-
treated sZnO NPs may escape into the cytoplasm and other organelles, where 
interference with intracellular processes may reduce IL-8 release. 
 
Surprisingly, only the surfactant-treated sZnO 200 particles (bulk) increased IL-6 
production in the A549 cells. The kinetic profile of IL-6 release by sZnO 200 
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particles showed a slight rise between 12 and 24 h (Figure 4.11). This may be due 
to release of preformed IL-6 that may be triggered by exposure to particles, which 
could then be followed by production and release (at a lower apparent rate) from 
that point on. Further studies may be carried out to analyse the mRNA expression 
at different time points, in order to differentiate between preformed IL-6 release or 
de novo production. Similarly, in vivo studies using nasal installation of NPs in mice 
models would strengthen and further clarify our in vitro findings.  
 
In this study, TiO2 NPs did not induce any cytokine expression and seemed to be 
inert. It’s probably because the TiO2 doesn’t dissolve at the low pH within 
lysosomes, unlike the more soluble ZnO NPs. Thus, it may be that much higher 
concentrations of TiO2 NPs are required (~1000 µg/mL) to induce biological 
changes. 
 
In conclusion, the results in this chapter show that NP size, composition, 
concentration, time of exposure and the interaction of NPs with different cell types 
are critical in determining the degree of cytotoxicity in in vitro studies. Moreover, 
the most pronounced proinflammatory signal of the production and release of the 
cytokine IL-8, was observed for the smallest ZnO NPs. The bulk ZnO particles and 
ZnCl2 also showed significant IL-8 proinflammatory responses. This work shows 
that surfactant-treatment of sZnO 30 NPs appears to reduce the proinflammatory 
IL-8 cytokine response to small ZnO NPs. Crystalline silica particles elevated IL-6 
production only. However, it was observed that TiO2 NPs had minimal cytotoxic 
effects and did not induce immune responses toward A549 lung epithelial cells.  
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Chapter 5: Chitosan nanocapsules as a non-toxic 
and non-allergenic drug delivery vector 
 
5.1 Introduction  
Chitosan is a biocompatible and biodegradable polymer, derived by deacetylation 
of chitin, which is the main component found in the exoskeleton of arthropods and 
usually derived from crustacea. In addition to its good mechanical properties, 
chitosan has found a broad range of applications in the medical field because of its 
low immunogenicity and toxicity (Zeng & Ruckenstein, 1996). Furthermore, it can 
be broken down by lysosomes to the innocuous N-acetyl glucosamine (Gan & ang, 
2007), making it a highly desirable material in drug delivery applications.  
 
Although different approaches have been undertaken in the past to prepare 
chitosan-based nanoparticulate systems (Aydin & Akbuǧa, 1996; Shu & Zhu, 
2000), most of these methods produce solid chitosan particles restricting their use 
as nanocapsule-based drug delivery systems. In contrast, particle templating 
methods such as layer-by-layer (LbL) assembly have been widely employed to 
prepare polymer capsules of well-defined chemical and structural properties 
(Caruso et al., 1998; Wang et al., 2007), along with improved homogeneity and 
monodispersity (Caruso, 2000; Sivakumar et al., 2009).  
 
Büchel et al. (1998) reported the fabrication of highly robust and monodispersed 
solid core/mesoporous shell (SC/MS) silica spheres, with a 420 nm solid core 
 156 
surrounded by a 75 nm mesoporous shell. The employment of these SC/MS silica 
particles as templates for nanocapsule synthesis offers an advantage over the 
solid particle templates used in LbL techniques, as a mesoporous shell enables 
polymeric material of controllable quantities to infiltrate into its porous matrix in a 
single step, using simple charge interactions. The polymeric chains can then be 
cross-linked covalently using an appropriate agent, adding tuneable stability and 
degradability characteristics to the capsules formed after the removal of the 
sacrificial silica template.  
 
Curcumin is a hydrophobic anticancer drug, naturally found in the yellow curry 
spice turmeric (Curcuma longa), which has shown growth inhibition of a number of 
human cancer cell lines (Ammon & Wahl, 1991). Curcumin is a potent anti-oxidant 
and possesses anti-proliferative activities against tumor cells in vitro, but has 
limited applicability in vivo due to its instability in the aqueous environment (Mehta 
et al., 1997). 
 
The aims of the study described in this chapter were to evaluate the role of 
different structural properties (size, wall thickness and porosity) of chitosan 
nanocapsules in drug delivery. Also the effects of curcumin-loaded chitosan 
nanocapsules and pristine chitosan nanocapsules on cellular uptake, cell viability 
and allergenic responses in mast cells (using the P815 mouse mastocytoma cell 
line) were investigated. 
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5.2 Materials and Methods 
5.2.1 Chitosan nanocapsules 
Chitosan nanocapsules in this study were provided by Dr. Vipul Bansal and Emma 
Goethals (RMIT University, Melbourne, Australia). Our group demonstrates for the 
first time that the monodispersed SC/MS silica templating approach can be 
extended to polysaccharides, thereby resulting in chitosan capsules of controllable 
size, wall thickness and porosity by tuning relevant features of the sacrificial 
SC/MS template. The approach presented here combines the versatility of solid 
core particles and the high loading capacity of mesoporous shells to prepare nearly 
monodispersed chitosan capsules of three different diameters (220, 270 and 440 
nm), three different wall thickness (28, 45 and 56 nm), and three different porosity 
levels (corresponding to a template pore size of 2.9, 3.68 and 4.85 nm). This led to 
seven different types of chitosan capsules, amongst which one capsule type was 
common with the intermediate features of 270 nm capsule size, 45 nm wall 
thickness and 3.68 nm template pore size (Figure 5.1).  The following chitosan 
nanocapsules were characterised by TEM (Figure 5.2): medium-size medium-shell 
medium-porosity (CapCSP); small-size medium-shell medium-porosity (CapC1SP); 
large-size medium-shell medium-porosity (CapC2SP); medium-size small-shell 
medium-porosity (CapCS1P); medium-size large-shell medium-porosity 
(CapCS2P); medium-size medium-shell high-porosity (CapCSP1); and medium-size 
medium-shell low-porosity (CapCSP2). The physico-chemical properties of the 
seven different types of chitosan nanocapsules, and the amount of curcumin 
loaded/capsule, are illustrated in Table 5.1. 
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Figure 5.1: Representation of the solid core/mesoporous shell (SC/MS) approach 
employed to fabricate seven different types of chitosan nanocapsules with different 
structural features. As shown in the schematic, the first step is the synthesis of 
solid silica particles (central core), which was followed by synthesis of a 
mesoporous shell around solid core particles, leading to SC/MS templates of 
different structural characteristics (middle layer). The SC/MS templates thus 
obtained varied in three different sizes, three different shell thicknesses and three 
different porosities, with one common type of SC/MS template in each category 
(highlighted by an arching triangle). SC/MS template synthesis was followed by 
infiltration of chitosan within the mesoporous shells of SC/MS silica templates, 
cross linking of infiltrated chitosan chains, and etching of SC/MS template, thereby 
resulting in chitosan nanocapsules of seven different structural characteristics 
(outermost layer) (from Emma Goethals, unpublished data).  
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Figure 5.2: TEM images of different chitosan nanocapsules (A-L). TEM images of 
chitosan nanocapsules of three different sizes: (A) CapC1SP (220 nm), (B) 
CapCSP (270 nm) and (C) CapC2SP (440 nm); scale bars correspond to 500 nm. 
Chitosan nanocapsules of three different wall thickness (D-I): (D) CapCS1P, (E) 
CapCSP and (F) CapCS2P; (G-I) show TEM images of ultramicrotomed chitosan 
nanocapsules shown in D-F, respectively, scale bars correspond to 200 nm. 
Chitosan nanocapsules of three different porosity levels: (J) CapCSP1, (K) 
CapCSP and (L) CapCSP2, scale bars correspond to 200 nm (from Emma 
Goethals, unpublished data). 
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Table 5.1: Physico-chemical properties of different types of chitosan capsules used 
in this study, wherein ‘Cap’ corresponds to the capsule, ‘C’ corresponds to the 
capsule diameter, ‘S’ corresponds to capsule shell thickness and ‘P’ corresponds 
to the capsule porosity (from Emma Goethals, unpublished data).  
 
Capsule 
Type 
Capsule 
Description 
Capsule 
Diameter 
(nm) 
Capsule 
Shell 
Thickness 
(nm) 
Chitosan 
Loading 
(mg/g of 
SC/MS) 
Curcumin 
Loading 
(fg/Capsule) 
CapCSP 
Medium size 
Medium shell 
Medium porosity 
270 45 76.35 2.155 
CapC1SP 
Small size 
Medium shell 
Medium porosity 
220 47 97.73 0.163 
CapC2SP 
Large size 
Medium shell 
Medium porosity 
440 42 73.36 23.492 
CapCS1P 
Medium size 
Small shell 
Medium porosity 
235 28 65.84 0.748 
CapCS2P 
Medium size 
Large shell 
Medium porosity 
325 56 83.25 6.870 
CapCSP1 
Medium size 
Medium shell 
High porosity 
269 40 47.11 0.851 
CapCSP2 
Medium size 
Medium shell 
Low porosity 
283 42 81.26 
 
4.507 
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5.2.2 Preparation of nanoparticles for cell culture 
Following the synthesis of the seven different types (various size, wall thickness 
and porosity) of chitosan nanocapsules, these capsules were dehydrated in 
ethanol and dispersed in curcumin/oleic acid mixture (0.01 mg curcumin per mL of 
oleic acid) to allow infiltration of the oil phase through the semi-permeable walls of 
chitosan nanocapsules over 12 hour period. The drug loading technique used here 
is similar to that previously demonstrated for the anticancer chemotherapeutic 
drugs doxorubicin and 5-fluorouracil into poly (methacrylic acid) capsules 
(Sivakuma et al., 2009). Curcumin in oleic acid was employed as a model 
hydrophobic drug-in-oil. Chitosan nanocapsules were centrifuged, the supernatant 
removed and the capsules washed twice with hexane to remove any extraneous 
curcumin/oleic acid. The capsules were washed and resuspended in milli Q water 
to make a stock solution 1012 nanocapsules/mL. The same procedure was done to 
non-loaded chitosan nanocapsules (negative control). The stock solution was 
vortexed, inverted for 10-20 times and resuspended by pipetting up and down 3-5 
times. The desired volume of stock solution was added to the RPMI-1640 media to 
make the working solution. 
 
Dilutions were made by inverting the working solution 3-5 times until no particles 
were stuck to the bottom of the tube, and pipetting up and down 5 times, then the 
desired volume of the working solution was added to the RPMI-1640 media. A 100 
µL aliquot of each dilution (ranging from 1010 to 107 nanocapsules/mL) were added 
to the 100 µL of volume in the control and cell-containing wells, to provide a total 
volume of 200 µL/well. 
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5.2.3 Cellular uptake method 
Mouse P815 mastocytoma cells (Manassas, VA, USA) were used to study both the 
uptake and cytotoxicity of the chitosan nanocapsules. These cells were cultured in 
RPMI-1640 media (Sigma) containing 10% FBS, gentamycin, glucose, pyruvate, 2-
mercaptoethanol and L-glutamine supplementation, and maintained in a humidified 
incubator at 37°C and 5% CO2. Phagocytic uptake of large chitosan nanocapsules 
was evaluated by confocal laser scanning microscopy (CLSM; Nikon, A1 Confocal 
Microscope). After 24 h, culture cells were harvested, centrifuged and washed 3 
times with phosphate-buffered saline (PBS) and the cells seeded onto glass slides 
for imaging. Chitosan nanocapsules are highly fluorescent by nature and therefore 
do not require labeling with a fluorescent dye. 
 
5.2.4 Cellular cytotoxicity assay  
The P815 mast cell viability was determined using a soluble tetrazolium based 
colourimetric assay (Promega MTS CellTiter 96® AQueous kit). A 100 µL aliquot of 
106 cells/mL in cell culture medium was seeded with equal density into each well of 
96-well plates (105 cells per well). A 100 µL aliquot of (i) chitosan nanocapsules, or 
(ii) chitosan nanocapsules loaded with curcumin suspended in RPMI-1640 media, 
were added to provide a final concentration range of 106-9 nanocapsules/mL (105-8 
nanocapsules per well). Untreated cells served as the control group. Cells were 
subsequently incubated for 20 h at 37°C before MTS was added to each well. The 
plates were incubated for an additional 4 h before being measured at 490 nm using 
a microplate reader (Perkin Elmer, USA) (see details for MTS assay in Chapter 
2.2.6). Each treatment was performed in quadruplicate in 3-4 series of 
experiments.  
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5.2.5 ELISA measurement of IL-4 
The P815 cells were seeded onto 96-well plates at 105 cells/well, and various 
concentrations of NPs (106-8 nanocapsules/well) were added to the cells, which 
were then stimulated using 1 µM ionomycin and 20 nM PMA while being incubated 
at 37°C for 24 h. Before the MTS reagent addition step, supernatant was collected 
from each well at the 20 h time point for storage at -80°C for the IL-4 cytokine 
analysis. An enzyme-linked immunosorbant assay (ELISA; BD OptEIA kit, BD 
Systems, Franklin Lakes, NJ, USA) was used to measure IL-4 in thawed cell 
supernatants. The absorbance at 450 nm was obtained using a microplate reader 
(Perkin Elmer EnSpire, Waltham, MA, USA) as per the manufacturer’s 
instructions. The same procedure was followed for wells containing unstimulated 
cells, but without the addition of the stimulants ionomycin plus PMA. 
 
The NPs alone were titrated against the IL-4 standard diluted in RPMI-1640 media 
to investigate the possibility of IL-4 cytokine absorption or binding onto the chitosan 
nanocapsules after 24 h incubation at 37°C. The IL-4 standard in RPMI-1640 
without NPs was used as a control. 
 
5.2.6 Statistical analysis 
Statistics were performed using the same methods described in the section 2.2.13. 
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5. 3 Results  
5.3.1 Chitosan nanocapsule uptake by P815 mast cells 
The cellular uptake of chitosan nanocapsules was imaged using confocal laser 
scanning microscopy (CLSM), as shown in Figure 5.3. Confocal fluorescent images 
of the P815 mast cells exposed to chitosan nanocapsules for 24 h confirmed that 
chitosan nanocapsules were present and visible within the cytoplasm (Figure 5.3 
C). Whereas, P815 mast cells alone (negative control) did not exhibit fluorescence 
(Figure 5.3 B). 
 
5.3.2 Effect of chitosan nanocapsules on the viability of P815 mast 
cells 
The cell viability was investigated to determine the cytotoxicity of both curcumin-
loaded and non-loaded chitosan nanocapsules after incubation with P815 mast 
cells for 24 h (Figure 5.4). The cytotoxicity of non-loaded chitosan nanocapsules 
(Control Cap) was found to be negligible, with >90% cell viability occurring during 
exposure to 1000 capsules per cell (Figure 5.4A). However, all types of curcumin-
loaded capsules caused 95-100% cell death on exposure to less than 1000 
capsules. The minimum number of capsules required to cause >95 % cell death 
varied with the type of capsule used (Figure 5.4A), wherein capsule size was found 
to have the most influential effect on cytotoxicity, followed by porosity and wall 
thickness, respectively. The cytotoxicity profile related to the number of capsules 
per cell showed that the largest capsules loaded with curcumin (CapC2SP) had the 
highest cytotoxicity, while the smallest capsules (CapC1SP) showed the lowest 
cytotoxicity, and all other capsule types had intermediate effects (in decreasing 
order of potency): CapCSP2 > CapCS2P > CapCSP > CapCS1P > CapCSP1. 
However, if one looks at the cytotoxic efficiency of the capsules with regards to the 
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amount of curcumin available to the cells during the exposure (Figure 5.4B), then a 
different cytoxicity profile is seen, i.e. capsule size and wall thickness were found to 
be very influential on cytotoxicity, but porosity had minimal effect. Nonetheless, all 
of the curcumin-loaded chitosan nanocapsules showed higher cytotoxic efficiency 
(per curcumin load) over free curcumin, except for the largest capsules (CapC2SP) 
(Figure 5.4B). 
 
A B
C D
 
Figure 5.3: Confocal microscopy images of the cellular uptake of chitosan 
nanocapsules by P815 mast cells. A & B – cells without chitosan; C & D – cells 
with chitosan. A & C – overlays of fluorescent and phase contrast images; B & D – 
fluorescence image only; Scale bars correspond to 20 µm.  
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Figure 5.4: Cytotoxicity response of P815 mouse mastocytoma cells on exposure 
to seven different types of chitosan nanocapsules. (A) Compares the cytotoxicity 
profile on exposure to equivalent numbers of different types of capsules per cell, 
and (B) depicts the cytotoxic efficiency of different types of capsules with regards to 
the amount of curcumin present in the specific capsule type (Mean ± SEM of three 
experiments in quadruplicate).  
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5.3.3 The effect of chitosan nanocapsules on IL-4 production from 
P815 mast cells 
The inhibitory effects on IL-4 release by small (CapC1SP) and large (CapC2SP) 
chitosan nanocapsules, without drug loading, were also evaluated in both 
unstimulated and ionomycin plus PMA-stimulated P815 mast cells. The IL-4 
cytokine is central in the allergic immune response, and down regulation of IL-4 
release might therefore have a beneficial anti-allergic effect.  
 
IL-4 production from stimulated P815 mast cells was significantly inhibited by both 
small and large chitosan nanocapsules compared to the stimulated cells, (p < 0.05) 
at the lowest investigated dose of 100 and 10 capsules/cell, respectively. Both 
small and large chitosan nanocapsules showed a dose-dependent decrease in IL-4 
production. Large nanocapsules caused more inhibition of IL-4 production than 
small nanocapsules at the same dose of 100 capsules/cell, which is comparable to 
an added chitosan concentration of 24 and 173 pg/cell, respectively (Figure 5.5).  
 
The effects of chitosan nanocapsules on spontaneous IL-4 production from P815 
mast cells without the addition of the stimulant, also confirmed that IL-4 was 
inhibited by both small and large chitosan nanocapsules in a dose-dependent 
manner (Figure 5.6). This effect was significant (p < 0.05) at the intermediate dose 
of 500 and 50 capsules/cell, respectively. The pristine chitosan capsules 
(curcumin-free) were found to have 100% cell viability from 1 to 700 chitosan 
nanocapsules/ cells in these experiments. Therefore, the diminished IL-4 
production was not due to a decrease in cell number caused by cytotoxicity at 
these concentrations doses (10, 50, 100 and 500 nanocapsules/ cells). In addition, 
chitosan nanocapsules alone were titrated against IL-4 standard curves to control 
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for the possibility of cytokine absorption onto the nanocapsules. The nanocapsule 
dose range employed in this study did not cause any alteration in the IL-4 
concentration standard curve (Figure 5.7).  
 
 
Figure 5.5: The inhibitory effects of small and large pristine chitosan nanocapsules 
on IL-4 release from PMA + ionomycin-activated P815 cells after 24 h of exposure. 
Data represents mean ± SEM of two experiments in triplicate. 
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Figure 5.6: Inhibitory effect of small and large pristine chitosan nanocapsules on 
IL-4 release from unstimulated P815 cells after 24 h of exposure. Data represents 
mean ± SEM of two experiments in triplicate.  
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Figure 5.7: Controls for the possibility of small and large chitosan nanocapsules 
binding or adsorbing IL-4 after incubation for 24 h at 37°C (Data represents mean ± 
SEM of two experiments in triplicate). 
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5.4 Discussion  
To the best of my knowledge, the present study was the first to investigate the 
cytotoxicity and anti-allergic responses of semi-permeable chitosan nanocapsules 
of various size, wall thickness and porosity. 
 
Seven different types of chitosan nanocapsules (of various size, wall thickness and 
porosity) were used in this study, and these capsules were loaded with 
curcumin/oleic acid mixture. Curcumin was used as a model lipophilic drug due to 
its well-established anticancer properties. To investigate the effect of different types 
of chitosan nanocapsules on their chemotherapeutic efficiency, the uptake of the 
chitosan capsules by P815 mouse mastocytoma cells (a tumour cell line) was first 
investigated. This was followed by the assessment of their cytotoxic profiles, and 
finally by an investigation of their immune inhibitory effect on IL-4 production, which 
may indicate the anti-allergenic potential of the pristine chitosan nanocapsules.  
 
Fluorescent microscopy clearly demonstrated that the chitosan capsules could be 
taken by the P815 mouse mastocytoma cells (Figure 5.3), justifying the subsequent 
investigation of the efficacy of the cytotoxic effects of chitosan capsules loaded with 
an anticancer agent (Figure 5.4). The pristine curcumin-free chitosan capsules 
were found to be highly biocompatible, showing negligible cytotoxicity. Conversely, 
all types of curcumin-loaded capsules caused 95-100% cell death on exposure to 
less than 1000 capsules/cell. Our investigations suggest that the minimum number 
of capsules required to cause >95 % cell death varied with the type of capsule 
used (Figure 5.4A), wherein capsule size (load of curcumin) was found to show the 
most influential effect on toxicity, followed by porosity and wall thickness, 
respectively.  
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The cytotoxicity data corresponding to number of capsules per cell (shown in 
Figure 5.4A) can be used to compare the ability of a single capsule of certain type 
towards causing cytotoxicity, while Figure 5.4B compares the chemotherapeutic 
efficiency of a particular capsule type with regards to the amount of curcumin 
available to cells. Figure 5.4A indicates that, if chemotherapeutic drugs are 
administered based on the lowest number of capsules required to cause 
cytotoxicity, the order of decreasing potency is: largest capsules (CapC2SP) > 
CapCSP2 > CapCS2P > CapCSP > CapCS1P > CapCSP1 > smallest capsule 
(CapC1SP). For instance, comparison of capsule size revealed that while exposure 
to only 100 of the largest size capsules (CapC2SP) per cell is required to cause 
100% cell death, it will require a ten-fold higher number of the smallest size 
capsules per cell to cause similar cytotoxicity (Figure 5.4A). This is not surprising 
considering that a large capsule will have a markedly higher amount of curcumin 
loading in comparison with a smaller capsule (Table 1).  
 
However, when we compare the overall efficiency of these nanocapsule systems to 
evaluate their therapeutic effect as a drug carrier (Figure 5.4B), it becomes evident 
that the capsules with the smallest diameter are likely to be the most efficient for 
therapeutic applications. This is notable because the overall amount of curcumin 
present in a dose of small capsules to achieve total cell death is significantly lower 
(0.16 pg) than that present in a dose of larger capsules (2.34 pg). This indicates 
that a 14.4-fold lower amount of drug is required to achieve similar cytotoxic effects 
if smaller size capsules are used for the drug delivery.  
 
Interestingly, if one compares the efficiency of free curcumin molecules with that of 
smallest capsules loaded with curcumin, the latter requires one-sixth of the 
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curcumin to achieve 95-100% cell death. In fact, all but one of the curcumin-loaded 
nanocapsular systems showed higher cytotoxic efficiency over free curcumin 
(Figure 5.4B). We believe that the higher efficiency of curcumin after encapsulation 
may be due to an increased stability of drug molecules in the biological 
environment, since it is well known that curcumin and several other 
chemotherapeutic drugs are unstable in aqueous environments (Oetari et al., 1996; 
Wang et al., 1997). The encapsulation of such drug molecules provides a 
significant opportunity to achieve higher efficiency of existing chemotherapeutic 
drugs. Similarly, it has been previously demonstrated that loading doxorubicin 
inside nanocarriers significantly enhances its efficiency by allowing a greater 
cellular uptake of drug over that seen with free drug molecules (Wang et al., 2008). 
This emphasizes the important role that small nanocarriers can play for drug 
delivery applications. 
 
The next most influential factor (after capsule size) in controlling chemotherapeutic 
efficiency was found to be the thickness of the capsule wall. This is evident from 
Figure 5.4B, where thinner capsules (CapCS1P) were found to outperform 
capsules of medium thickness (CapCSP) and thick walls (CapCS2P), respectively. 
In comparison with the capsule size and wall thickness, the porosity of the capsule 
was found to have minimal effect on the chemotherapeutic efficiency of curcumin. 
This was demonstrated by capsules of different porosities (CapCSP1, CapCSP and 
CapCSP2) showing very similar chemotherapeutic efficiencies (Figure 5.4B). 
 
In the current study, the impact of pristine (non-loaded) chitosan nanocapsules on 
cytokine release by a mast cell line, and thereby indirectly on the allergic immune 
response, was also evaluated. Mast cells produce Th2 type cytokines such as IL-4, 
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which can shift immune responses towards allergy (Galli et al., 2010). It has been 
reported that chitin significantly inhibited the allergen-stimulated Th2 cytokines (IL-
4, IL-5 and IL-10) produced by cultured spleen cells (Shibata et al., 2000). In the 
present study, both small and large chitosan nanocapsules strongly inhibited IL-4 
production from both non-activated and ionomycin plus PMA-stimulated P815 
mouse mastocytoma cells. Large chitosan nanocapsules had a greater IL-4 
inhibitory effect (p < 0.01) than smaller capsules at the same dose of 100 
capsules/cell. Furthermore, the IL-4 inhibitory effect of chitosan nanocapsules was 
dose dependent (Figure 5.5 and Figure 5.6). The inhibitory mechanism of chitosan 
capsules may be due to the inhibition of cell signalling, such as via nuclear factor 
kappaB (NF-KB). It has been found that chitosan can inhibit IL-6 production by LPS 
stimulated human umbilical vein endothelial cells (HUVECs) via regulation of cells 
signalling pathways such as p38 MAPK pathway independent of NF-KB activation 
and ERK1⁄ 2 pathway dependent on NF-KB activation (Liu et al., 2009). Moreover, 
Tahara et al. (2011) reported that chitosan NPs (338 nm) inhibited histamine 
release from IgE activated RBL-2H3 through impairing the exocytosis mechanism 
that involved in the release of histamine.  
 
In conclusion, the experiments conducted in this chapter showed that the loading 
of seven types of chitosan capsules possessing different structural features (size, 
wall thickness and porosity) with the lipophilic anticancer drug curcumin, enabled 
us to correlate the effect of these structural features with the efficiency of delivering 
an anticancer drug. In addition, pristine chitosan nanocapsules themselves were 
found to be highly biocompatible with negligible cytotoxicity, and also possessing 
anti-allergic potential by reducing IL-4 release from a mouse mast cell line. 
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Chapter 6: Summary and Conclusion 
 
6.1 Summary and Discussion 
 
The development of NPs for commercial products is undergoing a dramatic 
expansion. Nanomaterials have been used in many commercial products, such as 
sunscreens, cosmetics, antimicrobial agents, vaccines and drug delivery systems 
(Choksi et al., 2010). Recently, various sunscreen formulations containing ZnO and 
TiO2 NPs have been made commercially available; these materials are effective at 
filtering broad-spectrum UV from sunlight (Nohynek et al., 2007). However, there 
are currently aspects of the potential cytotoxic and immune allergy effects resulting 
from exposure to these NPs, that are poorly characterised, and this has prompted 
the work described in this thesis.  
 
The cytotoxicity and inflammatory responses to ZnO and TiO2 NPs were studied in 
vitro using mast cells and lung epithelial cells, to address the possible health risks 
resulting from the exposure of living tissue to these NPs. This study also 
investigated the relationship of structural properties to biological activity; i.e. the 
size, wall thickness and porosity of chitosan nanocapsules in drug delivery were 
examined. Chitosan nanocapsules were infiltrated with curcumin, which was used 
as a model lipophilic drug due to its well-established anti-cancer properties. The 
effects of chitosan nanocapsules on cellular uptake, cell viability and allergic 
responses in P815 mast cells were also studied. 
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Mast cells are present in all the tissue sites that NPs are likely to encounter first 
upon exposure of the body. Mast cells play essential roles in both activation and 
inhibition of innate immunity, adaptive immunity and allergic responses. Therefore, 
mast cells provide a very good model for studying the interaction between NPs and 
cells of immunity and how these interactions might alter the regulation of allergic 
immune responses. Lung epithelium cells were also used to study the potential 
cytotoxic and inflammatory effects of inhaled NPs. 
 
In the present study, the in vitro assessment of the cytotoxicity and immune 
responses caused by surfactant-treated and untreated ZnO NPs and pristine TiO2 
NPs were investigated using different cell types, including the immune cells P815, 
RLB-2H3 and BMMC mast cells, and the lung epithelial A549 and LA4 cell lines. Of 
these cell types, RBL-2H3, A549 and LA4 cells were adherent cells, whereas P815 
and BMMC cells were non-adherent cells.  These cells also included the cancer 
cells P815, RLB-2H3, A549 and LA4, and the primary (non-cancer) BMMC cells. 
 
The experiments showed that there was a dose-dependent cytotoxicity of ZnO NPs 
in all exposed cell types. The cytotoxicity profile of ZnO NPs varied with cell type, 
with LA4 cells being highly susceptible whilst BMMCs were the most tolerant cells 
(Table 6.1). The treatment of these NPs with a surfactant dispersant (sZnO 30) 
retained their cytotoxicity in all cell types, with the surfactant-treated ZnO NPs 
being equitoxic in P815, A549 and LA4 cells. However this surfactant, which was 
not cytotoxic by itself, further increased the cytotoxicity of ZnO 30 NPs in RBL-2H3 
cells, compared to the effects of the untreated NP counterpart. Furthermore, the 
cytotoxicity was increased by decreasing the size of the ZnO NPs. The cell culture 
media also had an impact on ZnO NPs cytotoxicity, as the faster growing P815 
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cells in the richer RPMI-1640 medium were more susceptible to ZnO NP exposure 
than those growing more slowly in the sparse DMEM medium. The current studies 
also showed that ZnO NPs have selective cytotoxicity toward cancerous cells 
(RBL-2H3) but not to normal mast cells (BMMCs). 
 
The dissolved ion control of ZnCl2 exhibited an equitoxic effect to the ZnO NPs and 
had higher cytotoxicity than bulk particulates. The viability of P815 cells exposed to 
Zn2+ dialysate from ZnO NPs confirmed that the cytotoxicity of ZnO NPs was not 
due to partial dissolution into the media producing extracellular Zn2+ ions, but was 
instead mainly due to the NPs being internalised within the cells. Thus the 
cytotoxicity occurs after the ZnO NPs are taken up by the cells. Inside the 
lysosomes, where the pH is low, ZnO NPs are highly soluble and produce a bolus 
of Zn2+ ions that elevate intracellular Zn2+  levels, as detected by the zinquin ethyl 
ester fluorescent probe. The high level of Zn2+ ions inside cells may damage the 
cell membrane and other cell components. Furthermore, some of these small ZnO 
NPs (30 nm) may also escape from lysosomes into the cytoplasm and cause 
further damage to cellular organelles, such as the mitochondria and nucleus. The 
damage of vital components of the cells may lead to the generation of ROS. The 
intracellular ROS data in the present study showed that ZnO NPs caused ROS 
generation in a concentration and dose-dependent manner, with smaller ZnO NPs 
causing more ROS production than larger NPs. In contrast, TiO2 NPs showed low 
cytotoxic effects and did not induce ROS generation (section 2.4). This may be 
because the TiO2 NPs are highly insoluble and do not dissolve at the low pH within 
lysosomes like the ZnO NPs to liberate metal ions, and therefore required a very 
high exposure concentration to induce biological changes in this in vitro system. 
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Table 6.1: Summary of EC50 values for ZnO NPs (µg/mL) in all cells used 
throughout the thesis, after 24 h of exposure. 
 
EC50/24 h ZnO 30 sZnO 30 ZnO 200 sZnO 200 ZnCl2  
P815 mast cells  
(Mean ± SEM) 25 ± 2 28 ± 1 N/A N/A 42 ± 3 
RBL-2H3 mast 
cells  
(Mean ± SEM) 
187 ± 4 57± 4 N/A N/A 114 ± 4 
BMMC mast cells  
(Mean ± SEM) N/A 122 ± 1 N/A N/A 142 ± 1 
A549 cells  
(Mean ± SEM) 55 ± 2 56± 2 N/A N/A 90 ± 2 
LA4 cells  
(Mean ± SEM) 13 ± 1 13 ± 1 13 ± 1 25 ± 1 13 ± 0 
N/A = Non-cytotoxic 
 
The immune responses of cells after NP exposure were also affected by surfactant 
dispersion and the specific size of NPs. The RBL-2H3 and BMMC mast cells were 
sensitized with TIB-142 IgE mAb in the presence and absence of ZnO NPs, TiO2 
NPs and ZnCl2 and then challenged with TNP-BSA hapten to stimulate 
degranulation. Release of β-hexosaminidase and histamine were markedly 
inhibited by ZnO NPs, but very weakly inhibited by bulk ZnO particulates. 
Surfactant-treated sZnO 30 showed the greatest inhibition of the degranulation 
markers, β-hexosaminidase and histamine. ZnO NPs also inhibited spontaneous β-
hexosaminidase release from non-activated mast cells (section 3.4), and caused 
more IL-4 inhibitory release than bulk ZnO in PMA and ionomycin-stimulated 
mouse P815 mast cells (section 2.4.6).  
 
Overall, these findings comprise the first comparison of the cytotoxicity and allergic 
inhibitory effects of ZnO NPs in their agglomerated and dispersed states, and have 
direct implications for the proven effectiveness of topical zinc oxide preparations in 
rashes and other skin conditions.  
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Generally, ZnCl2 showed similar effects to the smaller ZnO NPs, including inhibition 
of mast cell degranulation markers (β-hexosaminidase and histamine), which were 
stronger than with exposure to the larger ZnO 200 particulates. In all cases, TiO2 
NPs did not demonstrate any inhibition of immune function, but instead caused a 
significant increase in β-hexosaminidase release from mast cells.  
 
The findings of the current study show that NP size, composition, concentration, 
time of exposure and the interaction of NPs with different lung epithelial cell types 
are critical in determining the degree of cytotoxicity in in vitro studies. ZnO NPs 
caused lung epithelial cells to produce the proinflammatory cytokine IL-8, but did 
not stimulate other specific type 1 or type 2 cytokine responses. The levels of IL-8 
cytokine secretion increased with decreased ZnO NP size. The increase of 
proinflammatory IL-8 release may be due to the damage of epithelial cells caused 
by ZnO NPs themselves or due to releasing of high levels of Zn2+ ions from ZnO 
NPs inside the cells (section 4.4). 
 
Biopolymer based, chitosan nanocapsules were found to be highly biocompatible, 
showing negligible cytotoxicity and low immunogenicity. Seven types of chitosan 
capsules possessing different structural features, e.g. nanocapsule diameters 
ranging from 220 to 440 nm, nanocapsule shell thickness ranging from 31 to 55 
nm, and pore diameter varying from 2.9 to 5.1 nm, were loaded with curcumin, a 
lipophilic anticancer drug, which enabled the correlation of the effect of these 
structural features of different chitosan nanocapsules with anticancer efficiency 
against P815 mouse mastocytoma cells, the size of the nanocapsules is likely to 
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play the most important role in dictating the chemotherapeutic efficiency in this 
drug delivery system (section 5.4). 
 
6.2 Future directions  
Preliminary work was done in this thesis using the Australian Synchrotron x-ray 
fluorescence beamline, which was used to detect the distribution of intracellular 
ZnO and TiO2 NPs in P815 mast cells (section 2.3.8). Further mapping of the 
distribution of NPs inside the cell could be used to determine whether NPs are able 
to penetrate the nucleus. Limitations on this early work prevented accurate 
assessment of the precise intracellular position of the NPs, and techniques such as 
x-ray tomography or focussed ion-beam ablation will be necessary to confirm the 
NP localisation within the cytoplasm or nucleus.  
 
As ZnO NPs appeared to inhibit the allergic immune response, including the mast 
cells degranulation markers and IL-4 release, as well as the surfactant-treated 
sZnO 30 NPs having the strongest impact on the Akt signalling phosphorylation to 
induce apoptosis, future studies could further  evaluate these allergic inhibitory and 
apoptotic mechanisms by investigating the effect of ZnO NPs on cell signalling 
pathways, e.g. PI3K / Akt signaling, NF-kB signaling and MAPK signaling in 
IgE/antigen-activated mast cells. 
 
In vivo studies are also required to evaluate the safety of nanomaterials. Therefore, 
it would be necessary to investigate the effect of surfactant-dispersed ZnO NPs on 
cytotoxicity and inflammatory responses using an intra-nasal mouse model. 
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Moreover, the allergic inhibitory effects of ZnO NPs could be further examined 
using an ovalbumin intra-nasal sensitized mice model. 
 
In the current study, we have demonstrated the non-cytotoxic nature of chitosan 
nanocapsules, as well as their biodegradability and their down-regulation of IL-4 
Th2 allergic responses in PMA and ionomycin-activated mast cells. Thus, it would 
be expected that chitosan nanocapsules are applicable as a safe and efficient drug 
carrier, and as an anti-allergic drug delivery system. Therefore, we suggest a 
further study to examine chitosan nanocapsules as a suitable delivery system for 
therapeutics, such as heparin, used in asthma treatment.  
 
6.3 Conclusion 
This project has provided a significant contribution to the existing knowledge about 
cytotoxicity, immune inhibitory and immune stimulatory effects of NPs in their 
dispersed and aggregated states in several cell types using an in vitro exposure 
system. Dispersed ZnO NPs exhibited the stronger immune inhibitory effects in 
vitro; therefore, the ultimate health outcomes need to be investigated in vivo to 
evaluate the true risks of using formulations of NPs containing surfactants that 
prevent the agglomeration of ZnO and TiO2 NPs. Furthermore, it has also been 
demonstrated that non-cytotoxic chitosan nanocapsules are efficient as a drug 
carrier and can be exploited for further medical applications. 
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Appendix 1: Protein gel reagents 
Separating gel (12.5%): 
Reagent Volume 
1.5 M Tris pH 8.8 (Sigma-Aldrich, USA) 2.5 mL 
10% SDS (sodium dodecyl sulfate) (BDH, UK) 100 µL 
40% (w/v) Bisacrylamide (Amresco) 3.124 mL 
H2O 4.275 mL 
15% (w/v) Ammonium persulfate (Sigma-Aldrich)  50 µL 
TEMED (BioRad Laboratories, USA) 10 µL 
 
Stacking gel (4%): 
Reagent Volume 
0.5 M Tris pH 8.8 1.0 mL 
10% (w/v) SDS 40 µL 
40 % (w/v) Bisacrylamide 375 mL 
H2O 2.585 mL 
15% (w/v) Ammonium persulfate 20 µL 
TEMED 5 µL 
 
5x SDS sample buffer: 60 mM Tris Cl (pH 6.8), (Sigma), 25% (v/v) glycerol 
(Sigma), 2% (w/v) SDS (BDH), 14.4 mM mercaptoethanol (Biorad), 0.1% (w/v) 
bromophenol blue (BDH), (stored at -20 ºC). 
 
10x SDS Electrophoresis buffer (Tris – glycine): 30.2 g Tris, 144.0g 
Glycine and 10.0 g SDS made up to 1 litre with milli Q water, pH 8.3. 
 
Coomassie Stain: 0.1% (w/v) Coomassie R 250 (Biorad), 50% (v/v) methanol 
(lab scan), 10% (v/v) acetic acid (Scharlau, Germany).  
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Destaining solution: 10% (v/v) ethanol (Lab scan), 10% (v/v) acetic acid 
(Scharlau). 
 
Bradford reagent: 100 mg Coomassie Brilliant G-250 dye (Sigma), 50ml 
ethanol (BDH), 100ml 85% phosphoric acid (BDH), per litter of milli Q water, filtered 
through 0.45 µm filter and stored at 4°C. 
 
x10 Tris Buffer Saline (TBS): 12.11 g Tris. (Sigma), 87.8 g NaCl per litre of 
milli Q water. 
